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Macronutrient metabolism includes the suite of chemical transformations that sustain 
cells and allow for organismal growth and development. Mammalian pregnancy is perhaps the 
most nutritionally sensitive stage in life as all nutrients for fetal growth are provided by the 
mother. Glucose and oxygen are two of the most important molecules transferred to the fetus, and 
their metabolic fates converge at the metabolism of pyruvate in mitochondria. Pyruvate enters the 
mitochondrial matrix through the mitochondrial pyruvate carrier (MPC), a complex that consists 
of two essential components, MPC1 and MPC2. Here we define the requirement for 
mitochondrial pyruvate metabolism during development with a progressive allelic series of Mpc1 
deficiency in mouse. While Mpc1 deletion was lethal during mid-gestation, a hypomorphic 
knock-in (KI) allele of Mpc1 resulted in perinatal lethality. Late-gestation Mpc1 KI fetuses were 
smaller than littermates with tissue-specific compensatory changes in lipid and amino acid 
metabolism. These data show that impaired mitochondrial pyruvate transport results in 
biosynthetic deficiencies that can be partially mitigated by alternative anaplerotic substrates in 
utero. 
To further probe the capacity for metabolic plasticity in this model, late-gestation dams 
were fasted for 24 hours. Maternal fasting increased serum lipid metabolites, promoted fetal liver 
triglyceride accumulation, and stunted fetal growth. To determine the contribution of maternally-
derived lipids to the fetal fasting response, we used two genetic models of impaired fatty acid 
oxidation: (1) liver-specific loss of mitochondrial β-oxidation of long-chain fatty acids via 
carnitine palmitoyltransferase 2 (Cpt2) and (2) genetic loss of a transcriptional regulator of lipid 
oxidative metabolism, PPARα. Upon fasting, these mice exhibit differing degrees of hepatic lipid 
accumulation and impaired ketogenesis. The fetal response to maternal fasting was determined by 
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liver transcriptional program and steady-state metabolite measurements. The maternal fasting 
response is a better indicator of fetal outcome than is fetal genotype, suggesting that maternally-
derived factors dominate this communication. Furthermore, maternal effects persist into the early 
postnatal period, highlighting the importance of maternal lipid metabolism during gestation and 
lactation. The use of genetic models and biochemical approaches to obtain a greater mechanistic 
understanding of maternal-fetal metabolic communication may inform interventions for 
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Pregnancy may be the most nutritionally sensitive stage in the life cycle, which also 
means that nutritional interventions during pregnancy may have the greatest capacity to benefit 
maternal, fetal, and infant health. Furthermore, improved nutrition during gestation and early 
postnatal life may improve overall health and reduce the likelihood of chronic disease in 
adulthood (1). In this section, the basis of maternal-fetal metabolic communication will be 
introduced, including a discussion of the modes of communication and whether this maternal-
fetal dialogue is one of harmony, conflict, neither, or both. Additionally, the basic metabolic 
needs of the developing fetus will be addressed in terms of the physiological adaptations in place 
to ensure their proper allocation. Maternal energy expenditure and changing metabolic demands 
over the course of gestation will also be discussed. 
The placenta is a key regulator of fetal metabolism and it is the site where conflicts over 
maternal-fetal resource allocation and communication take place. The placenta is also unique in 
that it transiently provides this vital lifeline through which the developing fetus obtains all 
nutrients. Interestingly, placentation has independently evolved in multiple distinct lineages. Even 
within the same taxonomic order, different strategies of placentation exist (2, 3). The role of the 
placenta in nutrient transport will be discussed with particular attention to comparative 
placentation among different species and different model organisms. 
The discussion of nutrient transport at the organ level via the placenta will lead into a 
molecular survey of particular substrates and how they are transported across this barrier that is 
anything but passive. This will set the stage for a discussion of the particular metabolites that are 
key players in fetal metabolism and how genetic loss-of-function models can define the 




1.1  Maternal-Fetal Metabolic Communication: Harmony vs. Conflict 
Successful mammalian pregnancy and parturition requires metabolic, hormonal, and 
immunological communication between mother and fetus (4). The types and intensities of signals 
conveyed vary considerably across gestation, as do the responses elicited by these messages. 
Metabolic communication throughout pregnancy is essential as a growing fetus obtains all 
nutrients from (and excretes all wastes to) the mother. While hormonal cues from both mother 
and conceptus can affect nutrient mobilization, the metabolic demands of the growing fetus may 
also directly modify maternal metabolism and behavior (5, 6). Fetal metabolic demand is highest 
during late gestation, which is coincident with the highest basal metabolic rate and energy 
expenditure in pregnant women and mice (7-9). 
Alterations to macronutrient metabolism during pregnancy balance the competing 
interests of fetal growth and maternal fecundity (10, 11). However, the extent to which maternal-
fetal communication reflects coordinated adaptations versus conflicting interests is not well 
understood and is likely context-dependent. For example, the competing interests of the 
maternally-inherited and the paternally-inherited genomes have resulted in some genomic regions 
being imprinted—that is, transcriptionally silenced or expressed from only one allele in particular 
tissues or at particular times in development. Importantly, of the more than 100 imprinted genes 
that have been identified in mice, the majority are expressed and imprinted in the placenta, the 
hub of hormonal communication and resource allocation during pregnancy (12). In this way, 
genomic imprinting has been likened to a tug-of-war over resource allocation that would support 
fetal growth or maternal fecundity (13). However, the distinction between these two seemingly 
opposed goals is rarely so clear-cut: Consider, for example, if additional maternal investment now 
will result in a more vigorous offspring that will require less maternal investment later, such that 
the mother can begin preparing for future offspring. While a great deal of metabolic 
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communication is necessary between mother and fetus, particularly when nutrients are limiting as 
to be discussed in Part 3, fetal demands and maternal countermeasures are always at work to 
compromise for a balance that will suit both mother and fetus. There is both harmony and conflict 
under nearly all maternal-fetal interactions. 
 
1.2  Physiological Adaptations of Eutherian Pregnancy 
 Pregnancy demands a multitude of physiological adaptations that affect every organ 
system of the mother (4). Many changes are communicated by hormonal signals from both 
mother and conceptus (5), and the metabolic demands of the growing fetus may also directly 
modify maternal metabolism and behavior (6). Canonically, glucose is the principal substrate 
driving fetal growth (14). Many maternal metabolic adaptations ensure sufficient glucose delivery 
to the fetus by rendering the mother’s tissues transiently insulin resistant and by enhancing 
maternal glucose production by 30% from early to late pregnancy (15). Concomitant with this, 
blood flow to the uterus increases to 25% of cardiac output to ensure substrate and oxygen 
availability for mitochondrial oxidative metabolism (16). The rate of fetal blood delivery to the 
placenta via umbilical flow is approximately proportional to fetal weight and gestational age. 
The villous organization of the placenta increases the surface area such that the total surface area 
available for exchange during late pregnancy in humans is 10-15 m2 (the approximate surface 
area of a tennis court) (17).  
Interestingly, in multiparous species such as rats, there is a 2-fold difference in 
uteroplacental blood flow rates from middle positions to ovary/cervix positions (18). Studies from 
a crowded uterine horn mouse model demonstrate the effect of uteroplacental bloodflow on fetal 
outcomes (19). Mice were subjected to a unilateral ovariectomy and mated such that a normal-
sized litter was born from a crowded uterine horn, in which there is a 4-fold difference in blood 
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flow to offspring from the same pregnancy (19). Fetuses in the middle positions between the 
ovary and the cervix experienced the lowest perfusion pressure (18), and the smallest 5% of 
offspring were half the weight of the largest 5% of offspring from this crowded uterine horn 
model (19). The smallest pups exhibited dramatic catch-up growth over the first three weeks of 
postnatal life, and by adulthood, both intrauterine growth-restricted male mice and macrosomic 
male mice weighed significantly more than littermates born at median birth weights (19). These 
data suggest that both fetal undernutrition and overnutrition can result in similar adverse 
metabolic outcomes in adulthood, although the mechanisms behind these outcomes are likely 
different. Multiparous species have the additional challenge of meeting the metabolic demands of 
several fetuses that may be competing against one another for maternal resources. 
Another remarkable physiological adaptation of pregnancy is a greater metabolic 
flexibility than in the non-pregnant state in order to protect fetal growth from maternal nutrient 
deprivation (1). One way in which the pregnant woman is poised to provide this metabolic 
plasticity is through increased adipose tissue lipolysis and re-esterification, even in the fed state 
(20, 21). Maternal circulating lipids (triglyceride, free fatty acids, and phospholipids) increase 
throughout gestation (17, 22) and are mobilized from adipose depots established during early 
pregnancy (21, 23). Circulating lipids are further elevated by fasting and are available for 
placental transport (17, 22). Fetal uptake of lipids (and catabolic products such as ketones) may 
be particularly important during prolonged maternal nutrient deprivation (14). The extent to 
which fetal tissues rely upon lipids for energy metabolism is not well understood, but the early 
postnatal switch in nutrition from glucose in utero to lipid-rich milk suggests that late-gestation 
fetal tissues may have the capacity to utilize maternally-derived lipids (24). In this way, the 




1.3  Metabolic Demands of Pregnancy 
 Human weight increases 6 billion times over the course of prenatal life (25). As such, it is 
understandable how dramatically fetal metabolic demands must change over the course of 
gestation. Similarly, maternal energy expenditure also increases during gestation, but it is unclear 
if this increase is simply proportional to increased tissue mass and food intake (26). Longitudinal 
studies of energy expenditure and body composition have attempted to address this to better 
understand the metabolic costs of pregnancy. 
Primate reproduction is characterized by a slow rate of growth over a long gestation 
which results in a lower nutritional stress per unit time than what is observed in species with 
faster generation times (1). Interestingly, there is greater variation among mammals in birth 
weight than there is in terms of length of gestation; therefore, there are vast differences in rates of 
fetal growth across species (25). Fetal growth rates are not linear but growth accelerates as 
gestation advances. In humans, birth occurs on the steepest part of the growth curve, while in 
rodents, for example, the greatest rates of growth occur in the first two weeks of postnatal life 
(25), even though fetal rats exhibit a 25-30% increase in weight in the last day of gestation (27). 
Because of the slow rate of growth of humans, the daily energy stress of human pregnancy 
relative to maternal body size is lower than for most other mammals (1). Species with higher 
metabolic demands during pregnancy must meet that need through substantial increases in food 
intake, whereas humans, with a lower nutritional stress per unit time, may instate metabolic 
adaptations to protect fetal growth from adverse circumstances such as food shortages. 
In healthy human pregnancies, the average maternal weight gain was 12.5 kg (28 lbs) 
over the course of gestation (23). Fetal weight may account for 25% of the weight gained in a 
well-nourished human pregnancy, but up to 60% in suboptimal nutritional conditions (1). 
Calculations of the human energy budget during pregnancy suggests there are three ways in 
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which energy is used: (i) energy deposited as new tissue (~20 MJ); (ii) energy deposited as fat 
(~150 MJ); and (iii) energy required to maintain the new tissue (~150 MJ) (1). There are vast 
differences in energy budgets during pregnancy in the developed vs. developing world, depending 
on maternal (and pre-pregnancy) nutrition. When maternal resources are limited, energy 
deposition as fat is the metabolic fate that gets re-routed. Pair-feeding of pregnant mice based on 
non-pregnant controls revealed no reduction in fetal body weights from pregnancies fed ad 
libitum; however, there was a significant reduction in maternal body weight, suggesting that 
maternal hyperphagia in later rodent gestation fuels adipose deposition that is particularly 
important during lactation (28). In humans, maternal adipose deposition occurs in the first 
trimester, and it is these adipose stores that will be mobilized during late gestation to promote 
fetal fat accretion (17, 23). Fat accounts for 16% of birth weight in humans, but only 1 to 2% in 
mice and rats (25). Furthermore, this late-gestation increase in adiposity is unique to humans as 
most other mammals, including primates, are born lean (14, 24). Some species, such as rabbits 
and guinea pigs, accumulate fat in their livers just prior to birth, and it is these hepatic stores 
rather than adipose depots that are of principal importance for early postnatal metabolic 
adaptation in these species (24, 29). 
In small mammals such as rodents, fetal mass may account for 30% of maternal body 
weight, hence certain metabolic adaptations may, out of necessity, increase energetic efficiency 
over what is observed in human pregnancy (30). In sheep, fetal body weights are 8% of maternal 
body weight, which may make them a better model for human pregnancy (30), although there are 
fundamental differences in placental morphology between humans and sheep that will be 
addressed in the next section. The gold standard for assessing changes in bioenergetic demand 
during pregnancy is to collect longitudinal data on metabolic rates, however, it can be challenging 
to collect this data from a sufficient sample size since there is often considerable variation among 
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women (31). Several longitudinal studies of pregnant women have demonstrated increasing 
energy expenditure across gestation by indirect calorimetry measurements (7, 8, 32, 33). Women 
with a normal BMI displayed a 28% increase in basal metabolic rate and a 13% increase in total 
energy expenditure from pre-pregnancy to 36 weeks gestation (7). There is considerable 
variability in total energy expenditure (TEE)—some women have a net negative difference in 
TEE across the course of pregnancy—and this suggests that pregnant women use a diverse array 
of strategies to meet the metabolic demands of pregnancy (8). Therefore, a single 
recommendation for increased energy intake during pregnancy is likely not applicable to all 
women. Importantly, little or no increase in energy intake was observed during human pregnancy 
(8). Additionally, a study of early- and late-gestation pregnant women found no difference in 
postprandial energy expenditure compared to non-pregnant controls, suggesting that there are no 
significant alterations in efficiency of energy extraction from dietary sources (30). This is 
consistent with the studies of pair-fed mice in which reducing maternal food intake was still 
sufficient to meet the biosynthetic and bioenergetic needs of the developing fetus (28). While 
human nutrition varies greatly between and within populations around the world, remarkably, a 
healthy human newborn is the same in any population, in large part due to the adaptive measures 
that protect against nutritional deficiency in utero. 
 Another obstacle in studies of the energetic requirements of pregnancy, in laboratory 
model organisms in particular, is the challenge of accounting for fetal metabolic rate in a system 
where fetal mass may account for up to 30% of maternal weight. Measurements by indirect 
calorimetry in newborn mice suggest that metabolic rate relative to fetal body weight is likely 
30% lower than the metabolic rate of maternal body, such that maternal changes in energy 
expenditure account for the bulk of the increase in metabolic rate during pregnancy (9). 
Additionally, in a mouse model in which placentae persist after fetuses are rendered inviable 
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during late gestation (15 dpc), increased metabolic rate was still observed (9). This suggests that 
hormonal contributions from placenta, rather than fetal demand per se, may contribute 
significantly to the increase in metabolic rate across gestation. In rats, as in humans, energy 
expenditure was 10% higher than non-pregnant values at the peak of energy expenditure just prior 
to parturition (26). Altogether, the increased basal metabolic rate during pregnancy can be 
attributed to the combined effects of increased tissue mass, accelerated tissue synthesis, and 
increased cardiovascular, respiratory, and renal work (31). 
 
1.4  Placental Development and Comparative Placentation 
The placenta is a key regulator of fetal and maternal metabolism and it is the site where 
conflicts over maternal-fetal resource allocation and communication take place (10). The placenta 
is also unique in that it is a transient organ that provides the vital lifeline through which the 
developing fetus obtains all nutrients. The placenta develops from interactions between the 
trophectoderm of the implanting blastocyst and the endometrium. In humans, the placenta is 
functionally mature by 10-12 weeks’ gestation, and placental growth precedes fetal growth such 
that the placenta is larger than the fetus until 15-16 weeks (full term at 38 weeks) (4). In mice, 
placentation begins just before mid-gestation, the definitive placenta is established at e11, and the 
maximum placental volume is reached by e16.5, as determined by stereology (parturition at day 
19-20) (34, 35). The size and transport capacity of the placenta is often indicative of fetal health 
and growth. Placental insufficiency is linked to miscarriage, intrauterine growth restriction 
(IUGR), and preeclampsia. 
Humans and rodents both have hemochorial placentae where maternal blood comes into 
direct contact with the syncytiotrophoblast, which is the first barrier to maternal-fetal exchange 
(36, 37). The specialized syncytiotrophoblast has a microvillous membrane in contact with the 
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maternal blood and a basal membrane facing the fetal blood. Humans also have a villous 
placental organization where each chorionic villus is composed of (i) an epithelial layer derived 
from syncytiotrophoblast and cytotrophoblasts and (ii) an inner vascular network (including fetal 
vessels) and connective tissue stroma derived from embryonic mesoderm (4, 34). Invasive 
endovascular trophoblasts remodel the uterine spiral arteries and replace maternal endothelium 
such that maternal blood flows directly around the terminal villi (34, 37). This villous 
organization maximizes the surface area available for exchange. Although the discoid, 
hemochorial placentae of humans and rodents have similar forms, rodent placenta lacks the well-
defined villous structures of human placenta. Instead, in rodents, maternal blood bathes branching 
structures in a region called the placental labyrinth where most nutrient and gas exchange occurs 
(37, 38). The rodent structures analogous to human chorionic villi have a trichorial arrangement 
with two layers of syncytiotrophoblast in contact with fetal endothelium and a cytotrophoblast 
cell layer in contact with maternal blood (34, 36). The rodent placenta also has a junctional zone, 
comprised of spongiotrophoblasts, which serves an endocrine function (37). The multinucleated 
giant cells of the outer layer of the rodent placenta promote implantation and are somewhat 
analogous to the extravillous trophoblasts that invade the maternal spiral arteries in humans (36). 
Despite subtle differences in cell types and organization, the structures of rodent and human 
placentae are more similar than certain other modes of placentation among eutherian mammals. A 
comparison of several model organisms for the study of placental development and function 
highlights the advantages and limitations of using these models as they relate to human 
placentation and parturition (39). 
Placentation has independently evolved in multiple distinct lineages. Even within the 
same taxonomic order, different strategies of placentation exist (2, 3). Humans and rodents, with 
hemochorial placentae, are among the species with the most invasive form of placentation, as 
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fetal tissues are in direct contact with maternal blood (3). In the endotheliochorial placenta, 
maternal blood vessels are adjacent to fetal tissues but separated by maternal endothelium. In the 
least invasive type of placenta, the epitheliochorial placenta, maternal blood and fetal tissues are 
separated by maternal endothelium, connective tissue, and epithelia, which provides considerably 
more membranes across which nutrients must be transported to reach the fetal compartment (3). 
Species with the least invasive mode of placentation include sheep, which is an important 
consideration when comparing studies of fetal sheep metabolism to other species. For instance, 
that sheep have the least invasive form of placentation while rodents and lagomorphs have the 
most invasive form may help explain some of the discrepancies in placental fatty acid transport 
capacity observed across species (29, 40). In sheep, fetal blood concentrations of both free fatty 
acids and ketones remain low relative to maternal concentrations, even upon maternal nutrient 
deprivation (14). Consistent with this, radiolabeled palmitate was found to be transported poorly 
across the sheep placenta; however, circulating free fatty acid levels in newborn sheep were 
rapidly increased from 10% to 80% of maternal levels within an hour after birth (40). In rabbits, 
on the other hand, maternal fasting nearly doubled fetal fat storage in both adipose and liver (29). 
In this regard, the most invasive (hemochorial) placenta may allow for greatest lipid transport 
from mother to fetus, and species with this mode of placentation exhibit higher rates of prenatal 
brain growth and higher ratios of brain mass to body mass in both neonates and adult animals (2). 
In humans, for example, the brain of a newborn weighs 25% the weight of an adult brain, but the 
body weighs only 5% of the adult body weight (25). A study of brain-body allometry across 
eutherian mammals demonstrated patterns of faster prenatal brain growth and slower prenatal 
body growth among species with more invasive forms of placentation (2). This suggests that, in 
these species, nutrients essential for brain growth and development (such as essential fatty acids) 
are made more readily available to the fetus earlier in life. Modes of placentation across taxa 
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reflect life history traits that reveal how and when offspring obtain these essential nutrients during 
their development. The brain is an energetically expensive tissue, both in terms of development 
and maintenance (41-43), and the brain is characterized by a unique lipid composition (44). It is 
of no surprise that placentation strategies may affect nutrient availability for important 
developmental processes that vary among species. A more mechanistic understanding of how 
species-specific differences in nutrient transport affect these life history traits remains to be 
determined. 
A final point of interest about comparative placentation is the reproductive strategy 
employed by marsupials—the other lineage of mammals that gives birth to live young. 
Marsupials have more anatomically simple placentae and give birth to young at a much earlier 
stage of development than eutherian mammals. Lactation, therefore, plays a greater role in 
marsupial development, emulating later stages of eutherian in utero development (45). 
Marsupials have a more complex milk repertoire than eutherians, and some classes of genes 
expressed by marsupial mammary gland are shared with eutherian placenta and eutherian 
mammary gland while others are only shared with eutherian placenta (46). Among these genes 
are nutrient transporters and transcriptional regulators known to be important in eutherian 
placenta which are conserved by their expression in marsupial mammary gland (46). Altogether, 
mammals have a diverse array of strategies related to placental invasiveness, degree of maturity 
at parturition, and early postnatal nutritional approaches to ensure offspring health and manage 
the energetic costs of pregnancy and lactation. 
 
1.5  Placental Nutrient Transport: A Molecular Survey of Substrates 
 Placental structure maximizes the surface area available for exchange of membrane-
permeable molecules as well as ions and polar molecules which require transporter-mediated 
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movement across cellular membranes. The developing fetus is in a constant anabolic state, 
increasing biomass with substrates delivered from the mother. Canonically, glucose is the 
principal substrate driving fetal growth (14). In addition to carbohydrates, amino acids, and lipids 
are also required for fetal growth. While some of these molecules can be synthesized by the fetus, 
others are essential and must be supplied from the mother. Here, some of the key classes of 
nutrients provided by the placenta for fetal growth will be surveyed: carbohydrates, amino acids, 
and lipids. Their transport and metabolic fates will be reviewed, with special emphasis on the 
oxidative metabolism of these molecules within mitochondria. The requirement for mitochondrial 
oxidative metabolism of glucose-derived pyruvate during mammalian development will be 
defined in Part 2. 
 
1.5.1  Carbohydrates 
 Glucose and oxygen are arguably the two most important molecules transferred from 
mother to fetus during pregnancy. Pyruvate is the end-product of glycolysis, and pyruvate can be 
converted to lactate to regenerate NAD+, a necessary cofactor for glycolysis (Fig. 1). Oxygen, 
glucose, and lactate all coalesce at the transport and metabolism of pyruvate in mitochondria. 
While oxygen tension in utero is low relative to atmospheric levels, measurement of oxygen 
consumption and lactate uptake in fetal lamb provided evidence that the fetus is a net consumer 
rather than producer of lactate (14). Consistent with this, fetal myocardium consumes a large 
amount of lactate in addition to glucose, indicating that oxidative metabolism of carbohydrate is 
an important energy source in developing heart (47, 48). Additionally, lactate utilization is high in 
neonatal brain, and the capacity for lactate import is higher in neonatal brain than in adult (43, 
49). Furthermore, recent studies revealed significant lactate utilization in adult tissues, suggesting 
that circulating lactate is an important oxidizable substrate in mammals (50, 51). Together, these 
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observations provide evidence for the importance of mitochondrial oxidative metabolism early in 
mammalian development. 
 The predominant glucose transporter expressed in placenta is GLUT1, and it is found on 
both the microvillous and basal membranes of the syncytiotrophoblast (52). GLUT3 can be found 
in the vascular endothelium where it likely enhances placental uptake of glucose (52). In rodents 
and sheep, GLUT3 is expressed by the placenta and increases as gestation progresses. The 
expression of this high affinity glucose transporter may help scavenge glucose uptake in species 
with a faster rate of in utero growth and a higher daily energy stress of pregnancy than humans 
(52). Interestingly, placental GLUT1 expression has been found to be increased in gestational 
diabetes mellitus (GDM). Normally, there is more GLUT1 expression on the microvillous 
membrane than on the basal membrane, but in GDM pregnancies there is increased expression of 
GLUT1 on the basal membrane which could promote elevated glucose transport to the fetus (52, 
53). It is unclear whether maternal or fetal factors mediate this increase in GLUT1 expression in 
GDM, but it has been suggested that fetal hyperglycemia and increased IGF-1 expression could 
result in elevated glucose transporter expression (54). 
 It is unclear exactly how glucose is made available for transport across the basal 
membrane of the syncytiotrophoblast since hexokinase will readily phosphorylate glucose 
transported across the maternal microvillous membrane. There are a few reports of glucose-6-
phosphatase expression in the endoplasmic reticulum of the syncytiotrophoblast, and that may 
represent one path by which glucose can be transferred to the fetal side (55, 56). Some reports 
even provide evidence for glucose production by the placenta, but the capacity for and regulation 
of this potential source of increased glucose production during late gestation is not well 
understood (56, 57). In one study, women undergoing elective cesarean delivery at term (after a 
10 hour fast) were administered deuterated glucose, and the label was found to be diluted in the 
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umbilical vein with no further dilution in the umbilical artery, suggesting a uteroplacental source 
of this glucose rather than a fetal contribution (57). Glycogen stores are another potential source 
of glucose available for placental use or transport to the fetus. While glycogen stores have been 
observed in multiple cell types in human and rodent placentae, the functions of these stores and 
their role in normal physiology and pathogenesis are poorly understood and may vary across 
gestation (58). 
The placenta not only transports glucose to the fetus but it also catabolizes glucose. 
Umbilical uptake of oxygen and glucose were found to be 45% and 75% lower, respectively, than 
the total uterine uptake in sheep, suggesting significant glucose oxidation by the placenta (59). In 
an ovine model of impaired placental growth, oxidative metabolism of glucose by placenta was 
impaired, but lactate efflux to the umbilical vein was increased and fetal lactate consumption 
increased as a result (60). In late gestation, maternal gluconeogenesis is elevated to ensure 
adequate glucose supply to the fetal compartment, and lactate is an important gluconeogenic 
substrate. However, only 40-50% of lactate was used for gluconeogenesis in late-gestation 
pregnant rats, as compared to 70-80% in non-pregnant rats, suggesting that fetal utilization of 
lactate may account for the difference (27). Studies in fetal lamb confirm that lactate 
concentrations are higher in fetal umbilical vein than in fetal artery, again consistent with the 
fetus being a net consumer of lactate (61). Recent magnetic resonance imaging studies using 
hyperpolarized [1-13C]pyruvate administered to late-gestation pregnant rats resulted in clear 
placental localization of signal as well as evidence of conversion to [1-13C]lactate and [1-
13C]alanine in maternal organs and in placenta. Importantly, the intensity of the [1-13C]lactate 
signal from placenta was lower in a rat model of preeclampsia, and this reduction in signal is not 
due to changes in placental perfusion but rather likely represents impaired placental metabolism 
of pyruvate (62). Together, these observations challenge the dogma that in utero development is 
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characterized by low oxygen tension and is not conducive to mitochondrial oxidative metabolism. 
While this may be true during early development, once placental exchange function is developed 
and fetal mitochondrial biogenesis begins (63), the fetus is poised to utilize oxidative metabolism 
for energy production and anabolism. 
 
1.5.2  Amino Acids 
Amino acids can be utilized for protein synthesis and biomass accumulation as well as for 
energy production. In contrast to glucose utilization by placenta, similar rates of uterine and 
umbilical uptake of amino acids were measured in sheep, suggesting that amino acids are 
preferentially transferred to the late-gestation fetus (59). In humans, fetal umbilical vein 
concentrations of amino acid were higher than maternal circulating levels (64). A thorough 
catalog of placental amino acid transporters is beyond the scope of this survey, but the reader is 
directed to these excellent reviews (38, 65-68) and a comprehensive model of integrated placental 
amino acid transport (since some amino acids are accumulated against a concentration gradient 
and others are used in concert with exchangers/antiporters that will swap one amino acid for 
another across a membrane) (69). Impaired placental amino acid transport has been observed in 
intrauterine growth restriction (IUGR), and there was decreased mTOR activation in IUGR 
placentae, indicative of impaired nutrient sensing relative to healthy placentae (70). 
Hyperpolarized 13C magnetic resonance imaging was able to observe [1-13C]alanine and urea in 
vivo in rat placenta. Urea was demonstrated to cross the placenta and reach fetal liver, although 
the physiologically relevant direction of urea transport is from fetus to placenta as a waste 
product (62). A similar imaging approach in pregnant women could possibly be used to test for 




1.5.3  Lipids 
Lipids are an important class of molecules for cellular biosynthesis, biomass accretion, 
energy production, and signaling purposes during fetal development. The fetus is capable of de 
novo lipogenesis from precursors derived from the tricarboxylic acid (TCA) cycle (Fig. 1). 
Because of the predominance of glucose as a metabolic substrate in utero, much of the carbon 
available for lipogenesis likely derives from glucose. In mouse, whole-body deletion of acetyl-
CoA carboxylase 1 is embryonic lethal by day 8.5, and whole-body deletion of fatty acid synthase 
results in pre-implantation embryonic lethality (71, 72). Remarkably, adult mice with liver-
specific deletion of these essential enzymes in lipogenesis are not phenotypic when dietary fat is 
available, suggesting that, even in utero, liver fatty acid synthesis is not essential under normal 
dietary conditions (73, 74). De novo lipogenesis has been measured in fetal rat by the 
incorporation of 3H2O into the lipid fraction. From e17 to e20 in rats, there was a 3-fold increase 
in fatty acid synthesis; however this study failed to provide fetal tissue-specific resolution as to 
where these lipids were accumulating, although it was reported that fetal liver triglyceride content 
accounted for 20% of total fetal triglyceride content (75). The same study also compared 
exogenous uptake of [14C]oleate, but the relative contributions of lipogenesis vs lipid uptake to 
total tissue lipid accretion cannot be determined from these labeling experiments. Glucose-
derived lipogenesis is likely of greater significance in species with limited fatty acid transport 
across the placenta, such as species with epitheliochorial placentae like sheep and cows. Although 
the relative contribution of de novo synthesized lipid vs placental uptake of lipid is not well 
established, the importance of lipid accretion during late gestation cannot be contested. Human 
fetal liver accumulated 51mg fatty acid per week from 22 weeks of gestation to term (76). Much 
of this lipid is maternally-derived from maternal adipose depots that are mobilized in late 
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gestation (21, 23). How these lipids are made available for fetal uptake via the placenta is 
discussed next. 
1.5.3.1  Sources of lipids for placental transfer 
While some studies have suggested that rates of placental transfer of lipids (particularly 
in species with epitheliochorial placentae) are quite low, it is important to consider that 
cumulative lipid transfer and accumulation in fetal tissues may be highly significant even if rates 
of transfer are slow. During late gestation, maternal non-esterified fatty acid (NEFA) 
concentrations are elevated, but circulating triglyceride (TG) levels are increased even more 
dramatically, such that levels are 250% higher than levels in non-pregnant women (17). These 
concentrations are more than two-fold higher than the postprandial peak in TG after a high-fat 
meal. It is largely accepted that maternal circulating triglycerides do not cross the placenta intact, 
yet the acyl content of TG is available for fetal accumulation (6). In humans, for example, a TG 
emulsion administered to pregnant women near term was able to cross the placenta as evidenced 
by increased fetal arterio-venous lipid concentrations and by the observation that fetal circulating 
NEFA and TG fatty acid composition resembled the composition of the TG emulsion that was 
administered to the mother (77). NEFA availability at the placenta can be from mobilization of 
maternal adipose depots or from local TG hydrolysis by maternal or placental lipases. The human 
placental microvillous membrane is capable of binding lipoproteins that transport triglyceride and 
other esterified lipids (78, 79) and the placenta has lipase activity to liberate NEFA from 
triglyceride (80, 81). Indeed, studies from guinea pig indicate that more of the NEFA available to 
placenta is derived from maternal TG than from circulating NEFA (82). Increased lipase activity 
has been measured from placenta from diabetic pregnancies and the higher availability of 
maternal lipids may be associated with the increased fetal weight gain that is characteristic of 
gestational diabetes (80). Placental lipases may have increased selectivity to release long-chain 
18 
 
poly-unsaturated fatty acids from triglyceride because lipoprotein lipases preferentially hydrolyze 
the sn-2 position which is more likely to be unsaturated (17). Different placental cell types may 
also contribute to making fatty acids available for uptake. For example, placental macrophages 
express high levels of lipoprotein lipase, and endothelial cell expression of endothelial lipase may 
contribute significantly to hydrolysis of maternal lipoproteins throughout gestation (83). 
After fatty acids have been liberated from maternal TG at the microvillous membrane, 
they are available for placental transport and metabolism. Placental fatty acid binding proteins 
(FABPs) and fatty acid transport protein (FAT/CD36) may facilitate fatty acid transport down a 
concentration gradient (83). In humans, the concentration of NEFA in maternal blood is about 
three-fold higher than in fetal blood at term, but fetal blood has a higher concentration of albumin 
and a higher concentration of bound NEFA than maternal blood (17, 84). In this way, the fetus 
can exert a steeper effective concentration gradient to increase fetal fatty acid uptake which is 
particularly important during late gestation when fetal fat accretion is greatest in humans. The 
fatty acid transport proteins Fatp1 (Slc27a1) and Fatp4 (Slc27a4), two members of the very long-
chain acyl-CoA synthetase family, are also expressed in placenta (83) and may help shuttle acyl 
groups to particular metabolic fates within the placenta (85-88). Acyl-CoA thioesterases, which 
hydrolyze acyl-CoAs to free fatty acids and free coenzyme A in several cellular compartments, 
could conceivably play a role in making fatty acids available for transport as a free acid. One 
report has detected long-chain acyl-CoA thioesterase activity in BeWo human placental 
choriocarcinoma cells, and treatment of cells with particular fatty acids resulted in increased 
thioesterase activity and enhanced expression of PPARγ target genes (89). Another way acyl 
groups could be transported across the placenta is as acylcarnitine species. Transacylation of 
long-chain acyl-CoAs to acylcarnitines is essential for long-chain fatty acid transport into the 
mitochondrial matrix for β-oxidation (Fig. 1). The organic cation/carnitine transporter Octn2 is 
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expressed in placenta (90), and carnitine levels in cord blood are higher than in maternal blood 
(91). Moreover, in Part 4, evidence for acyl transfer from mother to fetus as acylcarnitines is 
presented. 
1.5.3.2  Metabolic fates of lipids within the placenta 
It has been speculated that NEFA transported into placenta are likely esterified to 
placental TG, and fetal TG levels may be better correlated with placental TG content than with 
maternal circulating lipid concentrations (75). Placental TG is comprised of that which has been 
taken up from maternal lipoproteins (VLDL) and also from placental TG synthesis. Studies of rat 
placenta demonstrated that NEFA could be esterified in a concentration-dependent manner (92). 
Placental TG content increased with progressing gestation, and a severe 48h fast also dramatically 
increased placental TG levels. Radiolabeled oleate was readily incorporated into TG, 
diacylglycerol, and cholesterol esters. There was no difference in the capacity for oleate 
esterification in fed vs fasted placentae, suggesting that the capacity for esterification cannot 
account for the difference in TG content and that the availability of maternal circulating lipids 
may be a more important regulator of placental TG content (92). A recent computational-
experimental approach used human placental ex vivo perfusions to model fatty acid uptake and 
transfer to the fetus (93). Placental uptake of fatty acids was largely dependent on placental 
metabolism of fatty acids rather than on microvillous membrane transport. The idea here is that 
when membrane transport capacity is high, the transmembrane gradient becomes small and the 
rate-determining factor becomes metabolism of the molecules of interest. Rates of fatty acid 
delivery to the fetal compartment were determined by placental metabolic pools and basal 
membrane transport (93). Further studies are needed to characterize the metabolic fates of 
placental fatty acids to better understand how these pools of lipids affect transport and whether 
fatty acid β-oxidation provides energy for placental nutrient transport. The observation that the 
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placenta may serve as metabolic pool for fatty acid delivery to the fetus is in agreement with the 
observation that glucose transport is also best understood in terms of a three-pool model where 
maternal, placental, and fetal metabolism are all taken into consideration (94). 
The capacity for and role of fatty acid oxidation in the placenta is not well understood. 
Human placenta was found to express the necessary enzymatic machinery for mitochondrial β-
oxidation (95, 96). Oleate oxidation by placental explants has been observed—although at lower 
rates than oleate esterification into neutral lipids—and was moderately increased with gestational 
age (92). This study, however, cannot account for differences in fatty acid utilization among 
placental cell types, which may account for some of the differences in fatty acid oxidation vs 
esterification. To this end, isolated trophoblasts can oxidize fatty acids as a significant metabolic 
fuel, but the contribution of other cell types is less well understood (95). Broadly, placental 
metabolism can affect nutrient availability by sequestering nutrients from the dam, by storing 
nutrients for subsequent delivery to the fetus, or by providing new or bio-transformed substrates 
for fetal nutrition that were produced as a result of placental metabolism (in the case of fatty 
acids, the production and transport of acylcarnitines or ketone bodies as possible metabolites for 
transport). 
1.5.3.3  Transport and availability of polyunsaturated fatty acids 
Now the transport and availability of a class of fatty acids that are particularly important 
for mammalian brain development—the long-chain polyunsaturated fatty acids (PUFAs)—will be 
discussed. Long-chain polyunsaturated fatty acids (LCPUFAs) can be derived from the essential 
fatty acids linoleic acid (18:2 n-6) and α-linolenic acid (18:3 n-3), but during pregnancy, 
LCPUFAs may become conditionally essential if dietary intake and biotransformation cannot 
keep pace with fetal demand (17). Arachidonic acid (20:4 n-6), eicosapentaenoic acid (20:5 n-3), 
and docosahexaenoic acid (DHA) (22:6 n-3) are the metabolically most important LCPUFAs, and 
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the very presence of these essential fatty acids in fetal tissues stands as evidence for fetal uptake 
and accumulation (17). In the human fetus, lipid deposition increases exponentially with 
gestational age until it reaches the maximal rate of accretion of 7g/day just before term (25), and 
DHA requirements triple from 100 mg/day to 300 mg/day from mid to late gestation (17). The 
measurement of elevated concentrations of LCPUFAs in fetal blood and tissues has been called 
biomagnification (17). One method of bioaccumulation of these lipids is the conversion of NEFA 
into phospholipids within the fetal liver to trap select fatty acids and accumulate them from the 
circulation (97). Similarly, other tissues, most notably adipose, may serve as a pool for these 
lipids. Remarkably, 16-fold more DHA is stored in fetal adipose tissue than is deposited in fetal 
brain, and this accumulation of DHA in adipose is specific to fetal adipose tissue and is not 
reflective of maternal adipose tissue DHA content (17). 
The placenta also likely plays a major role in the selective uptake of PUFAs. 
Administration of 13C-labeled fatty acids to pregnant women just prior to cesarean delivery 
revealed that placenta preferentially accumulated DHA relative to other labeled fatty acids 
(palmitate, oleate, and linoleate) at the concentrations tested at this time just prior to parturition 
(84). Furthermore, [13C]DHA was esterified in similar proportions in cord blood NEFA, 
phospholipids, and triglyceride, while other tracers were primarily retained as NEFA or 
incorporated into TG (84). These studies provide evidence for selective channeling of individual 
fatty acids into different placental pools and eventually into the fetal circulation. One way that 
DHA has been shown to cross membranes is via MFSD2a, the recently characterized 
lysophospholipid transporter that facilitates DHA accumulation in the developing brain (98, 99). 
Without this transporter, mice exhibit microcephaly, impaired blood-brain barrier function, 
neuronal cell loss, and cognitive deficits (98, 99). Placental expression of MFSD2a, the 
lysophosphatidylcholine-DHA transporter, was found to be decreased in women with gestational 
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diabetes, and low levels of the DHA transporter were found to correlate with low levels of DHA 
in cord serum total lipids, although these levels still exceeded maternal circulating levels (100). 
Placental elongation/desaturation is one way that fetal levels of LCPUFAs could be 
accumulated over maternal levels; however, there is little evidence of this activity in placenta 
(101). Fetal and neonatal liver microsomes have the capacity to elongate and desaturate fatty 
acids (101, 102). Additionally, isotopic labeling studies in human infants administered labeled 
linoleic (18:2 n-6) and linolenic (18:3 n-3) acid resulted in labeled PUFAs in plasma fatty acids 
and phospholipids (97, 103). Mice lacking Elovl2, a PUFA elongase, were used to characterize 
the maternal provision of and neonatal requirements for DHA (104). These mice exhibit a 
systemic deficiency in DHA, including a 90% suppression in serum DHA concentrations that can 
be rescued by dietary DHA supplementation. Importantly, neonatal heterozygous mice reared by 
DHA-deficient null dams were able to compensate via neonatal synthesis of DHA, although the 
exact timing of when this capacity is established is not fully known (104). Altogether, these 
examples demonstrate that there are multiple mechanisms in place to ensure adequate fetal uptake 
or neonatal synthesis of essential fatty acids required for mammalian brain development. 




1.6  Genetic Models of Impaired Mitochondrial Nutrient Transport 
 To determine the requirements of mitochondrial pyruvate metabolism and mitochondrial 
β-oxidation of long-chain fatty acids in oxidative metabolism in cultured cells and in vivo during 
mouse development, loss-of-function alleles were generated for two essential components of the 
transport processes by which pyruvate and long-chain acylcarnitines enter the mitochondrial 
matrix: the mitochondrial pyruvate carrier (MPC) component, Mpc1, and carnitine 
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palmitoyltransferase 2, Cpt2 (Fig. 1). Carnitine palmitoyltransferase 2 is an obligate component 
of the long-chain fatty acid carnitine shuttle in mitochondria that converts acylcarnitines back to 
acyl-CoAs that can enter the β-oxidation pathway, and Cpt2 will be discussed in further detail in 
Part 3 and Part 4. Here the history of the discovery of the mitochondrial pyruvate carrier is 
discussed as the molecular identity of this non-canonical mitochondrial carrier was only identified 
in 2012. In Part 2, the genetic requirement for mitochondrial pyruvate metabolism via the MPC 
during fetal mouse development is described. 
 
1.6.1  Sources and Fates of Mitochondrial Pyruvate 
Pyruvate is an important metabolite that lies at the intersection of carbohydrate, lipid, and 
amino acid catabolic and anabolic pathways (Fig. 1). Dysregulation of carbon metabolism 
between these fates is a hallmark of many metabolic disorders including diabetes, obesity, and 
cancer (105, 106). Most notably, pyruvate is the end product of glycolysis, and the transport of 
pyruvate from the cytoplasm into mitochondria allows for its oxidative decarboxylation to acetyl-
coenzyme A (CoA) via the pyruvate dehydrogenase complex. Mitochondrial acetyl-CoA is 
oxidized to carbon dioxide through the tricarboxylic acid (TCA) cycle which generates reducing 
equivalents for ATP production and provides the biosynthetic precursors of lipids, amino acids, 
and glucose (Fig. 1). 
The sources and fates of pyruvate depend upon cell-type-specific processes and 
physiological state. For example, pyruvate may be converted to oxaloacetate via pyruvate 
carboxylase in the first step of gluconeogenesis in fasting liver. Pyruvate that enters the TCA 
cycle may be siphoned off as citrate to support de novo lipogenesis in the cytoplasm of 
hepatocytes and adipocytes. In the central nervous system, neurons may convert astrocyte-derived 
lactate to pyruvate for oxidative phosphorylation. Although the fate of mitochondrial pyruvate 
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depends upon cell type and physiological state, the transport of pyruvate across the inner 
mitochondrial membrane (IMM) and into the mitochondrial matrix in all cells is mediated by the 
mitochondrial pyruvate carrier (MPC). Substrate partitioning is a fundamental way to regulate 
metabolic pathways. For a transport process to be a metabolic control point, it may be the rate-
limiting step (as in the case of the carnitine shuttle for mitochondrial β-oxidation of fatty acids) or 
there may be physiological mechanisms for activation and inhibition of the transporter (107). The 
MPC was first characterized in 1971, but its molecular identity remained a mystery for 40 years 
(reviewed in (108, 109)). Now that the identity of the genes encoding the MPC have been 
determined, it is possible to directly investigate mechanisms of regulation of the MPC. 
 
 
1.6.2  Identification of the Mitochondrial Pyruvate Carrier (MPC) 
While pyruvate, a weak acid, can freely diffuse across the IMM, the concentration of 
undissociated acid is very low at physiological pH (107, 110). Evidence for the presence of a 
specific transporter for pyruvate was first demonstrated in 1971 when pyruvate uptake into 
isolated rat liver mitochondria was shown to follow saturation kinetics and to be pH-dependent, 
with higher pyruvate import at acidic pH (111). The finding that pyruvate transport was coupled 
to a proton gradient was rationalized as a way to provide actively respiring mitochondria with 
additional fuel in a positive feedback loop (111). Despite this evidence, some researchers 
remained skeptical of the presence of a pyruvate transporter until a specific chemical inhibitor (α-
cyano-4-hydroxycinnamate) was identified in 1974 (112). The identification of a specific MPC 
inhibitor allowed for better characterization of pyruvate transport kinetics, including the ability to 
distinguish MPC transport activity from free diffusion of pyruvate or the activity of other 
transporters (113). However, the molecular identity of the MPC remained a mystery. Several 
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different groups worked to isolate the MPC (114, 115), including attempts to use immobilized 
inhibitor to purify MPC (116, 117), but none successfully identified the components of the 
mitochondrial pyruvate carrier. 
Many researchers expected that the mitochondrial pyruvate carrier would have sequence 
homology to other characterized mitochondrial carriers, such as the mitochondrial carrier family 
(MCF), of which there are 53 members in humans that have six transmembrane domains and are 
30-35 kDa in size (108, 118). Studies in yeast strains lacking the uncharacterized MCF members 
failed to identify the MPC, although one study identified a deletion strain lacking inhibitor-
sensitive pyruvate transport (119), but this carrier was later identified as the mitochondrial NAD+ 
transporter in yeast (120). 
 
Two groups, who were not actively trying to isolate the MPC, ultimately revealed the 
molecular identity of the MPC in 2012 (121, 122). Herzig et al. described that yeast strains 
lacking the MPC paralogs—Mpc1, Mpc2, (and Mpc3 in yeast)—had defects in lipoic acid 
biosynthesis and impaired pyruvate uptake into isolated mitochondria. Additionally, expression of 
mouse MPC1 and MPC2 in the bacteria Lactococcus lactis was sufficient for pyruvate uptake in a 
manner that was sensitive to membrane potential and to the known MPC inhibitor UK5099, an α-
cyanocinnamate compound (121). Bricker et al. show that Mpc1 and Mpc2 are approximately 15 
kDa by SDS-PAGE and that they are part of a ~150 kDa complex when separated by blue native-
PAGE that does not form in the absence of Mpc2. Mpc1 and Mpc2 have two to three predicted 
transmembrane domains and do not have sequence homology with members of the mitochondrial 
carrier family. Chromatographic purification and immunoprecipitation of tagged Mpc variants 
demonstrated that Mpc2 and Mpc3 are the major interacting proteins of Mpc1, and Mpc1 and 
Mpc3 are the major interacting proteins of Mpc2 (122). Another group has found that Mpc3, a 
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yeast paralog that does not seem to be conserved in higher eukaryotes, is expressed under 
different conditions from yeast Mpc2 such that Mpc3 replaces Mpc2 under stress conditions or 
when high respiration rates are required (123). That tissue-specific differential regulation of MPC 
subunits could be a mechanism of regulating mitochondrial pyruvate uptake and mitochondrial 
respiratory capacity in mammals is a tantalizing possibility. There is much to be learned about the 
structure and function of this non-canonical mitochondrial transporter (124, 125). 
 
1.6.3  Regulation of and Requirement for the MPC 
Both Herzig et al. and Bricker et al. demonstrated that yeast lacking Mpc1or Mpc2 
display growth defects on glucose media, non-fermentable carbon sources like glycerol, and a 
strong growth defect in the absence of leucine. Bricker et al. also show that loss of the MPC1 
ortholog in Drosophila is lethal when flies are switched to a sucrose-only diet. Characterization 
of metabolite changes in MPC1-deficient flies revealed decreased ATP, increased glucose and 
pyruvate, and decreased TCA intermediates. Bricker et al. identified two disease-causing point 
mutations in human MPC1, and re-expression of wild-type MPC1 was sufficient to rescue the 
defect in pyruvate oxidation in patient fibroblasts. Mutations in MPC1 cause devastating 
multisystem metabolic deficits characterized by hyperpyruvatemia and hyperlactacidemia even 
on low-carbohydrate diets, resulting in neurological defects and death early in childhood (126). 
Previously, defects in the MPC resembled deficiencies in the pyruvate dehydrogenase (PDH) 
complex, but no mutations in PDH components could be identified in these patients. The 
determination of the molecular identity of the MPC will allow better characterization of the 
regulation of the MPC and may lead to therapies to enhance mitochondrial pyruvate transport and 
oxidation in these patients. Additionally, knowledge about the role and regulation of the MPC 
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may have broader implications for understanding and/or treating pathologies such as cancer, 
diabetes, and ischemia/reperfusion injury. 
MPC1 had been previously named brain protein 44-like (Brp44L) from its abundance in 
brain and spinal cord cDNA libraries (127). Brp44L had also been detected at the protein level in 
a proteomics survey of the inner mitochondrial membrane from mouse liver (128). Brp44L 
(MPC1) and Brp44 (MPC2) were also detected in a proteomics study of the lysine acetylome in 
liver mitochondria, with one acetyl-lysine identified in MPC1 and 3 sites found in MPC2 (129). 
Brp44L mRNA expression has also been characterized in a model of tissue regeneration by 
studying expression in the spinal cord of geckos after tail amputation (127). In this study, MPC1 
(Brp44L) expression was found to be highest in brain, spinal cord, and liver, and in situ 
hybridization signal was confined to gray matter of the spinal cord. Expression of Brp44L 
increased 3 days after amputation, was highest after one week, and began to return to lower levels 
two weeks after injury (127). The authors had speculated that Brp44L might be involved in 
promoting the apoptotic events necessary for tissue remodeling in this system. Upregulation of 
the mitochondrial pyruvate carrier in regenerating tissue may be essential to promote rapid 
proliferation and may be coordinated with mitochondrial biogenesis. It is likely that the 
mitochondrial pyruvate carrier plays a similar role in fetal tissues during mouse development. 
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2. Requirement for the MPC in Mammalian Development 
 
Adapted from (130): Bowman CE, Zhao L, Hartung T, Wolfgang MJ. 2016. Requirement for the 
Mitochondrial Pyruvate Carrier in Mammalian Development Revealed by a Hypomorphic Allelic 
Series. Mol Cell Biol 36:2089-2104. 
 
2.1   Summary 
Glucose and oxygen are two of the most important molecules transferred from mother to 
fetus during eutherian pregnancy, and the metabolic fates of these nutrients converge at the 
transport and metabolism of pyruvate in mitochondria. Pyruvate enters the mitochondrial matrix 
through the mitochondrial pyruvate carrier (MPC), a complex in the inner mitochondrial 
membrane that consists of two essential components, MPC1 and MPC2. Here we define the 
requirement for mitochondrial pyruvate metabolism during development with a progressive 
allelic series of Mpc1 deficiency in mouse. Mpc1 deletion was homozygous lethal in mid-
gestation, but Mpc1 hypomorphs and tissue-specific deletion of Mpc1 presented as early perinatal 
lethality. The allelic series demonstrated that graded suppression of MPC resulted in dose-
dependent metabolic and transcriptional changes. Steady-state metabolomics analysis of brain 
and liver from Mpc1 hypomorph embryos identified compensatory changes in amino acid and 
lipid metabolism. Flux assays in Mpc1-deficient embryonic fibroblasts also reflected these 
changes, including a dramatic increase in mitochondrial alanine utilization. The mitochondrial 
alanine transaminase, GPT2, was found to be necessary and sufficient for increased alanine flux 
upon MPC inhibition. These data show that impaired mitochondrial pyruvate transport results in 





 Embryonic development in eutherian mammals is defined by ongoing metabolic 
interactions between mother and fetus. Placentas evolved a sophisticated suite of adaptations to 
ensure adequate nutrient, gas, and waste exchange between fetus and mother, as well as hormonal 
and immunological communication (38, 66). To meet the fetal requirements for nutrient and 
oxygen consumption during pregnancy, maternal cardiac output increases such that uteroplacental 
blood flow accounts for ~25% of total cardiac output (16). Glucose and oxygen are arguably the 
two most important molecules transferred from mother to fetus, both in terms of concentration 
and the multitude of physiological adaptations in place to ensure their adequate transport; 
however, the requirement for mitochondrial oxidative metabolism during embryonic development 
remains poorly defined. 
 While oxygen tension in utero is low relative to atmospheric levels, measurement of 
oxygen consumption and lactate uptake in fetal lamb provided evidence that the fetus is a net 
consumer rather than producer of lactate (14). Consistent with this, fetal myocardium consumes a 
large amount of lactate in addition to glucose, indicating that oxidative metabolism of 
carbohydrate is an important energy source in developing heart (47, 48). Additionally, lactate 
utilization is high in neonatal brain, and the capacity for lactate import is higher in neonatal brain 
than in adult (43). Together, these observations provide evidence for the importance of 
mitochondrial oxidative metabolism early in mammalian development. Supporting these 
metabolic preferences, a robust period of mitochondrial biogenesis has been characterized in mid-
gestation mouse embryos (63). Indeed, many mouse models deficient in genes involved in 
mitochondrial DNA metabolism, electron transport chain components, and mitochondrial 
biogenesis, fission, and fusion die during this time (embryonic day 8-13), (reviewed in (63)). 
These genetic models provide further evidence that mitochondrial oxidative metabolism plays an 
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essential role before parturition in meeting the bioenergetic and biosynthetic needs of the 
developing fetus. In fact, many inborn errors of metabolism in humans manifest early in postnatal 
life, suggesting that these metabolic insufficiencies can be somewhat mitigated in utero but are 
exacerbated after parturition in the absence of maternal exchange. 
 Oxygen, glucose, and lactate all coalesce at the transport and metabolism of pyruvate in 
mitochondria. Although the mitochondrial pyruvate carrier (MPC) has been characterized 
biochemically since the 1970s (111, 112), the molecular identity was only recently determined 
when two essential components, MPC1 and MPC2, were shown to be necessary and sufficient to 
promote pyruvate transport across a membrane (121, 122). Unlike any other mitochondrial 
transporter studied to date, yeast Mpc1 and Mpc2 are small 15 kDa proteins that are part of a 150 
kDa complex in the inner mitochondrial membrane as determined by blue native-polyacrylamide 
gel electrophoresis (BN-PAGE) (122, 124). While pyruvate is most notable as the end product of 
glycolysis in the cytosol, pyruvate lies at the intersection of carbohydrate, lipid, and amino acid 
catabolic and anabolic pathways. The transport of pyruvate into the mitochondrial matrix permits 
two main biochemical pathways: 1) its oxidative decarboxylation to acetyl-coenzyme A (CoA) 
via the pyruvate dehydrogenase complex or 2) its carboxylation to oxaloacetate via the biotin-
dependent pyruvate carboxylase. These two fates enable catabolic and anabolic pathways through 
the tricarboxylic acid (TCA) cycle to generate ATP and provide biosynthetic precursors of lipids 
and amino acids. Additionally, glucose can be derived from mitochondrial pyruvate and the 
cytosolic enzymes of gluconeogenesis in liver and kidney. Although the sources and fates of 
pyruvate depend upon cell-type-specific processes and physiological state, the transport of 
pyruvate across the inner mitochondrial membrane in all cells is mediated by the mitochondrial 
pyruvate carrier (MPC). 
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 Here we define the requirement for mitochondrial pyruvate metabolism during eutherian 
development with an allelic series for Mpc1 deficiency in mouse. Using a combination of steady-
state metabolomics and metabolic flux assays, we describe both tissue-specific and highly 
conserved compensatory adaptations to impaired mitochondrial pyruvate metabolism. 
Furthermore, substrate flux studies in cells derived from these genetic models define the 
metabolic requirement for mitochondrial pyruvate metabolism. These data provide evidence for 
significant crosstalk and counter-regulation between mitochondrial pyruvate utilization and other 
pathways of central carbon metabolism, highlighting the metabolic fate of pyruvate as a key 
regulatory node in carbohydrate, amino acid, and lipid metabolism. 
 
2.3 Materials and Methods 
Generation of Mpc1 conditional knock-in and deletion alleles in mice 
Mpc1 knock-in mice were generated by targeting loxP sequences to introns flanking exons 3 to 5 
of the mouse Mpc1 gene and targeting a transcriptional reporter construct to the 3’ untranslated 
region of Mpc1 (Fig. 2.S1A) by homologous recombination in C57Bl/6 embryonic stem cells by 
standard methods. To generate mice with a germline deletion of Mpc1, Mpc1lox/+ mice were bred 
to CMV-Cre transgenic mice, and deletion in Cre-negative F2 progeny was verified by PCR 
genotyping (Mpc1 D/+). Additionally, Mpc1lox/+ mice were bred to Nestin-Cre transgenic mice to 
delete Mpc1 specifically in the nervous system. Mpc1 knock-in (Mpc1 KI/+), Mpc1 deletion 
(Mpc1 D/+) and littermate controls were housed in a facility with ventilated racks on a 14h 
light/10h dark cycle with ad libitum access to a standard rodent chow (2018SX Teklad Global, 
18% protein). For timed matings, the presence of a copulatory plug in the morning was 




Ethical Statement  
All procedures were performed in accordance with the NIH’s Guide for the Care and Use of 
Laboratory Animals and under the approval of the Johns Hopkins Medical School Animal Care 
and Use Committee. 
 
Cell culture 
Mouse embryonic fibroblasts (MEFs) were obtained from timed pregnant dams by standard 
methods. Primary MEFs were maintained in DMEM (25mM glucose) supplemented with 10% 
fetal bovine serum and 1% pen/strep antibiotic (Invitrogen) at 37°C in a humidity-controlled 
incubator at 10% CO2.  For cell proliferation assays, MEFs were seeded in 35mm dishes at 
100,000 cells per well and cell number was counted every other day with regular media changes. 
 
Generation of GPT KO 293s 
HEK293T cells were grown in DMEM (25mM glucose) supplemented with 10% bovine calf 
serum and 1% pen/strep antibiotic and maintained as described above. Cells were transfected with 
plasmid expressing both hCas9 and hGPT1, hGPT2, or panGPT gRNA or hCas9 alone using 
FuGENE HD (Promega) transfection reagent according to manufacturer’s instructions. Selection 
with 7.5 µg/mL blasticidin was started 48 post-transfection and continued for two weeks. 
Individual clones were selected by limited dilution plating and screened for loss of GPT1, GPT2, 
or both by qRT-PCR, by genomic PCR and Sanger sequencing, and by functional assay. For 
rescue experiments, human GPT1 and GPT2 were cloned from HEK293T cell oligo(dT)-primed 
cDNA, were cloned into pEF6 expression vectors by InFusion Cloning (Clontech), and were 




CRISPR/Cas9 cloning strategy 
Human codon-optimized Cas9 expression vector was obtained from Addgene, plasmid #41815 
(131), and hCas9 was cloned into a pEF6 expression vector, downstream and in-frame with a 
nuclear-localized YFP, linked by a viral 2A bicistronic peptide, such that nls-YFP and Cas9 are 
expressed in approximate equimolar quantities. A 3x nuclear localization signal and a FLAG tag 
were also appended to the C-terminus of hCas9 to allow screening for loss of Cas9 protein in 
mutant cell lines. Guide RNAs (gRNAs) targeting human GPT1, GPT2, and a highly conserved 
site in both GPT1 and GPT2 were designed according to the recommendations of Mali et al. 
(131) and were computed as candidate unique gRNA targets. The gRNAs, including the U6 
promoter, were synthesized as 500bp gBlocks fragment (Integrated DNA Technologies) and were 
cloned into the pEF6-nls-YFP-2A-Cas9-3x-NLS-FLAG vector by InFusion Cloning (Clontech). 
 
Metabolic flux assays 
To measure glucose uptake, MEFs were plated in 24-well dishes and labeled with 0.5µCi [1,2-
3H]2-deoxy-glucose at a final concentration of 6.5mM 2-deoxy-glucose for 5, 10, and 20 minutes 
after 2h in KRH buffer (20mM HEPES, 136mM NaCl, 4.7mM KCl, 1.25mM MgSO4, 1.25mM 
CaCl2, 0.1% bovine serum albumin). After incubation, cells were washed 4x with KRH buffer 
and lysed with 0.3mL 1% TritonX-100 in PBS. Lysate was transferred to a vial containing 3mL 
of scintillation fluid, and counts were normalized to total protein as determined by bicinchoninic 
acid (BCA) assay (Thermo Scientific). 
To determine substrate incorporation into the total lipid fraction, MEFs were plated in 24-well 
dishes and labeled with radiolabeled substrates ([2-14C]pyruvate, [U-14C]L-glutamine, [U-14C]L-
alanine, or [3H]acetate) for 4h. Total lipids were extracted with 2:1 chloroform:methanol via the 
Folch method (132), and radioactivity was counted by liquid scintillation. For pyruvate, 
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glutamine, and alanine incorporation, 0.2µCi/mL of radioactivity was used, and 0.3µCi/mL for 
[3H]acetate, in serum-free DMEM containing 2.5 mM glucose, 2 mM glutamine (or 0.5 mM cold 
glutamine for glutamine-labeling experiments), 0.25 mM pyruvate, and 0.1 mM L-alanine. All 
counts were normalized to total protein as determined by BCA assay. For pharmacological 
inhibition of the MPC, cells were pre-incubated with 1µM UK-5099 (Santa Cruz Biotechnology) 
or 0.2% (v/v) DMSO vehicle for 4 hours, and 1µM UK-5099 or DMSO was included in the 
labeling media.  
 
Stable isotope labeling and LC-MS/MS Analysis 
Control and Mpc1 D/D primary MEFs were labeled with 2.5mM [2-13C]pyruvate (Cambridge 
Isotope Laboratories) in DMEM containing 2.5mM glucose, 2mM glutamine, and 0.1mM alanine 
for 30 minutes. Cell extracts were collected in ice-cold HPLC-grade 80:20 methanol: water with 
rapid quenching in liquid nitrogen. Cellular debris was pelleted by centrifugation, and the 
supernatant was dried by vacuum centrifugation prior to resuspension in 50% acetonitrile and 
analysis by LC-MS/MS. Targeted metabolic analysis were performed on an Agilent 6490 triple 
quadropole LC-MS/MS system with iFunnel and Jet-Stream technology (AgilentTechnologies, 
Santa Clara, CA) equipped with an Agilent 1260 infinity pump and autosampler. 
Chromatographic separation was performed on a Diamond Hydride column (150mm x 2.1 mm 
i.d., 4μm particle size, Microsolv, Eatontown, NJ). The LC parameters were as follows: 
autosampler temperature, 4°C; injection volume, 4 μl; column temperature, 35°C; and flow rate, 
0.4 ml/min. The solvents and optimized gradient conditions for LC were: Solvent A, 50% 
methanol with 0.05% acetic acid; Solvent B, 90% acetonitrile with 10mM ammonium acetate, 
pH=7.0; elution gradient: 0 min 99.5% B; 12–14 min 50% B; 15–19 min 0% B; post-run time for 
equilibration, 5 min in 99.5% B. MS/MS experiment was performed in positive/negative 
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switching electrospray mode as described previously (133). The optimized operating ESI 
conditions were: gas temperature 230°C (nitrogen); gas flow 15 L/min; nebulizer pressure 40 psi; 
sheath gas temperature 350°C and sheath gas flow 12 L/min. Capillary voltages were optimized 
to 4000V in both modes with nozzle voltages of 2000 V. All data processing was performed with 
Mass Hunter Quantitative Analysis software package. 
 
Steady-state metabolite analysis 
To reliably determine the concentration of short-lived metabolites in vivo, e17.5 embryos were 
rapidly frozen in liquid nitrogen in utero, and tissues were collected from frozen embryos for 
determination of tissue-specific metabolite concentrations by enzymatic methods or by unbiased 
metabolomics analysis as we have done previously (134, 135). For metabolomics analysis on 
e17.5 brain and liver from Mpc1 KI/KI embryos and WT littermate controls (n=8 for each tissue), 
metabolite concentrations are expressed as fold-change over WT, and Welch’s two-sample t-test 
was used to determine statistically significant differences between genotypes (p<0.05) To 
quantify total fatty acid content and the abundance of individual acyl species, fatty acids were 
measured by GC-MS as pentafluorobenzyl bromide esters with abundance normalized to protein 
content at the Kennedy Krieger Diagnostic Laboratory. 
Steady-state lactate, ATP, glycogen, triglyceride, and cholesterol concentrations were determined 
from rapid frozen embryonic tissue by enzymatic assay and were normalized to protein 
concentration as measured by BCA assay. Lactate (Sigma), cholesterol (Wako), and triglyceride 
(Sigma) assays were performed according to manufacturer’s instructions. Steady-state ATP was 
determined by a luciferase-based assay (Promega Enliten ATP assay). For glycogen 
measurements (136, 137), approximately 10mg of rapid frozen liver was homogenized on ice in 
300 µL 2M HCl and another piece of tissue from the same liver homogenized in 300 µL 2M 
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NaOH. Homogenates were boiled on a 100° heat block for 5 minutes and cooled to room 
temperature before neutralization with an equal amount of NaOH or HCl. Samples were spun at 
16,000g for 10 minutes at 4°, and supernatant was transferred to a new tube and used for glucose 
determination by hexokinase-coupled enzymatic assay (Sigma Glucose (HK) kit) per 
manufacturer’s instructions. The glucose content of base-homogenized control samples was 
subtracted from the corresponding acid-hydrolyzed samples in order to determine glycogen 
content in terms of µg glucose per mg protein, as determined by BCA assay. 
 
Immunoblotting 
Tissue lysates for SDS-PAGE were prepared by homogenization of tissue in RIPA buffer (50mM 
Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.25% deoxycholate) with 
protease inhibitor cocktail (Roche), followed by pelleting of insoluble debris at 13,000g for 15 
min at 4°C. Protein concentrations of lysates were determined by BCA assay (Thermo Scientific), 
and 30µg of lysate was separated by Tris-Glycine SDS-PAGE (15% polyacrylamide), unless 
otherwise noted. Proteins were transferred to PVDF membranes (Immobilon), blocked in 5% 
nonfat-milk TBST, and incubated with primary antibodies overnight. Primary antibodies used 
include: We generated and validated affinity-purified rabbit polyclonal antibodies against mouse 
Mpc1 and Mpc2; Complex V alpha subunit (Atp5a) mouse monoclonal at 1:1000 (ab14748); 
aconitase 2 (Aco2) rabbit polyclonal at 1:1000 (Cell Signaling 6922); heat shock chaperone 70 
(Hsc70) mouse monoclonal at 1:1000 (Santa Cruz sc-7298); MitoProfile total OXPHOS mouse 
monoclonal antibody cocktail at 1:500 (Abcam ab110413); phospho-mTOR (Ser2448) rabbit 
polyclonal at 1:1000 (Cell Signaling 5536); total mTOR rabbit polyclonal at 1:1000 (Cell 
Signaling 2983); phospho-AMPK (Thr172) rabbit polyclonal at 1:1000 (Cell Signaling 2535); 
total AMPK rabbit polyclonal at 1:1000 (Cell Signaling 5831). Cy3-conjugated anti-mouse 
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(Invitrogen) or Cy5-conjugated anti-rabbit (Invitrogen) secondary antibodies at 1:1500, or 
horseradish peroxidase (HRP)-conjugated anti-mouse (GE Healthcare NA931V) or anti-rabbit 
(GE Healthcare NA934V) secondary antibodies at 1:2000 were incubated with washed 
membranes, and proteins were visualized with Amersham Prime enhanced chemiluminescent 
substrate (GE Healthcare) or epifluorescence on an Alpha Innotech MultiImage III instrument. 
Protein abundance was quantified using Alpha Innotech FluorChem Q software (Santa Clara, 
CA) and was normalized to Hsc70 expression. 
 
Quantitative real-time-PCR and mtDNA content determination 
Total RNA was extracted using Trizol reagent, per manufacturer’s recommendations (Life 
Technologies) and was further purified using the RNeasy Mini kit (Qiagen). RNA was quantified 
by NanoDrop, and cDNA was synthesized using random primers and MultiScribe High-Capacity 
cDNA reverse transcription kit (Applied Biosystems). RT-PCR was performed using 10 ng of 
template cDNA in a 20µL reaction using Bio-Rad SsoAdvanced SYBR Green master mix with 
primers specific to the genes of interest (Table 2.1). All PCR reactions were carried out in a Bio-
Rad CFX Connect Thermocycler and were concluded with a melt-curve determination step. 
Expression data from mouse tissues was normalized to the average Ct values for 4 reference 
genes: 18S, Rpl22, β-actin, and Gapdh, and data are expressed as 2-dCt and shown relative to e17.5 
or relative to wild-type, as appropriate. 
Genomic DNA (gDNA) was isolated from Trizol extracts as per manufacturer’s 
recommendations, and 10 ng of template gDNA was used per 20µL reaction using Bio-Rad 
SsoAdvanced SYBR Green master mix with primers specific to the mitochondrially-encoded Nd1 
(NADH dehydrogenase subunit 1) and to two nuclear loci. Nd1 abundance was calculated by the 
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2-dCt method, relative to the average Ct value of the two nuclear reference genes, and data are 
expressed as fold-change relative to controls (mean ± SEM). 
Mouse glucose metabolism qPCR arrays (Qiagen RT2 Profiler PCR arrays) were prepared with 
10ng template cDNA per 20µL reaction using Bio-Rad SsoAdvanced SYBR Green master mix, 
as per manufacturer’s instructions. Gene expression was calculated relative to the provided 
reference genes using the 2-dCt method. 
 
Transmission electron microscopy 
Liver was excised and fixed in 2% paraformaldehyde, 2% glutaraldehyde-PBS solution and was 





Tissue-specific developmental regulation of the mitochondrial pyruvate carrier 
The high dependence of the fetus on glucose metabolism and the tremendous increase in 
blood flow/oxygen delivery via the placenta converge at mitochondrial pyruvate metabolism. A 
period of robust mitochondrial biogenesis occurs during mid-gestation, coincident with the 
initiation of organogenesis, and persists through early postnatal life (63). Therefore, we 
characterized MPC expression across development by immunoblotting for mouse Mpc1 and 
Mpc2 in three metabolically distinct tissues (brain, heart, and liver) from late-gestation 
(embryonic day 17.5 (e17.5)) through the first week of postnatal life (through postnatal day 7 
(P7)) and into adulthood (8 weeks) (Fig. 2.1A). Atp5a, a component of the ATP synthase 
(Complex V) and resident of the inner mitochondrial membrane, and aconitase 2 (Aco2), a 
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mitochondrial matrix enzyme, were used as additional markers. In all three tissues, dramatic 
upregulation of the mitochondrial pyruvate carrier components, Mpc1 and Mpc2, was observed 
across development at the level of both protein and transcript (Fig. 2.1B). We observed tissue-
specific differences, however, in the timing of increased MPC abundance and subtle differences 
in the ratio of Mpc1 to Mpc2 protein across development (Fig. 2.2A). For example, in liver, 
approximately equal ratios of Mpc1: Mpc2 were seen across development. Mpc2 expression in 
brain was higher than Mpc1 early during development, and Mpc1 increased dramatically by P14. 
MPC expression in heart followed a different trend, where Mpc1 was expressed more 
constitutively across development while Mpc2 increased later, around P6-7. Interestingly, there 
were no differences detected in the ratio of Mpc1: Mpc2 in adult cerebral cortex, heart, or liver 
(Fig. 2.2B). These data show tissue-specific regulation of the mitochondrial pyruvate carrier 
across development. 
 
Mpc1 is required for mammalian embryonic development and efficient pyruvate 
metabolism 
To define the metabolic requirement for mitochondrial pyruvate metabolism in vivo, we 
generated mice with a deletion allele of Mpc1 (Mpc1 D). The last three exons (encoding 84/109 
amino acids) of Mpc1 were flanked by loxP sites that were deleted by Cre-mediated 
recombination in the germline to generate a line of mice carrying the Mpc1 deletion allele (Fig. 
2.S1A). We observed expected Mendelian ratios of inheritance of the Mpc1 deletion allele in late-
gestation e17.5 embryos; however, Mpc1 D/D e17.5 embryos were significantly developmentally 
delayed compared to wild-type (WT) and D/+ littermates and did not appear to be viable (Fig. 
2.3A and B). These data are consistent with the deletion of other MPC components (138, 139). 
40 
 
Rapid cell division requires biosynthesis of nucleic acids, proteins, and lipids, and 
mitochondrial metabolism supports these anabolic processes (140-142). To determine the 
requirements for the mitochondrial pyruvate carrier in mitochondrial metabolism, we 
characterized the flux of radiolabeled substrates in mouse embryonic fibroblasts (MEFs) null for 
Mpc1. Despite the embryonic lethality, primary Mpc1 D/D MEFs were successfully isolated and 
cultured. Mpc1 D/D MEFs did not exhibit altered growth rates under standard culture conditions 
(Fig. 2.3C). As expected for a block in mitochondrial pyruvate metabolism and an increased 
glycolytic demand, Mpc1 D/D MEFs exhibited increased glucose uptake, analogous to the 
Pasteur effect (Fig. 2.3D). With few exceptions, in order for the carbons of glucose, pyruvate, or 
glutamine to effectively contribute to de novo fatty acid synthesis, these substrates must first be 
metabolized in mitochondria. To determine the mitochondrial flux of pyruvate and glutamine in 
Mpc1 D/D MEFs, we measured the rate of 14C-labeled substrate incorporation into the total lipid 
fraction. Pyruvate contribution to the total lipid fraction was dramatically reduced in Mpc1 D/D 
MEFs, as expected (Fig. 2.3E). Glutamine incorporation was unchanged in Mpc1 D/D MEFs 
relative to controls (Fig. 2.3E), suggesting that glutamine anaplerosis was not compensating for 
the loss of mitochondrial pyruvate metabolism in these non-transformed cells. [3H]acetate 
incorporation into lipid was included as a control (Fig. 2.3E) to demonstrate that these cells have 
equal capacity for de novo fatty acid synthesis from a substrate that does not require 
mitochondrial metabolism to provide cytosolic acetyl-CoA. These metabolic adaptations 
demonstrate the plasticity of cellular metabolism to maintain cellular proliferation in cultured 





Mpc1 hypomorphic allelic series reveals requirements for mitochondrial pyruvate 
metabolism in embryonic development  
The floxed Mpc1 gene used to generate the deletion allele was designed to have higher 
utility by the introduction of a reporter in the 3’ untranslated region of Mpc1 (Fig. 2.S1A). 
Unexpectedly, inclusion of this reporter resulted in a hypomorphic allele, such that steady-state 
levels of Mpc1 transcript and protein were dramatically reduced in heterozygous knock-in 
animals (KI/+) and below the level of detection by immunoblotting in homozygous knock-in 
animals (KI/KI) (e.g. >30-fold suppression in heart) (Fig. 2.4A and B). We did not observe a loss 
of Mpc2 mRNA (Fig. 2.4B) but Mpc2 protein was not present in the absence of Mpc1 protein 
(Fig. 2.4A). Inclusion of the reporter directly following the stop codon resulted in an allele-
specific suppression of transcript abundance. To assess the degree to which Mpc1 KI/KI 
functionally suppresses pyruvate metabolism, we derived Mpc1 KI/KI primary MEFs and 
measured the contribution of radiolabeled pyruvate to de novo lipid synthesis. Mpc1 KI/KI MEFs 
had reduced incorporation of radiolabeled pyruvate into lipids but not to the same degree as Mpc1 
D/D MEFs (Fig. 2.4C). Treatment of WT and Mpc1 KI/KI MEFs with 1μM UK-5099, a 
pharmacological inhibitor of the MPC, reduced pyruvate incorporation into the total lipid fraction 
to the same level of suppression observed in Mpc1 D/D MEFs (Fig. 2.4C). Consistent with an 
intermediate pyruvate transport capacity in Mpc1 KI/KI MEFs, these cells also exhibited an 
intermediary glucose uptake phenotype, more than WT but less than D/D (Fig. 2.3D). Although 
the mitochondrial pyruvate carrier could not be detected by immunoblotting, Mpc1 KI/KI mice 
survived through gestation and died in the early perinatal period (Fig. 2.4D).  Consistent with the 
substantive anabolic role of glucose in mammalian development, late-gestation Mpc1 KI/KI 
homozygotes were 22% smaller than littermate controls (Fig. 2.4E). These data demonstrate that 
the Mpc1 knock-in allele is hypomorphic and significantly reduces, but does not ablate, 
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mitochondrial pyruvate flux. Additionally, a very small fraction of Mpc1 is sufficient for 
embryonic development but not perinatal survival. 
Mutations in human MPC1 cause devastating multisystem metabolic deficits 
characterized by hyperpyruvatemia and hyperlactacidemia, resulting in neurological defects and 
death early in childhood (126). Indeed, we observed an accumulation of lactate in brain of Mpc1 
KI/KI e17.5 embryos with only slight elevations in liver (Fig. 2.4F). Fetal liver has a high degree 
of accessibility to the maternal circulation, and, as such, lactate levels may be more efficiently 
cleared from this tissue in Mpc1 KI/KI late-gestation embryos. Neither Mpc1 KI/KI brain nor 
liver demonstrated a suppression in ATP concentration (Fig. 2.4G).  Consistent with these data, 
we did not find alterations in canonical energy sensing pathways in Mpc1 KI/KI embryos (Fig. 
2.5A). The lactate accumulation and perinatal lethality observed in the Mpc1 hypomorph mouse 
model closely resemble human inborn errors in MPC1, and this model permits study of metabolic 
compensation and pathologies associated with MPC deficiency. 
Next we wanted to understand if the loss of such a critical component of mitochondrial 
metabolism affected other mitochondrial components. We did not observe differences in 
mitochondrial DNA content in Mpc1 KI/KI cerebral cortex, heart, or liver compared to controls 
(Fig. 2.5B). Additionally, there were no differences in mitochondrial protein abundance in Mpc1-
deficient tissues (Fig. 2.5C). These data suggest that canonical mitochondrial structural 
components remain largely intact upon MPC deficiency. 
Interestingly, we observed that the severity in suppression of Mpc1 transcript abundance 
in Mpc1 KI/KI mice varied in a tissue-specific manner, such that Mpc1 transcript was most 
severely decreased in liver (11% remaining) while more Mpc1 steady-state transcript remained in 
brain (25% remaining) (Fig. 2.6A). To gain perspective on the amount of Mpc1 transcript 
remaining in KI brain, we crossed Mpc1 KI/+ mice to Nestin-Cre transgenic mice (134, 143) to 
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produce mice with tissue-specific deletion of Mpc1 in the developing nervous system. Overt 
phenotypes of Nestin; Mpc1 knockout (KO) late-gestation embryos, such as e17.5 body weight 
and perinatal survival, were not different from homozygous Mpc1 KI littermate embryos (Fig. 
2.6B); however, Mpc1 transcript abundance was further reduced in Nestin; Mpc1 KO cortex 
(<4% of WT) compared to Mpc1 KI/KI cortex (Fig. 2.6A). Surprisingly, given the putative 
dependence of the nervous system on carbohydrate oxidation, the tissue-specific deletion of 
Mpc1 in the nervous system was compatible with mammalian development. 
In order to further define the role of Mpc1 in embryonic development we expanded the 
Mpc1 allelic series by crossing Mpc1 KI/+ and Mpc1 D/+ mice to generate Mpc1 D/KI mice 
(Fig. 2.6C). In liver and heart of Mpc1 KI/KI embryos, <12% of WT levels of Mpc1 expression 
remained. Due to the codominant expression of the Mpc1 gene, the deletion of Mpc1 in the 
context of the hypomorphic Mpc1 KI allele (D/KI) further sensitized Mpc1 expression and 
suppressed Mpc1 abundance by approximately half. This left only 7% expression of Mpc1 in 
heart and liver and 15% in brain (Fig. 2.6A). Lowering Mpc1 expression to this degree did not 
further perturb embryonic development by e17.5 body weight or viability (Fig. 2.4C and Fig. 
2.S1B). Additionally, further suppression of Mpc1 expression in D/KI embryos and tissue-
specific deletion of Mpc1 in the nervous system did not affect mitochondrial DNA content (Fig. 
2.5B) nor the abundance of mitochondrial proteins (Fig. 2.6D). These data further support the 
observation that a very small amount of pyruvate transport in mitochondria by the MPC is 






Mitochondrial pyruvate carrier deficiency alters central carbon metabolism in a tissue-
specific manner in vivo 
Pyruvate-mediated anaplerosis is particularly relevant to mammalian pregnancy that 
relies heavily on glucose as the main macronutrient. It is generally thought that circulating fatty 
acids are not readily oxidized by fetal tissue (144), although mice null for enzymes in the rate-
setting step of mitochondrial β-oxidation of long-chain fatty acids (Cpt1a and Cpt1b) exhibit 
embryonic lethality before e10 (145, 146). The extent to which fatty acids and other lipids are 
able to cross the placenta and contribute to lipid accumulation in the fetus is also contended and 
varies from species to species (24, 147). Nevertheless, de novo fatty acid synthesis from glucose, 
due to its abundance and importance as a biosynthetic and bioenergetic substrate in utero, is a 
significant source of lipid synthesis in late-gestation embryos. Because we observed dramatic 
differences in de novo lipid synthesis from pyruvate in Mpc1 KI/KI and D/D MEFs (Fig. 2.4C), 
we hypothesized that Mpc1 KI/KI embryos may also exhibit defects in fatty acid synthesis. 
Indeed, we observed decreased total fatty acid content by GC-MS (Fig. 2.S2) and dramatically 
lower triglyceride levels in Mpc1 KI/KI livers, with a slight compensation via increased total 
cholesterol content (Fig. 2.7A-C). Glycogen content was not affected (Fig. 2.7D). Transmission 
electron microscopy of e17.5 Mpc1 KI livers revealed fewer and smaller lipid droplets than WT 
littermates (Fig. 2.7E). Consistent with mitochondrial protein and DNA content across tissues, 
there were no abnormalities in mitochondrial abundance, size, or morphology in fetal hepatocytes 
(Fig. 2.7E). Together, these results suggest that Mpc1 deficiency alters lipid metabolism in vivo 
and further underscore the notion that the MPC-dependent metabolic fate of pyruvate is an 
important regulatory node in central carbon metabolism. 
Given the central role of mitochondrial pyruvate flux in carbohydrate metabolism, we 
profiled genes of glucose metabolism by qRT-PCR arrays in WT and Mpc1 KI/KI brain, heart 
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and liver (Fig. 2.S3). Although there were multiple small tissue-specific changes in several genes, 
the transcript for phosphoenolpyruvate carboxykinase (PEPCK), Pck, was consistently up-
regulated across tissues. Therefore, we again took advantage of the Mpc1 allelic series to 
understand the role of a graded defect in Mpc1 on Pck expression. Interestingly, in liver, the 
greater suppression in Mpc1 expression resulted in a concomitant increase in Pck1 expression, 
which encodes cytosolic PEPCK (Fig. 2.7F). Pck2, which encodes mitochondrial PEPCK, also 
increased upon decreasing Mpc1 expression, however not to the same extent as Pck1 (Fig. 2.7F). 
These data are consistent with recent reports that glucose deprivation results in an increase in Pck 
expression (148, 149) which promotes metabolic flexibility when nutrients are limiting (150, 
151). Also, these data show the utility of assessing a phenotype across a series of genetic 
perturbations. 
To probe the global metabolic effects of loss of the mitochondrial pyruvate carrier in 
mammalian development, unbiased steady-state metabolomics analysis was conducted on brain 
and liver of late-gestation Mpc1 KI/KI and WT littermate embryos. To ensure stable steady-state 
measurements, the embryos were snap frozen in liquid nitrogen in utero and subsequently 
genotyped and dissected frozen. In brain and liver, 416 and 541 total metabolites were identified, 
respectively, and of these, 155 and 157 were found to be significantly altered between Mpc1 
KI/KI embryos and WT controls (p<0.05 as determined by Welch’s two-sample t-test). The entire 
list of differentially regulated metabolites is included in Table 2.S1. Of those metabolites 
differentially regulated in Mpc1 KI/KI brain, amino acid-related metabolites were over-
represented as a class, while lipids were enriched among differentially regulated metabolites in 
liver (Fig. 2.8A). Furthermore, of the 86 metabolites differentially regulated in both liver and 
brain, 75 were changed in the same direction in Mpc1-deficient brain as in liver, highlighting that 
the consequences of impaired mitochondrial pyruvate metabolism are highly conserved in 
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embryonic brain and liver. For example, lactate and pyruvate were both dramatically up-regulated 
in Mpc1 KI brain and liver, with greater accumulation of these metabolites in brain than in liver 
(Fig. 2.8B), consistent with the enzymatic measurement of lactate in Fig. 2.4F. Steady-state 
concentrations of TCA cycle intermediates were down in both Mpc1 KI tissues, and glucose 
levels were down in Mpc1 KI liver. These observations, together with the metabolic flux data 
above, provide evidence for enhanced glycolysis upon impaired mitochondrial pyruvate 
metabolism. 
 
Amino acids provide anaplerotic compensation upon impaired mitochondrial pyruvate 
transport  
Several interesting changes were noted in amino acid metabolism in Mpc1 KI/KI tissues. 
Broadly, amino acids that are catabolized to or synthesized from TCA cycle intermediates were 
downregulated, while those that can be derived from glycolytic intermediates were up-regulated 
in both tissues (Fig. 2.8B). Hypotaurine, an amino acid derivative that may function as a 
neurotransmitter or antioxidant in addition to its role in osmolyte balance (152, 153), was the 
most dramatically up-regulated metabolite in Mpc1 KI/KI brain at more than 15-times the 
concentration in WT brain (Fig. 2.8B). The high levels of hypotaurine are likely a consequence of 
and response to the hyperosmotic stress that lactate accumulation may cause (152). 
Alanine was the most dramatically downregulated metabolite in Mpc1 KI/KI brain and 
was also found to be significantly downregulated in liver (Fig. 2.8B). Glutamine was the second 
most-downregulated metabolite in Mpc1 KI/KI brain, and glutamate was also decreased, 
suggesting that Mpc1-deficiency in developing brain likely affects neurotransmitter synthesis 
along with macronutrient metabolism (Fig. 2.8B). In agreement with the changes in steady-state 
amino acid concentrations observed in vivo, alanine and glutamate were also downregulated in 
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primary Mpc1 D/D MEFs (Fig. 2.8C). Aspartate was slightly increased in Mpc1 D/D MEFs, 
which may be consistent with a role for cytosolic pyruvate in stimulating aspartate synthesis to 
enable proliferation in cells with mitochondrial deficiencies (154). 
To better understand how impaired mitochondrial pyruvate transport contributed to 
alterations in amino acid concentrations, 13C-tracer experiments were conducted on primary 
Mpc1 D/D MEFs. When labeled with [2-13C]pyruvate, the abundance of m+1 labeled TCA cycle 
intermediates in Mpc1-deficient cells was decreased as expected (Fig. 2.8D). Additionally, 
labeling of amino acids that can be derived from the TCA cycle (glutamate and aspartate, for 
example) was reduced in Mpc1 D/D MEFs relative to WT controls. Interestingly, m+1 labeling of 
alanine from pyruvate was dramatically reduced along with the decrease in steady-state alanine 
(Fig. 2.8D). Alanine can be interconverted with pyruvate in either the cytosol or the 
mitochondrial matrix by the alanine transaminase activity of glutamic-pyruvate transaminase 1 
(GPT1, cytosolic) or glutamic-pyruvate transaminase 2 (GPT2, mitochondrial), as shown in Fig. 
2.9A. The dramatic decrease in alanine labeling from pyruvate and the low steady-state alanine 
levels in Mpc1-deficient cells and tissues provide evidence that mitochondrial pyruvate is a 
significant source of cellular alanine. Indeed, in WT MEFs, 60% of total alanine was m+1 labeled 
from [2-13C]pyruvate, while this was decreased to just 6% in Mpc1 D/D MEFs. To further test 
whether low steady-state alanine concentrations were the result of increased alanine flux or 
decreased alanine synthesis, we measured mitochondrial flux of alanine by labeling Mpc1 KI/KI 
and D/D MEFs with [U-14C]L-alanine and measuring incorporation into the total lipid fraction as 
we did previously for pyruvate and glutamine. Alanine incorporation was up-regulated in a 
graded manner in Mpc1 KI/KI and Mpc1 D/D MEFs greater than 7-fold (Fig. 2.9B), indicative of 
higher mitochondrial flux of alanine. We also observed that HEK293T cells treated with UK-
5099 exhibited a dose-dependent suppression of [2-14C]pyruvate incorporation into lipids (Fig. 
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2.S4) and recapitulated the increase in mitochondrial alanine flux that we observed in primary 
MEFs also in a dose-dependent manner (Fig. 2.9C). UK-5099 also stimulated an increase of 
mitochondrial glutamine flux in a dose-dependent manner in HEK293T cells (Fig. 2.9D) although 
glutamine did not contribute significantly to anaplerosis in non-transformed Mpc1 D/D MEFs 
(Fig. 2.3E). These data show that alanine represents a major compensatory substrate in 
mitochondrial pyruvate carrier deficiency. 
We next sought to use the HEK293T system as a model to determine the relative 
contributions of the cytosolic (GPT1) and mitochondrial (GPT2) alanine transaminases to the 
observed increase in alanine flux upon impaired mitochondrial pyruvate transport. To this end, 
we used CRISPR/Cas9-mediated genome editing to induce loss-of-function mutations in GPT1, 
GPT2, and both GPT1 and GPT2 (pan GPT) in HEK293T cells (131). Mutant clonal cell lines 
were screened by genomic PCR and functional assays (Fig. 2.S4). Control cells (which were 
derived from expression of Cas9 with no gRNA), GPT1 KO, GPT2 KO, and pan GPT KO 
HEK293T cells were subjected to a [U-14C]L-alanine to lipid incorporation assay in the presence 
or absence of UK-5099. In addition, pan KO cells were transiently transfected with hGPT1 or 
hGPT2 expression vectors and subjected to the same alanine flux assay in the presence or absence 
of UK-5099. Loss of GPT2 completely abrogated the UK-5099-stimulated increase in 
mitochondrial flux of alanine (Fig. 2.9E). GPT1 was found to be dispensable for this 
phenomenon, suggesting that GPT1 does not promote increased alanine flux by converting 
pyruvate into alanine upon MPC inhibition. Indeed, overexpression of GPT1 in the pan GPT null 
background significantly reduced alanine incorporation into lipid upon UK-5099 treatment, 
suggesting that the equilibrium for GPT1 lies in favor of converting alanine to pyruvate within 
these cells (Fig. 2.9E). In further support of this, overexpression of GPT1 in the pan GPT null 
background significantly increased glutamine incorporation into lipid upon UK-5099 treatment 
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(Fig. 2.9F). These data show that GPT2 is necessary and sufficient for increased mitochondrial 
flux of alanine in the absence of mitochondrial pyruvate transport. Additionally, these data 
suggest that the increased utilization of alanine is largely from exogenous alanine, not alanine 
which is derived from cytosolic pyruvate by GPT1. In this way, GPT2 might be acting to use 
exogenous alanine as a source for mitochondrial pyruvate rather than working in concert with 




The placenta segregates maternal and fetal circulation while enabling selective nutrient 
uptake and waste excretion between fetus and mother. The fetus is a substantial oxygen consumer 
and preferentially transports and utilizes glucose as its main macronutrient (reviewed in (14)). 
Fetal glucose and oxygen consumption converge at the transport of pyruvate into mitochondria; 
therefore, we targeted Mpc1, an essential component of the mitochondrial pyruvate carrier, to 
determine the requirements for mitochondrial pyruvate metabolism during fetal development. 
Due to the severe metabolic and developmental derangements observed in patients with mutations 
in enzymes that participate in mitochondrial pyruvate metabolism (126, 155-159) and the 
embryonic lethality of mouse models with null mutations in these enzymes (138, 160), we were 
surprised that such a small fraction of mitochondrial pyruvate metabolism was sufficient for in 
utero development. MPC deficiency was well tolerated in egg-laying Drosophila under standard 
laboratory conditions; however, these mutations were lethal when carbohydrate (sucrose) was 
provided as the main macronutrient (122). Mammalian pregnancy is also a carbohydrate-
dominated environment; however, mammals seem to be capable of more metabolic plasticity than 
previously envisioned. Maternal glucose utilization is spared to provide the fetus with adequate 
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glucose to sustain its biosynthetic and bioenergetic needs. The inability to properly communicate 
and regulate glucose availability can result in adverse consequences for maternal health (e.g. 
gestational diabetes) and fetal wellbeing (e.g. fetal growth). It will be interesting to further 
delineate the contribution and convergence of maternal nutrition and fetal metabolism on 
pregnancy-specific pathologies and long-term health of the offspring. 
To define the metabolic requirement for mitochondrial pyruvate metabolism during 
mammalian embryonic development, we generated mice with a null deletion of Mpc1. While 
knockout mice provide an excellent model for assigning the physiological requirement for genes 
involved in metabolism, we sought to determine the effect of a graded suppression of MPC in 
vivo by generating a hypomorphic allelic series. We devised a series of genetic perturbations 
including the null allele, a less-severe hypomorphic allele, and tissue-specific loss of Mpc1 in 
developing nervous system to enable a more detailed definition of gene-phenotype relationships. 
Indeed, we have shown that the transcriptional regulation of some genes (e.g. Pck1) is directly 
related to the degree of Mpc1 suppression in a tissue-specific manner in vivo (Fig. 2.7F). Further 
characterization of an allelic series may identify phenotypes that are regulated by particular 
metabolites in a graded fashion or by impaired metabolism in a particular tissue (161, 162). Our 
approach highlights the utility of genetic approaches to dissect metabolic requirements and 
compensatory mechanisms in vivo. 
Human inborn errors in MPC1 are compatible with development to term but in the 
absence of maternal metabolite exchange result in severe adverse consequences in the perinatal 
period including lactic acidosis (126). Organic acidosis can be acutely life-threatening by 
lowering the oxygen-carrying capacity of hemoglobin (163). In agreement with Mpc1 KI/KI 
embryos being in a state of metabolic acidosis, we observed a 15-fold higher hypotaurine 
concentration in Mpc1 KI/KI brains, a likely adaptation to the hyperosmotic stress that lactate 
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accumulation may cause (152). Additionally, we observed 3-fold higher heme levels in Mpc1 
KI/KI liver, along with elevated biliverdin (Fig. 2.8B). Fetal liver is the principal site for 
erythropoiesis during mid- to late-gestation in mouse embryonic development (164), and the 
observed increase in heme likely represents a response to lactic acidosis and impaired oxygen-
carrying capacity of fetal hemoglobin. While the late-gestation fetus has adaptive mechanisms to 
survive acute hypoxia/acidosis during parturition (165), less is known about the fetal response to 
chronic acidosis. Mild acidosis has been shown to reprogram mitochondrial metabolism by 
increasing respiratory efficiency to preserve ATP production during cellular stress (166), and it is 
likely that similar adaptations occur in Mpc1-deficient tissues. Our finding that 75 of 86 
metabolites significantly regulated in both brain and liver of Mpc1 KI/KI embryos were regulated 
in the same direction suggests that the metabolic effects of MPC deficiency are largely conserved 
across tissues, but that some responses are tissue-specific. Among those metabolites oppositely 
regulated by Mpc1 deficiency in brain and liver were carnitine, an important molecule in fatty 
acid metabolism, and argininosuccinic acid, an intermediate in the urea cycle (Fig. 2.8B). The 
tissue-specific regulation of these molecules may reflect broader patterns of altered lipid and 
amino acid metabolism in Mpc1-deficient liver and brain, respectively.  
High rates of metabolic flux are particularly important in rapidly dividing cells such as 
cancer cells and during development. Mitochondria are the principal sites of cellular energy 
production via the generation of ATP for all cellular compartments. Additionally, the TCA cycle 
provides substrates for anabolic processes in the cytosol, and, as such, substrate partitioning 
between mitochondria and other subcellular locations is a fundamental way to regulate 
mitochondrial metabolic flux. While high rates of flux are necessary to maintain rapid growth and 
division, the requirement for mitochondrial oxidative metabolism and anaplerosis within the 
mitochondria is poorly defined. For example, it has long been observed that cancer cells rely 
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heavily on glycolysis for ATP production (the Warburg effect); yet, even highly glycolytic cells 
require mitochondrial metabolic flux to provide carbon and energy equivalents for nucleotide, 
protein, and lipid biosynthesis (140, 141, 167-169). Indeed, in mammalian cell culture and tumor 
xenograft models, chemical or enzymatic depletion of mitochondrial DNA results in impaired 
respiratory capacity and reduced proliferation (170-173). 
Deletion of Mpc1 in primary non-transformed MEFs did not affect cellular proliferation 
and resulted in enhanced glucose uptake (Fig. 2.3), consistent with the Pasteur effect, which 
describes the inhibitory effects of glucose oxidation on glycolysis. Interestingly, non-transformed 
MEFs did not exhibit enhanced anaplerosis via glutamine (Fig. 2.3E), although transformed cells 
robustly utilized glutamine and pharmacological inhibition of mitochondrial pyruvate transport 
further pushed this adaptation (Fig. 2.9D). Increased oxidative glutaminolysis and reductive 
carboxylation upon MPC inhibition was observed in transformed cell lines, although the relative 
contribution of these fates of glutamine was dependent on cell line and growth conditions (174, 
175). Glutamine anaplerosis supports cellular proliferation in transformed cells, and inhibition of 
glutaminase or glutamate dehydrogenase sensitized cells to growth inhibition upon treatment with 
UK-5099 (175). Analogous to the differences in glutamine metabolism observed in primary and 
transformed cultured cells, glutamine seems to play a more significant anaplerotic role in the 
brain than in the fetal liver, as glutamine was the second most-downregulated metabolite in Mpc1 
KI/KI brain. Not surprisingly, there are tissue-specific differences in anaplerosis during normal 
development as well. Liver-specific deletion of MPC components in mice led to defects in 
gluconeogenesis from pyruvate/lactate; however both glutamine and alanine were found to 
compensate and contribute to fasting gluconeogenesis in MPC-deficient adult liver (176, 177). 
We find that alanine provides a robust anaplerotic substrate in several cellular models of MPC 
deficiency as well as in vivo in embryonic brain and liver. It has been demonstrated that Mpc2-
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deficient mitochondria exhibit no alterations in alanine uptake (177), and decreased steady-state 
alanine concentrations have been observed in several MPC-deficient cell models and in vivo (174, 
175, 177). The decrease in steady-state alanine has been interpreted as a result of most cellular 
alanine being derived from mitochondrial pyruvate, but we sought to test the flux of alanine itself. 
In addition to demonstrating increased mitochondrial flux of alanine into lipid in MPC deficiency, 
we have shown by deleting the cytoplasmic and mitochondrial alanine transaminases (GPT1 and 
GPT2) that alanine provides a direct source of mitochondrial pyruvate dependent upon the 
mitochondrial GPT2 while the cytoplasmic GPT1 is dispensable for this compensation (Fig. 2.9). 
This finding is consistent with knockdown of Gpt2 in mice with liver-specific deletion of Mpc2, 
which further decreased blood glucose during a pyruvate tolerance test (177). Interestingly, the 
expression of GPT2 and several other transaminases that use glutamate as a co-substrate was 
found to be positively correlated with proliferative capacity in human tumors (178), and 
knockdown of GPT2 decreased glutamine-dependent growth in cancer cells with mutant Kras 
(179). Our data suggest that GPT1 may also support glutamine anaplerosis, especially upon 
impaired mitochondrial pyruvate transport (Fig. 2.9F). The GPT1-catalyzed transamination 
reaction in these cells seems to favor the production of pyruvate and glutamate, at the expense of 
alanine and α-ketoglutarate. Glutamate and α-ketoglutarate are well characterized negative 
regulators of glutaminase (180) and glutamate dehydrogenase (181), respectively, and the 
regulation of glutaminolysis by allosteric regulation and product inhibition may depend on 
compartment-specific concentrations of these metabolites. The GPT1 reaction could relieve 
inhibition of glutamate dehydrogenase or elevate glutamate levels to promote glutamine 
anaplerosis; however, the flux of glutamate-utilizing transaminases and glutamate dehydrogenase 
is likely regulated at levels beyond substrate concentrations, as recently demonstrated (178). The 
metabolic plasticity demonstrated by MPC-deficient and GPT-deficient cells is evidence that 
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mitochondria have multiple mechanisms to generate mitochondrial pyruvate and provide 
anaplerotic carbon from alternative substrates when glucose is limiting. 
Here we have shown that, although the mammalian fetus consumes large quantities of glucose 
and oxygen, a surprisingly small quantity of the mitochondrial pyruvate carrier is sufficient for 
mammalian development. MPC-deficient cells utilize alternative anaplerotic metabolites to meet 
the high biosynthetic burden of highly replicative cells, and this compensation varies in a tissue-
specific manner in vivo. Further defining the cellular and organismal requirements of 
macronutrient metabolism has important implications in broad areas of biology including cancer, 
neurochemistry, obesity and diabetes. 
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3. Metabolic Response to Fasting during Pregnancy 
Our mouse model of Mpc1 deficiency in utero revealed that a surprisingly small quantity 
of the mitochondrial pyruvate carrier is sufficient for mammalian development and that 
alternative anaplerotic substrates are able to compensate to meet biosynthetic demand. The 
lethality associated with severe Mpc1 deficiency is likely due to lactic acidosis, and the maternal-
fetal lactate gradient steepens at parturition (61). The complete interruption of maternal-fetal 
metabolic exchange and communication at birth overwhelms the Mpc1-deficient neonate’s ability 
to compensate. Among the alternative substrates that contributed to meeting metabolic demand 
during late gestation were amino acids and lipids. Mitochondria play a key role in regulating fuel 
switching and crosstalk between these major branches of macronutrient metabolism as naturally 
occurs during times of nutrient deprivation. In this way, mitochondria help regulate transitions 
between fed and fasted states to promote metabolic flexibility that capitalizes on current nutrient 
availability while anticipating future nutrient limitation (182). Consistent with our observations 
that lipids and amino acids can compensate for Mpc1-deficiency in utero, another group 
developed a model of Mpc1 deficiency and lethality during embryonic development that can be 
rescued by feeding the dam a ketogenic diet (183, 184). Given that the ketogenic diet is meant to 
imitate a low-carbohydrate time of fasting, we sought to understand the role of impaired pyruvate 
metabolism on the maternal and fetal response to a metabolic challenge during late gestation. We 
chose a 24h fast as a nutritional stress that would increase lipid availability and test the capacity 
of both maternal and fetal mitochondria to demonstrate metabolic plasticity in the context of 






3.1  Accelerated Response to Fasting in Late Gestation 
Human pregnancy is characterized by greater metabolic flexibility than in the non-
pregnant state in order to protect fetal growth from maternal nutrient deprivation (1). One way 
that this metabolic plasticity is maintained is by promoting increasing maternal serum 
concentrations of triglyceride, phospholipids, and non-esterified fatty acids (NEFA) throughout 
gestation (17). Circulating triglyceride levels, for example, increase more than 250% by the end 
of pregnancy, which is almost twice the post-prandial concentration in a non-pregnant individual 
(185). The elevated levels of circulating lipid metabolites in fasting pregnant women combined 
with an earlier than normal shift from glucose to fat utilization by maternal tissues has been 
termed “accelerated starvation” (6, 186). The acceleration is so dramatic that overnight fasting 
(14-18h) in normal late term pregnancy leads to serum metabolite concentrations that rival the 
effects of 2-3 days of starvation in non-pregnant individuals (186, 187). The features of the 
accelerated starvation response include increased fat mobilization from adipose, exaggerated 
ketone production, decreased blood glucose despite enhanced gluconeogenic capacity, and 
increased maternal muscle catabolism (reviewed in (6)). Increased maternal utilization of lipids as 
metabolic fuel spares glucose and amino acids for fetal uptake (187). Maternal hormones 
certainly play a role in these adaptations, but the accelerated fasting response is most apparent 
during late-gestation when the conceptus is large enough to challenge maternal energy reserves. 
Additionally, both lean and obese women exhibit the accelerated fasting response on the same 
timescale (187). When paired with the “facilitated anabolism” that is also characteristic of late 
term pregnancy, this results in a pattern of dynamic metabolic oscillations in maternal fuel 
utilization between fed and fasted states—all in an effort to meet immediate maternal and fetal 




3.2  Epidemiology of Famine Exposure in Human Populations 
Impaired fetal growth may be indicative of fetal metabolic deficiency, placental 
aberrations, or maternal undernutrition (1). Nutrient deprivation during pregnancy has been 
studied in human populations experiencing famine (188, 189) or electing to fast during Ramadan 
(190-192). Findings from these populations suggest that nutrient limitation during early vs. late 
gestation may affect the nature and severity of maternal effects and postnatal outcomes. For 
instance, intermittent fasting during Ramadan reduced abdominal visceral fat thickness in 
pregnant women from 12-27 weeks gestation but was not associated with any discernable 
differences in fetal outcomes (191). In another study, women who observed the Ramadan fast 
during the second- or third-trimester had significantly less maternal weight gain than others who 
did not fast (192). Children born to mothers who fasted in the first trimester had lower birth 
weights than children born to mothers who fasted in the second or third trimesters (190). 
Moreover, elevated cortisol levels were measured in women who fasted, and this could contribute 
to the maternal and fetal differences in weight gain (193). Related to this, placental expression of 
11β-hydroxysteroid dehydrogenase, which normally serves to protect the fetus from maternal 
glucocorticoids, is down-regulated by maternal undernutrition, especially low-protein diets (194). 
The nature of nutrient deprivation experienced by populations faced with food shortages 
and famine is entirely different from elective fasting. From patients who endured the Dutch 
famine of 1944-1945, prenatal famine exposure during early gestation led to increased rates of 
obesity and elevated risk of cardiovascular disease while exposure during late gestation was 
correlated with impaired glucose tolerance in adulthood (188). Famine exposure during mid or 
late gestation was associated with lower birth weights, while early gestation exposure led to 
slightly heavier and larger babies than controls not exposed to famine (188). Low birth weight, 
especially when small for placental size, is strongly associated with the risk for cardiovascular 
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disease later in life (54). Early nutrient deprivation and the associated “catch-up” growth upon 
transitioning back to adequate nutrition may be particularly detrimental (195). The Great Chinese 
Famine of 1959-1961 affected a larger population for a longer length of time than other widely 
studied food shortages of the twentieth century; as a result, studies of this population have 
revealed more subtle effects of nutritional deficiency. For example, women who were exposed to 
famine as fetuses have a higher risk of metabolic syndrome than women who were exposed 
postnatally, and that risk is higher than for men regardless of whether they were exposed to 
famine prenatally or postnatally (196). Another famine cohort from the Nigerian civil war (1967-
1970) also associated fetal-infant exposure to famine with increased risk of hypertension and 
impaired glucose tolerance as adults (197). The effects of fetal undernutrition among this sub-
Saharan cohort were even more pronounced and emerged at earlier ages than European cohorts. 
The hypothesis of “early programming of disease” posits that many chronic adult diseases—
including immune diseases, neuropsychiatric disorders, and other conditions that are not overtly 
“metabolic”—are in part determined by fetal and infant nutrition (1, 198). The timing and 
duration of undernutrition during early development greatly affect chronic disease risk and 
manifestation. 
 
3.3  Fetal and Placental Responses to Fasting 
Despite the multitude of adaptations in place to protect the fetus from experiencing 
nutrient depletion, what is the fetal response to maternal nutrient deprivation, especially that 
which is beyond her capacity to maintain substrates for fetal metabolism? How does the fetus 
sense this metabolic state? Which metabolites, endocrine molecules, and metabolic pathways 
contribute to the metabolic communication between mother and fetus? And what is the role of the 
placenta in both sensing and adapting to this affront to fetal metabolism? In this section, the 
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placental and fetal responses to fasting will be described in order to provide context for the 
genetic mouse models we have used to begin to address some of these outstanding questions in 
maternal-fetal metabolic communication. 
As the key interface for regulation of nutrient availability during pregnancy, how the 
placenta responds to maternal nutrient deprivation has the potential to greatly alter fetal 
outcomes. The placental response could include changes to placental metabolism, changes in 
hormonal communication, or changes in transporter expression or activity. The timing of 
placental sensing and responding to maternal nutrient deprivation could occur before the fetus 
experiences nutrient limitation, at the same time as the fetus, or in response to fetal signals of 
metabolic demand not being met. One thing known about the placental response to fasting is that 
triglycerides accumulate, consistent with the elevation in maternal circulating lipid concentrations 
upon fasting (92). Studies in late-gestation pregnant rats demonstrated that placental 
incorporation of radiolabeled triglyceride preceded fetal incorporation of the radiolabeled lipid 
(75). In addition, placental glycogen stores were decreased 40% by prolonged maternal fasting 
(199). Select glycolytic, lipogenic, and gluconeogenic enzyme activities were measured in 
maternal liver, fetal liver, and placenta in fed or fasted rats. While maternal liver enzyme 
activities were dramatically altered by fasting, fetal liver enzyme activities were only modestly 
changed, and placental enzyme activities were unaffected (199). Gestational age was found to be 
a better predictor of placental enzymatic activity than regulation by nutritional or hormonal 
influences, at least in the context of these in vitro assays that test the enzymatic capacity of a 
tissue. 
During maternal starvation, or during an insulin-suppressed state such as streptozotocin-
induced diabetes, fetal tissues were found to accumulate lipid in concert with elevated maternal 
serum triglyceride concentrations, which rose two-fold in this rat model of diabetes during 
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pregnancy (75). A rabbit model of late-gestation maternal fasting demonstrated a similar dramatic 
increase in fetal lipid uptake and accumulation (29). Moreover, the fetal capacity for lipid 
accumulation in rats increased over the course of gestation, tripling from day 17 to day 20 of 
gestation (75). The accumulation of maternally-derived lipids by the fetus may represent an 
adaptive mechanism to protect against further nutrient deprivation in utero and to prepare the 
fetus for the possibility of nutrient deficiency after parturition. Fatty acid oxidation by the fetal 
liver may fuel gluconeogenesis as it does in the adult fasting liver. Although the contribution of 
fetal liver gluconeogenesis in vivo is unknown, fetal rat liver from severely fasted dams 
demonstrated increased activity of gluconeogenic enzymes and increased conversion of 
gluconeogenic substrates to glucose by tissue explants (200). A uteroplacental source of glucose 
during fasting in late term pregnant women has also been suggested based on umbilical vein and 
artery blood glucose measurements (57). The enhanced gluconeogenic potential prior to birth  
provides evidence for a strong demand for glucose to fuel energy production at the cost of 
promoting growth because fetal weight was decreased with prolonged maternal fasting in rats 
(200). Liver glycogen could also be an important source for endogenous glucose availability in 
the fetal liver during a time of nutritional challenge. Glycogen stores accumulate during the last 
weeks before birth in humans and are critical for the first hours of postnatal life when hormonal 
signals such as glucagon promote glucose mobilization from these glycogen stores before the 
neonate consumes any milk (24, 25). The fetus can respond to maternal fasting, and if the 
nutritional challenge occurs in late gestation, the method of response may greatly alter neonatal 







3.4  Metabolic Derangements in Pregnancy 
The previous examples demonstrate how maternal-fetal metabolic communication can be 
dynamic to respond to changing nutrient status, but it raises the question: What happens when 
metabolic communication is disrupted or metabolic/hormonal signals misinterpreted? Not only is 
pregnancy a nutritionally sensitive time during the life cycle, the extreme physiological demands 
of mammalian pregnancy may lead to gestational complications which could affect both mother 
and fetus. Here, some metabolic disorders of pregnancy are described with particular attention to 
the miscommunication driving or resulting from these conditions. 
Some pathologies of pregnancy develop as a result of a mismatch between fetal demands, 
maternal response, and maternal capacity to meet these needs. Gestational diabetes mellitus 
(GDM) is the most common metabolic abnormality during pregnancy, affecting 5-9% of pregnant 
women in the U.S. (201). Complications of GDM include increased birth weight (macrosomia) 
and predisposition of the mother to develop type 2 diabetes in the future (202). Pregnancy has 
been described as a diabetogenic challenge where the increased glucose demand for fetal growth 
and development means changes in maternal metabolism to support and sustain this high glucose 
demand while maintaining maternal euglycemia (6). In addition, GDM has been described as a 
“disorder of total fuel metabolism” since all major classes of insulin-dependent substrates are 
affected: Overnight fasted plasma glucose, NEFA, and TG are higher in patients with gestational 
diabetes than in unaffected pregnant women (6). Several adaptive responses to pregnancy 
contribute to the development of gestational diabetes, and many of these responses are likely 
mediated by hormonal (mis)communication. First, pregnancy is characterized by elevated insulin 
secretion and decreased peripheral insulin sensitivity. There was a 50-60% decrease in insulin-
mediated glucose disposal in lean women from pre-gravid to late gestation (15, 203). Pregnant 
women are tested for GDM with an oral glucose tolerance test at 24 to 28 weeks gestation, and a 
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patient is diagnosed with GDM if her blood glucose is elevated after fasting or glucose challenge 
(202). Elevated insulin concentrations are not part of the diagnostic criteria, but fasting plasma 
insulin of women with GDM during late gestation was 250% the levels of late-gestation weight-
matched non-diabetic pregnant controls (204). Women with GDM also demonstrated a two-fold 
increase in fasting plasma insulin levels in late gestation relative to pre-gravid measurements 
(204). A second adaptation of pregnancy that is dysregulated in GDM is the increase in 
gluconeogenic capacity. Isotopic labeling studies in pregnant women have demonstrated a 30% 
increase in total gluconeogenesis from early to late pregnancy (11 to 34 weeks gestation) (15). 
Absolute rates of glucose infusion to maintain euglycemia were 22% lower in late-gestation 
GDM pregnancies relative to lean non-diabetic pregnant controls (203). One explanation of GDM 
is that gluconeogenic placental hormones outpace the ability of maternal insulin secretion (and 
sensitivity) to maintain euglycemia. Some studies have implicated placental growth hormone or 
placental lactogen as molecules which could contribute to the development and progression of 
GDM (5, 205). Placental lactogen increases pancreatic beta cell proliferation during pregnancy, 
but it remains to be determined if the increase in insulin secretion is what induces insulin 
resistance during gestation (5). Placental growth hormone may contribute to increased placental 
GLUT1 expression and fetal hyperglycemia. Diabetogenic contributions for prolactin, cortisol, 
and glucagon have also been described (206). Patients with GDM may manage their condition 
with diet and physical activity or with insulin treatment if deemed necessary. Monogenic diabetes 
or “mature onset diabetes of the young” (MODY), although rare and representing only 1 to 2% of 
diabetes cases worldwide, presents some additional challenges during pregnancy. The treatment 
plan for pregnant diabetics may depend on maternal response to treatment, fetal genotype, and the 
placental transfer of certain classes of drugs (sulfonylureas). The treatment plan may change 
during gestation depending on fetal growth rates and maternal glycemic control (207). Glycemic 
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control is an important metabolic adaptation during pregnancy that, when dysregulated, may 
result in gestational diabetes. 
Maternal liver is one of the main tissues regulating the metabolic effects of fasting during 
late gestation, including gluconeogenic potential and maternal lipid availability. Several liver 
disorders may present during the second half of gestation including preeclampsia; hemolysis, 
elevated liver enzymes, and low platelet count (HELLP); intrahepatic cholestasis of pregnancy; 
and the rare but life-threatening acute fatty liver of pregnancy (AFLP) (208). AFLP is 
characterized by liver failure and microvesicular steatosis, and there is a strong genetic 
connection to fetal fatty acid oxidation defects, most notably long-chain 3-hydroxyacyl-CoA 
dehydrogenase (LCHAD) deficiency (208). Lcad-/- mice were born at lower than expected 
Mendelian ratios suggesting frequent gestational loss and an important role for fetal fatty acid 
oxidation (209). Impaired fetal fatty acid degradation generates metabolic signals that also impair 
lipid-handling by the mother. These complications of pregnancy demonstrate the intricate nature 
of maternal-fetal metabolic communication, particularly during late-gestation when fetal energy 




4. Mitochondrial Oxidative Metabolism Regulates Late-Gestation Maternal-
Fetal Metabolic Communication 
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Mitochondrial oxidative metabolism regulates late-gestation maternal-fetal metabolic 
communication. In Preparation. 
 
4.1  Summary 
 
Mammalian pregnancy is perhaps the most nutritionally sensitive stage in life as all 
nutrients for fetal growth are provided by the mother. Glucose is the principal macronutrient 
available for fetal biomass accretion, and the mitochondrial metabolism of glucose-derived 
pyruvate supports the bioenergetic and biosynthetic needs of rapidly dividing cells. We developed 
a mouse model of impaired mitochondrial pyruvate metabolism by generating a hypomorphic 
knock-in (KI) allele of an essential component of the mitochondrial pyruvate carrier (MPC), 
Mpc1, which resulted in perinatal lethality (130). Late-gestation Mpc1 KI fetuses were smaller 
than littermates with tissue-specific compensatory changes in lipid and amino acid metabolism. 
To further probe the capacity for metabolic plasticity in this model, late-gestation dams were 
fasted for 24 hours. Maternal fasting increased serum lipid metabolites, promoted fetal liver 
triglyceride accumulation, and stunted fetal growth. Transcriptional changes in Mpc1 KI fetal 
livers resembled the wild-type response to maternal fasting, and select aspects of fetal metabolic 
dysfunction in this model were ameliorated by maternal fasting. To determine the contribution of 
maternally-derived lipids to the fetal fasting response, we used two genetic models of impaired 
fatty acid oxidation: (i) liver-specific loss of mitochondrial β-oxidation of long-chain fatty acids 
via carnitine palmitoyltransferase 2 (Cpt2) and (ii) genetic loss of a transcriptional regulator of 
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lipid oxidative metabolism, PPARα. Upon fasting, these mice exhibit differing degrees of hepatic 
lipid accumulation and impaired ketogenesis. The fetal response to maternal fasting was 
determined by liver transcriptional program and steady-state metabolite measurements. The 
maternal fasting response is a better indicator of fetal outcome than is fetal genotype, suggesting 
that maternally-derived factors dominate this communication. A better understanding of 




4.2  Introduction 
Successful eutherian pregnancy and parturition requires metabolic, hormonal, and 
immunological communication between mother and fetus (4). The types and intensities of signals 
conveyed vary considerably across gestation, as do the responses elicited by these messages (10). 
Metabolic communication throughout pregnancy is essential as a growing fetus obtains all 
nutrients from (and excretes all wastes to) the mother. While hormonal cues from both mother 
and conceptus can affect nutrient mobilization, the metabolic demands of the growing fetus may 
also directly modify maternal metabolism and behavior (5, 6). Fetal metabolic demand is highest 
during late gestation, which also coincides with the highest rates of energy expenditure during 
pregnancy (7, 8, 26, 32, 33). Some pathologies of pregnancy develop as a result of a 
miscommunication over fetal metabolic demands, maternal response, and maternal capacity to 
meet these needs. Gestational diabetes mellitus (GDM), for example, is thought to arise from a 
mismatch in maternal-fetal hormonal and metabolic communication, and GDM is the most 




There are a host of physiological adaptations in place to ensure the adequate transport of 
glucose and oxygen to the developing conceptus (4). While oxygen tension in utero is low 
relative to atmospheric levels, measurement of lactate uptake and utilization by fetal tissues 
(including fetal heart and brain) provided evidence that the fetus is a net consumer rather than 
producer of lactate (14, 43, 47-49). Furthermore, recent studies revealed significant lactate 
utilization in adult tissues, suggesting that circulating lactate is an important oxidizable substrate 
in mammals (50, 51). Together, these observations challenge the dogma that in utero 
development is characterized by low oxygen tension and is not conducive to mitochondrial 
oxidative metabolism. While this may be true during early development, once placental exchange 
function is developed and fetal mitochondrial biogenesis begins (63), the fetus is poised to utilize 
oxidative metabolism for energy production and anabolism. 
 The mitochondrial pyruvate carrier (MPC) facilitates pyruvate transport across the inner 
mitochondrial membrane and thereby represents a control point at which the metabolic fates of 
glucose, lactate, and oxygen coalesce. The MPC is unlike any mitochondrial carrier identified to 
date and is made of two essential components, MPC1 and MPC2 (121, 122). Previously, we 
developed a mouse model of MPC deficiency by generating a hypomorphic knock-in (KI) allele 
of Mpc1that results in early perinatal lethality (130). This mouse model of Mpc1 deficiency in 
utero revealed that a surprisingly small quantity of the mitochondrial pyruvate carrier is sufficient 
for mammalian development and that alternative anaplerotic substrates are able to compensate to 
meet biosynthetic demand. The lethality associated with severe Mpc1 deficiency is likely due to 
lactic acidosis, and the maternal-fetal lactate gradient steepens at parturition (61). The complete 
interruption of maternal-fetal metabolic exchange and communication at birth overwhelms the 
Mpc1-deficient neonate’s ability to compensate. Among the alternative substrates that contributed 
to meeting metabolic demand during late gestation were amino acids and lipids. Mitochondria 
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play a key role in regulating fuel switching and crosstalk between these major branches of 
macronutrient metabolism as naturally occurs during transitions between fed and fasted states 
(182). Consistent with our observations that lipids and amino acids can compensate for Mpc1-
deficiency in utero, another group developed a model of Mpc1 deficiency and lethality during 
embryonic development that can be rescued by feeding the dam a ketogenic diet (183, 184). 
Given that the ketogenic diet is meant to imitate a low-carbohydrate time of fasting, we sought to 
understand the role of impaired pyruvate metabolism on the maternal and fetal response to a 
metabolic challenge during late gestation. We chose a 24h fast as a nutritional stress that would 
increase lipid availability and test the capacity of both maternal and fetal mitochondria to 
demonstrate metabolic plasticity in the context of impaired mitochondrial pyruvate metabolism. 
Here we describe the effects of maternal and fetal mitochondrial pyruvate transport on the 
response to nutrient deprivation during late-gestation. A better understanding of maternal-fetal 
metabolic communication may inform interventions for metabolic disorders of pregnancy. 
 
4.3  Materials and Methods 
Generation of genetic mouse models 
Mpc1 knock-in mice were generated by targeting loxP sequences to introns flanking 
exons 3 to 5 of the mouse Mpc1 gene and targeting a transcriptional reporter construct to the 3’ 
untranslated region of Mpc1 by homologous recombination in C57Bl/6 embryonic stem cells by 
standard methods, as previously described (130). To generate mice with a germline deletion of 
Mpc1, Mpc1lox/+ mice were bred to CMV-Cre transgenic mice, and deletion in Cre-negative F2 
progeny was verified by PCR genotyping (Mpc1 D/+). A conditional knock-out (KO) allele of 
mouse Cpt2, carnitine palmitoyltransferase 2, was generated by the same approach (211-217).  To 
generate mice with a liver-specific loss of mitochondrial fatty acid β-oxidation, Cpt2 floxed mice 
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were crossed to Albumin-Cre (Alb-Cre) transgenic mice (218) to generate animals (Cpt2L-/-) that 
cannot oxidize long-chain fatty acids in hepatocytes (213, 219). PPARα-/- mice (stock number 
008154) were obtained on a C57Bl/6 background from The Jackson Laboratory and were crossed 
to wild-type (WT) mice for studies of heterozygotes (220). Fgf21 floxed mice (stock number 
022361) were obtained from The Jackson Laboratory and were crossed to Alb-Cre or Cpt2L-/- 
mice in order to obtain liver-specific KO of Fgf21 or liver-specific KO of both Cpt2 and Fgf21 
(221). 
All mutant mice and littermate controls were housed in a facility with ventilated racks on 
a 14h light/10h dark cycle with ad libitum access to a standard rodent chow (2018SX Teklad 
Global, 18% protein). For timed matings, the presence of a copulatory plug in the morning was 
designated as 0.5 days post coitus (dpc), and pregnant females were housed separately. For 24h 
fasting experiments, food was removed from pregnant dams at 16.5 dpc between 13:00-15:00, 
and tissues were collected 24h later at 17.5 dpc. 
 
Glucose tolerance tests 
 Oral glucose tolerance tests were administered to pregnant dams at 17.5 dpc. Mice were 
fasted for 6h from 7:00-13:00, and a 2g/kg dose of glucose in 0.9% NaCl was administered orally 
by a straight gavage needle (bolus volume 110-120µL). Blood glucose and lactate were measured 
at 0, 15, 30, 60, and 120 minutes after glucose challenge, and serum was collected for insulin 
measurement by ELISA at 0 and 15 min (Millipore EZMRI-13K). Blood glucose and lactate were 






Body composition, calorimetry, and diet studies 
Body composition of 11-week old male Mpc1 D/+ mice and littermate controls was 
determined by magnetic resonance imaging (MiniSpec MQ10) and reported in terms of percent-
body fat and lean mass. To measure whole-body calorimetry under chow-feeding, fasting, and re-
feeding, 12-week old male Mpc1 D/+ mice and littermate controls were individually housed in 
Comprehensive Laboratory Animal Monitoring System cages (OxyMax Equal Flow, Columbus 
Instruments) on a 12 hour light/dark cycle. O2 consumption and CO2 production were measured 
every 24 minutes, and food intake, water intake and ambulation were measured continuously. 
After a 2-day acclimation period, data were collected for 48 hour ad libitum feeding followed by 
a 24-hour fast. After re-feeding and a short 6-hour fast, the mice were subjected to an 
intraperitoneal glucose tolerance test (2g/kg body weight) to determine energy expenditure and 
respiratory exchange ratio (RER) (VCO2/VO2) in response to the glucose challenge. Five days 
later, the glucose tolerance test was repeated and blood glucose and lactate measurements were 
recorded from tail vein samples at 0, 15, 30, 60, and 120 minutes upon glucose administration 
after a 4h fast. 
For high-fat diet studies, male Mpc1 D/+ mice and littermate controls were placed on a 
60% (kcal%) high-fat diet D12492 (Research Diets, Inc., New Brunswick, NJ) from ages 6 wks 
to 18 wks. At 10 wks on the diet, an intraperitoneal glucose tolerance test (0.75g/kg body weight) 
was administered after a 4h fast, and at 12 wks on the diet an intraperitoneal insulin tolerance test 
was administered after a 4h fast (0.6 U/kg body weight). Body composition was determined by 






Ethical Statement  
All procedures were performed in accordance with the NIH’s Guide for the Care and Use of 
Laboratory Animals and under the approval of the Johns Hopkins Medical School Animal Care 
and Use Committee. 
 
Serum and tissue metabolite measurement 
Serum metabolites were determined by enzymatic, colorimetric assays, according to the 
manufacturer’s instructions: β-hydroxybutyrate (Stanbio B-HB LiquiColor Assay, EKF 
Diagnostics, Boerne, TX), NEFA (NEFA-HR(2), Wako Diagnostics, Richmond, VA), 
triglyceride (TR0100, Sigma-Aldrich, St. Louis, MO). Placental and liver triglyceride content was 
also determined by enzymatic measurement after chloroform: methanol (2:1 (v/v)) extraction, 
drying, and resuspension in 3:1:1 (v/v/v) t-butanol: methanol: Triton X-100. Triglyceride levels 
were normalized to protein content as determined by bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific). Tissue lactate concentrations were determined enzymatically after 
homogenizing frozen tissues in lactate assay buffer on ice and were normalized to protein content 
(MAK065, Sigma-Aldrich, St. Louis, MO).  
For 1H-NMR of tissue and serum metabolites, extraction was performed as previously 
reported (219). For 1H-NMR of cell extracts, mouse embryonic fibroblasts (MEFs) were washed 
with ice-cold PBS and scraped into ice-cold methanol and snap frozen in liquid nitrogen before 
two additional freeze-thaw rounds with methanol extraction (222). Cell extracts were subjected to 
a final spin at 15,000g for 1 min at 4°C, then the supernatant was dried under vacuum and the 
extract resuspended in 20 mM phosphate buffer, pH 7.4 ± 0.1, with 0.1 mM TMSP as an internal 
reference and 0.1 mM sodium azide. 1H spectra were recorded on a Bruker Avance III 500MHz 
(Bruker Instruments, Germany) NMR spectrometer, operating at 499.9MHz and equipped with 
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room temperature quadruple nuclei probe. Typical 1H spectra were acquired using presaturation 
solvent suppression pulse sequence (noesyprld). Acquisition parameters were set as follows; 
spectral width of 8012.820 with a 64K data points, 512 scans, with a relaxation delay of 7s for a 
total collection time of 1.14h. Samples were automatically tuned and match, and shimmed to 
TMSP signal. Spectra were exported into Bruker format and were processed with Chenomx NMR 
Suit 8.2 Professional (Chenomx Inc, Edmonton, Alberta, Canada). TMSP signal (0.0 ppm) was 
used as a reference peak, spectra manually phase corrected and spline function was applied for 
the baseline correction. Metabolites were profiled and quantified using built-in Chenomx 
500MHz library. Metabolite concentrations were normalized to protein content. 
 
Cell culture 
Mouse embryonic fibroblasts (MEFs) were obtained from timed pregnant dams by 
standard methods. Primary MEFs were maintained in DMEM (25mM glucose) supplemented 
with 10% fetal bovine serum and 1% pen/strep antibiotic (Invitrogen) at 37°C in a humidity-
controlled incubator at 10% CO2. For 1H-NMR of cell extracts, cells were switched to serum-free 
DMEM containing 2.5mM glucose, 2.5mM pyruvate, and 2mM glutamine in the presence or 
absence of 1mM D,L-β-hydroxybutyrate (Sigma-Aldrich, H6501) for 24h before collection of 
cell extracts for steady-state metabolite measurements as described above. 
 
Immunoblotting 
Tissue lysates for SDS-PAGE were prepared by homogenization of tissue in RIPA buffer 
(50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.25% deoxycholate) 
with protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor (Roche), followed 
by pelleting of insoluble debris at 13,000g for 15 min at 4°C. Protein concentrations of lysates 
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were determined by BCA assay (Thermo Scientific), and 30µg of lysate was separated by Tris-
Glycine SDS-PAGE (15% polyacrylamide), unless otherwise noted. Proteins were transferred to 
PVDF membranes (Immobilon), blocked in 5% nonfat-milk TBST, and incubated with primary 
antibodies overnight. Primary antibodies used include: We generated and validated affinity-
purified rabbit polyclonal antibodies against mouse Mpc1 and Mpc2 (130); heat shock chaperone 
70 (Hsc70) mouse monoclonal at 1:1000 (Santa Cruz sc-7298); acyl-CoA thioesterase 1 (Acot1) 
rabbit polyclonal at 1:1000 (abcam ab133948); phospho-S6 (Ser240/244) ribosomal protein rabbit 
polyclonal at 1:1000 (Cell Signaling 2215); S6 ribosomal protein (total S6) rabbit polyclonal at 
1:1000 (Cell Signaling 2217); phospho-ACC (Ser79) rabbit polyclonal at 1:1000 (Cell Signaling 
11818), total ACC rabbit polyclonal at 1:1000 (Cell Signaling 3676); glutamic-pyruvate 
transferase 1 (Gpt1) rabbit polyclonal at 1:1000 (abcam ab154034); aspartate aminotransferase 1 
(Got1) rabbit polyclonal at 1:1000 (Novus NBP1-54778); fibroblast growth factor 21 (Fgf21) 
goat polyclonal at 1:2000 (R&D Systems AF3057); acetyl-lysine rabbit polyclonal at 1:1000 
(Cell Signaling 9441). Cy3-conjugated anti-mouse (Invitrogen) or Cy5-conjugated anti-rabbit 
(Invitrogen) secondary antibodies at 1:1500, or horseradish peroxidase (HRP)-conjugated anti- -
rabbit (GE Healthcare NA934V) or anti-goat (Millipore AP180P) secondary antibodies at 1:2000 
were incubated with washed membranes, and proteins were visualized with Amersham Prime 
enhanced chemiluminescent substrate (GE Healthcare) or epifluorescence on an Alpha Innotech 
MultiImage III instrument. Protein abundance was quantified using Alpha Innotech FluorChem Q 
software (Santa Clara, CA) and was normalized to Hsc70 expression. 
 
Quantitative real-time PCR 
Total RNA was extracted using Trizol reagent, per manufacturer’s recommendations 
(Life Technologies) and was further purified using the RNeasy Mini kit (Qiagen). RNA was 
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quantified by NanoDrop, and cDNA was synthesized using random primers and MultiScribe 
High-Capacity cDNA reverse transcription kit (Applied Biosystems). RT-PCR was performed 
using 10 ng of template cDNA in a 20µL reaction using Bio-Rad SsoAdvanced SYBR Green 
master mix with primers specific to the genes of interest (Table 4.1). All PCR reactions were 
carried out in a Bio-Rad CFX Connect Thermocycler and were concluded with a melt-curve 
determination step. Expression data from mouse tissues was normalized to the average Ct values 
for 4 reference genes: 18S, Rpl22, β-actin, and Gapdh, and data are expressed as 2-dCt and shown 
relative to wild-type or fed controls, as appropriate. 
 
Histology 
Livers were collected in formalin (10%, neutral buffered), paraffin-embedded, sectioned, 
and stained with hematoxylin and eosin (H&E) (AML Laboratories, Inc.). 
 
Acylcarnitine analysis of blood and liver 
Acylcarnitine abundances were determined from dried blood spot samples (223, 224) or 
from frozen liver, as previously described (213, 219). Tissues acylcarnitine concentrations were 
normalized to frozen tissue weight. Briefly, samples were methanol extracted and butylated in the 
presence of acid, further extracted, and analyzed on an API 3200 (AB SCIEX) operated in 
positive ion mode, with a precursor ion scan for m/z 85, which is a characteristic product ion of 







4.4  Results 
Maternal response to nutrient deprivation with impaired mitochondrial pyruvate transport.   
The rapidly growing fetus requires a continuous delivery of glucose and oxygen that 
places an incredible demand on maternal metabolism. The metabolism of glucose and oxygen 
converge at the transport of pyruvate into mitochondria via the Mitochondrial Pyruvate Carrier 
(MPC). We previously showed that late-gestation (e17.5) fetuses with a hypomorphic knock-in 
(KI) allele of Mpc1 exhibited impaired growth and lactic acidosis (130). To understand the role of 
impaired pyruvate metabolism on the maternal and fetal response to a metabolic challenge during 
late gestation, we subjected both wild-type (WT) and Mpc1 KI heterozygous (Mpc1KI/+) pregnant 
dams to a 24 hour period of food deprivation from 16.5 to 17.5 dpc. Mpc1KI/+ dams have a 50% 
reduction in Mpc1 and Mpc2 protein expression in liver in both the fed and fasted state (Fig. 
4.1A). The 24 hour starvation paradigm induced an 8% loss in maternal body weight in both 
genotypes (Fig. 4.S1A). We observed that 24 hour food deprivation was sufficient to stunt fetal 
growth of WT and KI/+ littermates while Mpc1KI/KI fetal body weights were not further perturbed 
by maternal fasting (Fig. 4.1B). Maternal nutrient deprivation also reduced the average body 
weight of WT fetuses from WT dams (Fig. 4.S1B). Maternal blood glucose was suppressed by 
fasting, independent of Mpc1 expression (Fig. 4.1C), and blood lactate levels were not altered 
(Fig. 4.S1C). Fasting induced a marked upregulation of circulating β-hydroxybutyrate in both 
WT and Mpc1KI/+ dams (Fig. 4.1C), consistent with the accelerated fasting response observed 
during pregnancy (6, 187). Serum non-esterified free fatty acid (NEFA) levels were also up-
regulated by fasting, and Mpc1KI/+ dams exhibited a slight decrease in circulating NEFA 
concentrations relative to WT dams (Fig. 4.1C). Consistent with this, liver triglyceride content in 
Mpc1KI/+ dams was lower than WT dams with no difference in serum triglycerides (Fig. 4.S1C). 
Additionally, the induction of several fasting-regulated gene products involved in nutrient sensing 
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was blunted in the livers of Mpc1KI/+ dams (Fig. 4.S1D,E). Together, these data suggest that 
Mpc1KI/+ dams rely more on the utilization of fatty acids as an alternative energy source upon 
impaired mitochondrial pyruvate metabolism, as others have implicated in non-pregnant rodent 
models of MPC deficiency (176, 177, 225, 226). 
 We reasoned that the high glucose demands of mammalian pregnancy may reveal 
differences in whole-body glucose homeostasis beyond what was observed in non-pregnant 
Mpc1-deficient mice in response to fasting or diet challenges. Non-pregnant mice heterozygous 
for Mpc1 deletion (Mpc1D/+) did not exhibit differences in body weight, body composition, 
energy expenditure, or glucose tolerance (Fig. 4.S2A-C). Upon a 12-week high-fat diet challenge, 
Mpc1D/+ mice responded similarly to littermate controls (Fig. 4.S2D-E). Others have 
demonstrated that a whole-body hypomorphic allele of Mpc2 leads to defects in glucose 
homeostasis (138), and liver-specific loss of Mpc1 or Mpc2 leads to defects in gluconeogenesis 
(176, 177). Heterozygosity for Mpc1 deletion is less severe than the Mpc2 hypomorph or tissue-
specific loss-of-function, and no significant differences were observed in Mpc1 D/+ mice. 
Glucose production and disposal are dramatically different during mammalian pregnancy in order 
to ensure sufficient nutrient delivery to the developing conceptus without compromising maternal 
health and fecundity (10, 11, 15). The high glucose demands of pregnancy may provide an 
additional metabolic stressor in the context of impaired mitochondrial pyruvate metabolism. To 
test this, Mpc1KI/+ and WT pregnant dams were subjected to an oral glucose tolerance test at 17.5 
dpc. Healthy pregnancy has been characterized as a state of glucose intolerance, and Mpc1KI/+ 
dams were found to be slightly less glucose intolerant than WT dams (Fig. 4.1D). Mpc1KI/+ dams 
were more prone to have higher blood lactate concentrations during the duration of the glucose 
tolerance test, similar to non-pregnant Mpc1D/+ mice subjected to an acute glucose challenge (Fig. 
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4.S2C,E).  These data show that pregnancy potentiates metabolic dysfunction upon impaired 
Mpc1 function. 
 
Mpc1 hypomorphic fetuses exhibit a fasting metabolic program.   
In Mpc1KI/KI hypomorphic fetal liver, the expression of both components of the MPC, 
Mpc1 and Mpc2, was below the level of detection by immunoblotting (Fig. 4.2A).  Maternal 
fasting does not alter the expression of these components. Previously, we observed that the 
expression of several genes that are regulated by fasting in adult liver were up-regulated in an 
Mpc1 dose-dependent manner in fetal liver (130). Interestingly, this same set of genes, including 
Pck1, Acot1, and Cpt1b, were up-regulated to the same degree by fasting in WT fetal liver (Fig. 
4.2B). Maternal fasting did not further increase the expression of these genes in Mpc1KI/KI 
hypomorphic fetuses. The expression of these same genes was also increased during the normal 
course of late-gestation (Fig. 4.2C), consistent with a PPARα-dependent transcriptional program 
initiated in late gestation (227). Together, these data suggest that when mitochondrial pyruvate 
metabolism is impaired, the fetal liver initiates an alternative metabolic program similar to the 
fetal response to maternal fasting and approaching a liver transcriptome that is poised for 
independent life after parturition. 
 
Maternal fasting rescues metabolic dysfunction in Mpc1 hypomorphic fetuses.   
To better characterize nutrient allocation between the maternal and fetal compartments, 
we compared steady-state maternal serum metabolites and maternal liver and fetal liver 
metabolites by 1H-NMR metabolomics. Consistent with the decrease in blood glucose and 
increase in serum β-hydroxybutyrate upon fasting, concentrations of these metabolites in 
maternal liver were similarly regulated (Fig. 4.S1F). As expected, Mpc1KI/KI fetal livers exhibited 
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elevated lactate relative to WT littermates. Interestingly, maternal fasting rescued the lactic 
acidosis in Mpc1KI/KI fetal liver by reducing lactate concentrations to WT levels (Fig. 4.2D). 
Mpc1KI/KI fetal brain lactate concentrations were also ameliorated by maternal fasting, while 
lactate levels in heart tissue were not regulated by maternal nutritional status (Fig. 4.2E). Fetal 
liver aspartate was also high in Mpc1KI/KI fetuses and was suppressed by fasting similar to liver 
lactate concentrations (Fig. 4.2D). Fasting induced a greater than 5-fold increase in β-
hydroxybutyrate (βHB) levels in fetal liver, and Mpc1KI/KI fetal livers had slightly higher 
concentrations than WT littermates (Fig. 4.2D). To test whether βHB contributed to the fasting-
induced suppression of lactic acidosis, WT and Mpc1 deletion mouse embryonic fibroblasts 
(MEFs) were cultured in the presence or absence of 1mM βHB for 24h, and steady-state lactate 
concentrations were measured. Consistent with its role as a fasting-induced alternative oxidative 
substrate, βHB treatment was sufficient to rescue lactate accumulation in cells lacking the MPC 
(Fig. 4.2E). These data are consistent with the finding that a maternal ketogenic diet can rescue 
fetal lactic acidosis and developmental delay in another model of impaired MPC function (183). 
Together, these data show that maternal fasting can ameliorate fetal defects in mitochondrial 
pyruvate metabolism. 
Fasting induces adipose triglyceride mobilization and subsequent hepatic ketone 
generation. To begin to understand the role of the enhanced lipid mobilization during pregnancy 
(20, 21), we measured several indicators of fetal lipid metabolism during maternal fasting. First, 
we observed that placental triglyceride content was increased upon fasting in placentae from both 
Mpc1KI/+ and WT dams, but fetal genotype did not affect placental TG levels (Fig. 4.2F). Fetal 
liver triglyceride content, however, depended on fetal genotype (Fig. 4.2F). Previously, Mpc1KI/KI 
late-gestation fetal livers were shown to have significantly lower triglyceride content in the fed 
state (130). Maternal fasting increased fetal liver triglyceride levels in Mpc1KI/KI fetuses, but WT 
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littermates did not demonstrate increased lipid accumulation during a maternal fast. WT fetuses 
from WT dams, however, did acquire more liver triglyceride upon fasting (Fig. 4.2F), likely 
consistent with the higher circulating NEFA in WT fasted dams relative to Mpc1KI/+ dams (Fig. 
4.1C). Despite the observed changes in liver triglyceride content, there were no obvious structural 
differences in WT and Mpc1KI/KI fetal livers (Fig. 4.2G). These data show that maternal fasting 
can alter lipid metabolism within the fetal compartment. 
 
Maternal lipid metabolism drives the fetal response to fasting.   
To determine the contribution of maternal lipid metabolism to the fetal response to 
fasting, we used a genetic model of impaired fasting—liver-specific loss of mitochondrial β-
oxidation of long-chain fatty acids via carnitine palmitoyltransferase 2 (Cpt2) (213, 219). Cpt2 
catalyzes an obligate step in the mitochondrial import of long-chain fatty acids and is encoded by 
a single gene, which makes it a genetically tractable target to block mitochondrial β-oxidation. 
Mice with liver-specific loss of Cpt2 (Cpt2L-/-) have massive hepatic lipid accumulation and 
impaired ketogenesis upon fasting with, surprisingly, no defects in gluconeogenic capacity (213). 
Female mice homozygous for the floxed Cpt2 allele (ff) were crossed to males with albumin-
driven Cre recombinase expression (C;ff), and C;ff females were crossed to ff males, such that 
both ff and C;ff fetuses could be studied from control Cpt2 ff or mutant Cpt2L-/- (C;ff) dams (Fig. 
4.S3A). Cpt2 ff and Cpt2L-/- dams were subjected to 24h food deprivation from 16.5 to 17.5 dpc, 
and, remarkably, Cpt2L-/- dams were able to maintain blood glucose concentrations to the same 
level as fasted ff dams (Fig. 4.3A). Consistent with a defect in liver fatty acid oxidation, however, 
Cpt2L-/- dams could not produce β-hydroxybutyrate (βHB) during a fast, and circulating βHB 
levels in fasted Cpt2L-/- dams were even lower than fed ff controls (Fig. 4.3A). Fasting also 
induced triglyceride accumulation in maternal liver (Fig. 4.S3B), and fasting Cpt2L-/- dams had 
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elevated circulating free fatty acid and triglyceride concentrations (Fig. 4.3A, Fig. 4.S3B). 
Altogether, the impaired ketogenesis, hepatic lipid accumulation, and elevated circulating lipid 
metabolite concentrations of Cpt2L-/- dams provide a useful model of impaired maternal fasting to 
better understand the fetal response to maternal nutrient deprivation. 
 In the model of impaired maternal fasting by liver-specific deletion of Cpt2, fasting 
reduced late-gestation fetal body weights to the same extent as had been observed in WT litters, 
with no effect of fetal or maternal genotype (Fig. 4.3B). Importantly, loss of mitochondrial β-
oxidation of long-chain fatty acids in fetal liver did not alter βHB concentrations as determined 
by 1H-NMR (Fig. 4.3C). Instead, fetal liver βHB levels reflected maternal circulating 
concentrations such that fetuses from fasted Cpt2L-/- (C;ff) dams had levels as low as fetuses from 
fed dams of either genotype (Fig. 4.3C). Fetal liver triglyceride content was also increased upon 
maternal fasting, but there was no significant effect of fetal or maternal genotype (Fig. 4.3D). 
Fetal liver and placental triglyceride content were tightly correlated, and triglyceride content was 
not increased in tissues from fetuses of fasted C;ff dams, despite their having higher circulating 
concentrations of free fatty acids and triglycerides (Fig. 4.3D). Although liver triglyceride content 
was unaffected by fetal or maternal genotype, the transcriptional response to maternal fasting was 
highly dependent on maternal genotype but not fetal genotype (Fig. 4.3E). The mRNA 
abundances of several fasting-regulated genes (Acot1, Acot2, and Pdk4) were increased in fetal 
liver in response to maternal nutrient deprivation. While fetuses from fasted ff dams responded 
similarly to WT fetuses from WT fasted dams, both ff and C;ff fetuses from fasted C;ff dams had 
significantly higher induction of these fasting-regulated genes than litters from ff dams (Fig. 
4.3E). This suggests that there may be some molecular signal whose presence or absence in 
fasted Cpt2L-/- dams promotes the exacerbated fasting transcriptional program observed in fetuses 
exposed to this intrauterine environment. 
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To further determine the effects of altered maternal lipid metabolism on fetal response, 
we sought to characterize the abundance of a class of molecules that can serve as substrates for 
the enzymatic function of Cpt2: the long-chain acylcarnitines. Cpt2 catalyzes the transacylation 
of long-chain acylcarnitines to become long-chain acyl-CoAs in the mitochondrial matrix; 
therefore, loss of Cpt2 would be expected to increase long-chain acylcarnitine concentrations. 
Acylcarnitines can be transported out of cells and into the circulation, and the profiling of 
acylcarnitine species is useful for the diagnosis of certain metabolic disorders including 
impairments in fatty acid oxidation (228). We measured both maternal blood acylcarnitines and 
fetal liver acylcarnitines from ff and C;ff dams in both the fed and 24h fasted state (Fig. 4.4A-B). 
Similar to Cpt2L-/- mice on a ketogenic diet, pregnant Cpt2L-/- mice had elevated circulating long-
chain acylcarnitine concentrations during fasting and suppressed short-chain acylcarnitines such 
as C2 (acetylcarnitine) (213). Additional short-chain acylcarnitines (C4, C5), which are derived 
from amino acid catabolism, were also down-regulated in Cpt2L-/- circulation. Free carnitine 
concentrations (C0) were also suppressed in Cpt2L-/- dams, both in the fed and fasted state (Fig. 
4.4A), consistent with previous observations that the abundance of long-chain acylcarnitines may 
be driving a systemic carnitine deficiency (213).  
We reasoned that comparing maternal blood acylcarnitines to fetal liver acylcarnitines 
may reveal patterns of similar regulation among classes of acylcarnitines while differences may 
highlight fetal liver-autonomous responses to maternal fasting. Indeed, we observed similar 
patterns of suppressed carnitine and acetylcarnitine (C2) in fetal livers from C;ff dams (Fig. 
4.4B). Again, fetal genotype did not affect acylcarnitine concentrations, and all ff and C;ff fetuses 
from the same intrauterine environment had the same acylcarnitine profiles. Interestingly, C4 and 
C5 acylcarnitines were elevated in fetal livers from ff dams upon fasting, suggesting that the 
increase of these species is part of the WT response to maternal nutrient deprivation. C4 and C5 
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acylcarnitines were not induced to higher levels in fetuses from fasted C;ff dams. These short-
chain acylcarnitines may be derived from amino acid catabolism, particularly of branched-chain 
amino acids. Interestingly, while the concentrations of isoleucine, leucine, and valine were 
slightly up-regulated in fetal liver upon fasting, steady-state concentrations of these amino acids 
were further increased in fetal livers from fasted C;ff dams, despite lower concentrations of the 
acylcarnitines that can be derived from these amino acids (Fig. 4.4C). Again, this response was 
independent of fetal genotype. The upregulation of these particular amino acids in fetal liver 
while maternal circulating concentrations of the corresponding acylcarnitines are unchanged may 
point to a fetal liver-autonomous response to maternal fasting.  
Long-chain acylcarnitine abundances were up-regulated in fetal liver from fasted ff dams, 
consistent with the increases in maternal circulating concentrations in response to fasting (Fig. 
4.4B). Interestingly, however, long-chain acylcarnitine abundances in fetal livers from C;ff dams 
were not increased to the extent that is seen in maternal blood (Fig. 4.4A). One reason for this 
may be increased maternal utilization of long-chain acylcarnitines by tissues other than liver in 
fasted Cpt2L-/- dams. Alternatively, the lower concentrations of long-chain acylcarnitines in fetal 
liver from fasted Cpt2L-/- dams could be indicative of impaired fatty acid catabolism in the fetal 
liver, perhaps related to the lower free carnitine levels observed in these livers. Acylcarnitines are 
an important class of metabolites regulated by maternal fasting that could participate in mediating 
metabolic communication between mother and fetus. 
 
Loss of hepatic fatty acid oxidation improves maternal glucose tolerance. 
 Since glucose is one of the most important metabolites made available for fetal uptake 
and metabolism, we next characterized maternal glucose homeostasis via an oral glucose 
tolerance test in late-gestation pregnant liver-specific Cpt2 KO mice. We had previously shown 
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that chow-fed Cpt2L-/- mice exhibit a modest improvement in glucose tolerance which becomes 
more apparent upon high-fat feeding (219). Much of this effect can be attributed to impaired 
hepatic gluconeogenic capacity in liver-specific Cpt2 KO mice, despite their ability to maintain 
euglycemia during a fast. Pregnancy is also a state of enhanced hepatic gluconeogenic capacity 
and transient maternal insulin resistance to promote glucose availability for fetal uptake. Late-
gestation Cpt2L-/- dams at 17.5 dpc exhibited improved glucose clearance relative to ff controls 
(Fig. 4.5A). Glucose-stimulated insulin secretion was lower in Cpt2L-/- dams, suggestive of 
enhanced insulin sensitivity in combination with the improved glucose tolerance (Fig. 4.5B).  
The secreted hepatokine Fgf21 is known to modulate glucose homeostasis (229), and, 
previously, Fgf21 mRNA in liver and circulating Fgf21 were found to be dramatically up-
regulated in Cpt2L-/- mice, particularly in response to fasting (213, 219). Fgf21 is known to be 
regulated by PPARα and to play an important role in pro-catabolic states such as fasting (230, 
231). Interestingly, we observed no difference in circulating Fgf21 between ff and C;ff dams in 
the fed state, but upon fasting, serum Fgf21 levels were halved in C;ff dams but unchanged in ff 
dams (data not shown). Liver Fgf21 transcript abundance followed this same trend, but 
suppression of Fgf21 transcript in fasted C;ff liver was even greater with levels just 30% of 
controls (data not shown). The failure to induce Fgf21 upon fasting during pregnancy may be 
consistent with the massive up-regulation in Fgf21 expression that has been observed in late-
gestation pregnant mice (232). Liver expression of Fgf21 was 60-fold higher and serum Fgf21 
was more than 8-fold higher in late-gestation mice than in non-pregnant controls (232). We 
reasoned that elevated Fgf21 during pregnancy may contribute to impaired glucose tolerance. To 
test the contribution of Fgf21 to glucose homeostasis during late gestation, we generated mice 
with liver-specific KO of Fgf21 as well as mice with liver-specific loss of both Fgf21 and Cpt2 
(221). When subjected to an oral glucose tolerance test at 17.5 dpc, we observed that loss of 
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Fgf21 did not affect glucose homeostasis and that double-knockout of Fgf21 and Cpt2 did not 
modify the enhanced glucose tolerance of liver-specific Cpt2 KO mice (Fig. 4.5C). The 
contribution of elevated Fgf21 to metabolic adaptation during pregnancy remains to be 
determined. 
 
The fetal response to fasting is Pparα-dependent and regulated by maternal metabolism.   
We next turned our attention to another model of impaired fatty acid oxidative 
metabolism, mice with whole-body deletion of the transcriptional regulator PPARα (220). Many 
of the genes observed to be transcriptionally regulated in fetal liver in response to impaired 
mitochondrial pyruvate metabolism or in response to maternal fasting are canonical PPARα target 
genes. Late-gestation fetuses with heterozygous and homozygous PPARα deletion from PPARα-/- 
dams exhibited a decrease in body weight comparable to WT litters upon subjecting the dam to 
24h food deprivation (Fig. 4.6A). Moreover, PPARα+/- and PPARα-/- fetuses from PPARα-/- dams 
were no smaller than the same fetal genotypes from PPARα+/- dams. To examine the intersection 
of maternal fasting metabolism and fetal liver response, fasting-regulated gene induction was 
measured in fed and fasted fetal livers from WT dams, PPARα+/- dams, and PPARα-/- dams (Fig. 
4.6B). All genes shown in Fig. 4.6B demonstrated PPARα-dependent fasting induction in that 
PPARα-/- livers failed to induce expression of these genes upon fasting. Interestingly, although 
not induced by fasting, Acot1 and Acot2 were higher in PPARα-/- fed livers than WT or PPARα+/- 
livers. While the fetal liver transcriptional response to fasting requires PPARα, the effect of the 
intrauterine environment is also important for eliciting these responses. Remarkably, all genes 
tested were more robustly induced in PPARα+/- fetal livers from fasted PPARα-/- dams than from 
fasted PPARα+/- dams. This suggests that a maternally-derived signal from models of impaired 
fasting can potentiate the fetal liver response to maternal nutrient deprivation. This is consistent 
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with the Cpt2L-/- model in which fetuses from fasted Cpt2L-/- dams had higher liver expression of 
certain fasting-regulated transcripts than fetuses from fasted ff control dams (Fig. 4.3E). 
 
 
4.5  Discussion 
Eutherian pregnancy is characterized by greater metabolic flexibility than in the non-
pregnant state in order to protect fetal growth from maternal nutrient deprivation (1). Here, we 
have subjected mouse models of impaired carbohydrate and lipid metabolism to metabolic 
challenge during late-gestation in order to determine both the maternal and fetal effects of 
impaired mitochondrial oxidative metabolism. Consistent with studies in fasted pregnant rats, we 
observed decreased fetal body weights, dramatic increases in maternal circulating ketone levels, 
and increased placental and fetal lipid accretion (29, 75, 92, 200). Our genetic models provide 
further insight into the metabolic factors behind these outcomes. For example, fasting-induced 
increases in placental and fetal liver triglyceride content were higher in WT dams relative to 
Mpc1-deficient dams, and these changes were proportional to maternal circulating free fatty acid 
and triglyceride concentrations. In addition, in a model of impaired hepatic ketogenesis by liver-
specific deletion of Cpt2, fetal liver concentrations of β-hydroxybutyrate were directly related to 
maternal circulating concentrations, and the capacity for fetal liver fatty acid oxidation made no 
contribution to ketone levels. The dramatic increase in circulating ketones is one hallmark of the 
“accelerated starvation” response of pregnancy (6, 186). We demonstrate that maternal liver fatty 
acid oxidation, in combination with increased serum concentrations of triglyceride, 
phospholipids, and non-esterified fatty acids (NEFA), may help mediate this metabolic 
adaptation. Levels of these metabolites increase over the course of gestation, and circulating 
triglyceride levels, for example, increase more than 250% by the end of pregnancy, which is 
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almost twice the post-prandial concentration in a non-pregnant individual (17, 185). The increase 
in concentrations of these lipids and lipid-derived metabolites is so dramatic that overnight 
fasting (14-18h) in normal late term pregnancy leads to serum metabolite concentrations that rival 
the effects of 2-3 days of starvation in non-pregnant individuals (186, 187). Fasting during 
pregnancy results in an earlier than normal shift from glucose to fat utilization by maternal tissues 
to spare glucose and amino acids for fetal uptake (187), and mitochondrial metabolism is an 
important regulator of these changes in substrate utilization. 
Maternal hormones certainly play a role in the adaptive response to fasting, but 
accelerated fasting is most apparent during late gestation when the conceptus is large enough to 
challenge maternal energy reserves. Fetal signals may also contribute, as suppressed insulin and 
elevated glucagon were measured in fetal circulation upon maternal nutrient deprivation (200). In 
addition, another endocrine molecule that has been shown to promote the accelerated maternal 
fasting response during pregnancy is delta-like homolog 1 (DLK1). Loss of DLK1 increased 
adiposity in females before pregnancy, and circulating levels of DLK1 increased 5-fold in the 
first two weeks of mouse pregnancy (233). The majority of circulating DLK1 during pregnancy is 
from the fetus, and females without pregnancy-associated DLK1 failed to up-regulate ketogenesis 
during a fast (233). However, other secreted molecules that regulate fuel utilization in adult 
animals may have different roles during pregnancy. For instance, serum Fgf21 concentrations 
increase 8-fold over the course of mouse gestation (232), but we have found that liver-derived 
Fgf21 does not alter maternal glucose homeostasis during late gestation. Loss of hepatic fatty acid 
oxidation by liver-specific deletion of Cpt2, however, does improve maternal glucose tolerance. 
This is likely due to an impaired capacity for hepatic gluconeogenesis by maternal liver without 
Cpt2, as enhanced gluconeogenesis during pregnancy may contribute to the transient glucose 
intolerance and insulin resistance of pregnancy. In addition, long-chain acylcarnitines have been 
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associated with insulin resistance, but it is unclear if these molecules play a role in promoting 
insulin resistance or are simply evidence of impaired metabolic plasticity (234). Serum samples 
from pregnant women undergoing an oral glucose tolerance test around 25 weeks gestation 
revealed a decrease in several medium- and long-chain acylcarnitine species upon glucose 
administration, as expected (235). Although acylcarnitine species were not associated with 
glucose intolerance in this cohort, several triglyceride species were found to be correlated with 
gestational diabetes status in these women (235). Long-chain acyl-CoAs, diacylglycerides, 
ceramides, and triglycerides have all been implicated in lipotoxic mechanisms of insulin 
resistance as these molecules are up-regulated in models of diet-induced obesity as a result of 
metabolic overload (236). It is interesting that, despite having elevated concentrations of long-
chain acylcarnitine species, pregnant mice with liver-specific deletion of Cpt2 have better glucose 
homeostasis than controls. This finding suggests that hepatic gluconeogenesis may be a larger 
contributor to glucose intolerance during pregnancy than particular classes of lipids or impaired 
hepatic fatty acid oxidative metabolism. 
 Hepatic lipid metabolism is a critical regulator of the maternal response to fasting during 
pregnancy. Rates of mitochondrial β-oxidation of [U-14C]palmitate to acid-soluble products by 
mouse liver mitochondria decreased by 50% during late gestation relative to non-pregnant 
controls (237). Similarly, rates of [14C]CO2 exhalation from gastric administration of uniformly 
labeled or 1-14C-labeled fatty acids were also decreased in pregnant dams (237). A challenge of 
these experiments is the proper dosing of fatty acids with increased maternal body weight and 
also increased endogenous circulating lipid levels during late gestation. Nevertheless, this study 
suggests that maternal liver fatty acid oxidation may change over the course of gestation, 
consistent with a changing role of and demand for lipids and lipid-derived metabolites by the 
developing fetus. It is well known that fatty acid oxidation fuels gluconeogenesis and that 
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maternal gluconeogenic capacity increases over the course of gestation. Isotopic labeling studies 
in pregnant women have demonstrated a 30% increase in total gluconeogenesis from early to late 
pregnancy (11 to 34 weeks gestation) (15). It is unclear, however, to what extent placental or fetal 
gluconeogenesis could contribute to meet metabolic demand. A few reports provide evidence for 
glucose production by the placenta, but the capacity for and regulation of this potential source of 
increased glucose production during late gestation is not well understood (56, 57). Fetal liver 
extracts have demonstrated increased PEPCK and glucose-6-phosphatase activity upon fasting. In 
addition, fetal liver explants demonstrated increased lactate, alanine, serine, and glycerol 
conversion to glucose (200). This capacity is consistent with our observation that Pck1 expression 
in fetal liver increased upon fasting and with increasing gestational age. Furthermore, Pck1 was 
still induced in fetal livers with impaired fatty acid oxidation, but it is unclear to what extent fetal 
liver fatty acid oxidation may contribute to meeting the energetic and reducing power needed to 
fuel gluconeogenesis. These studies suggest that during late gestation and upon extreme maternal 
fasting it is possible to prematurely implement fetal gluconeogenesis, a capacity that is normally 
reserved for the early postnatal period after the maternal fuel supply has been interrupted at birth 
(24). The increase in Pck1 expression suggests that disruption of maternal nutrient supply and 
metabolic communication by a severe fast is sufficient to induce these adaptations in the fetus. 
 Although deletion of Cpt2 in fetal liver did not affect triglyceride content, acylcarnitine 
abundance, β-hydroxybutyrate levels, or the fetal liver transcriptional program, it is significant 
that fetal liver acylcarnitine concentrations largely reflected maternal circulating acylcarnitine 
abundances. Studies in humans demonstrated that carnitine levels in cord blood are higher than in 
maternal blood and that pregnant women have lower free carnitine concentrations than non-
pregnant women (91, 238). These data are strong evidence for placental transport and fetal 
accumulation of these molecules. Remarkably, placental carnitine concentrations were found to 
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be more than 7-fold higher than in heart or any other tissue tested (239). Free carnitine accounts 
for 85% of placental total carnitines (53% of total placental carnitines in humans (240)), and 
deletion of the carnitine transporter OCTN2 (Slc22a5) in mouse reduced placental carnitine 
concentrations to less than 10% of wild-type levels (239). In addition to the placental transport of 
maternal acylcarnitines, we also observed some species of acylcarnitines that were selectively up-
regulated in the fetal liver, for example C4 and C5 short-chain acylcarnitines were increased upon 
fasting in fetal liver only. These molecules may be derived from amino acid catabolism, and 
fasting led to significant increases in circulating total amino acid concentrations in both maternal 
and fetal circulation (200). Related to fetal capacity for amino acid catabolism and biosynthesis, 
we observed that Glud1, which encodes glutamate dehydrogenase, was down-regulated while 
Got1, a cytosolic aspartate aminotransferase, was up-regulated by fasting in fetal liver (Fig. 
4.2A,B). Counter-regulation of these two enzymatic activities has been previously described in 
the context of the transition from proliferation to quiescence in order to ensure non-essential 
amino acid biosynthesis by the transaminases during proliferation (178). As pharmacological 
inhibition of the mTOR pathway has been linked to increased Glud1 and decreased transaminase 
expression (178), the regulation in fetal liver may be consistent with mTOR activation; however, 
preliminary studies revealed no evidence for mTOR activation in fetal liver upon maternal fasting 
(data not shown). Moreover, Mpc1KI/KI fetal livers demonstrated a trend toward increased Got1 
expression, and this could be related to the elevated aspartate levels observed in this model. 
GOT1 promoted aspartate consumption in nutrient replete conditions and was required for 
aspartate production in the context of impaired electron transport chain function (154). 
Interestingly, the elevated aspartate observed in Mpc1KI/KI fetal livers was decreased back to WT 
levels in response to maternal fasting. 
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 Importantly, lactate accumulation in Mpc1-deficient fetal tissues was rescued to WT 
levels upon maternal fasting. Using mouse embryonic fibroblasts with Mpc1 deletion, we 
demonstrated that the addition of 1mM D,L-β-hydroxybutyrate for 24h was sufficient to rescue 
lactate accumulation in this culture model. Ketones can serve as alternative oxidative substrates 
for mitochondrial metabolism during fasting, and concentrations of ketones in the maternal 
circulation are dramatically up-regulated as part of the accelerated fasting response. We 
demonstrated that loss of fatty acid oxidation in fetal liver did not affect concentrations of β-
hydroxybutyrate (βHB), but that fetal liver concentrations were largely reflective of maternal 
circulating levels. Consistent with this, maternal fasting was found to increase the capacity for 
βHB transport in late-gestation microvillous membrane vesicles isolated from rat placenta (241). 
Towards a mechanism for how the presence of ketones could affect lactate concentrations, a 
study of first-trimester human trophoblasts demonstrated that ketones decreased glucose uptake in 
a dose-dependent manner (242). Also, the presence of βHB and acetoacetate could alter 
NAD+/NADH redox balance and regulation of lactate dehydrogenase, pyruvate dehydrogenase, 
and other cellular dehydrogenases. Although the capacity for ketogenesis from medium- and 
long-chain fatty acids was low in hepatocytes from newborn fetal rat liver, fatty acid oxidation 
and ketogenesis increased in fasted neonatal liver relative to newborn controls (243). 
Nevertheless, the capacity to utilize maternally-derived ketones may be intact before birth, and 
ketones may represent an important oxidative substrate for the fetus during maternal nutrient 
limitation. 
In addition, fetal utilization of lactate could be another way in which steady-state lactate 
levels are reduced by maternal fasting. Umbilical uptake of oxygen and glucose were found to be 
45% and 75% lower, respectively, than the total uterine uptake in sheep, suggesting significant 
glucose oxidation by the placenta (59). In an ovine model of impaired placental growth, oxidative 
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metabolism of glucose by placenta was impaired, but lactate efflux to the umbilical vein was 
increased and fetal lactate consumption increased as a result (60). In late gestation, maternal 
gluconeogenesis is elevated to ensure adequate glucose supply to the fetal compartment, and 
lactate is an important gluconeogenic substrate. However, only 40-50% of lactate was used for 
gluconeogenesis in late-gestation pregnant rats, as compared to 70-80% in non-pregnant rats, 
suggesting that fetal utilization of lactate may account for the difference (27). Studies in fetal 
lamb confirm that lactate concentrations are higher in fetal umbilical vein than in fetal artery, 
again consistent with the fetus being a net consumer of lactate (61). Recent magnetic resonance 
imaging studies using hyperpolarized [1-13C]pyruvate administered to late-gestation pregnant rats 
resulted in clear placental localization of signal as well as evidence of conversion to [1-13C]lactate 
and [1-13C]alanine in maternal organs and in placenta. Importantly, the intensity of the [1-
13C]lactate signal from placenta was lower in a rat model of preeclampsia, and this reduction in 
signal is not due to changes in placental perfusion but rather likely represents impaired placental 
metabolism of pyruvate (62). Together, these observations challenge the dogma that in utero 
development is characterized by low oxygen tension and is not conducive to mitochondrial 
oxidative metabolism. While this may be true during early development, once placental exchange 
function is developed and fetal mitochondrial biogenesis begins (63), the fetus is poised to utilize 
oxidative metabolism for energy production and anabolism. 
Together, our genetic mouse models of impaired mitochondrial pyruvate and fatty acid 
metabolism demonstrate the importance of mitochondrial oxidative metabolism in regulating both 
the maternal and fetal response to nutrient deprivation. Despite the nutritionally-sensitive nature 
of this stage in mammalian development, there exists remarkable metabolic plasticity and 
crosstalk among these major pathways of central carbon metabolism. Maternal-fetal metabolic 
communication helps ensure adequate nutrient exchange and is particularly important during 
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times of nutrient limitation. Miscommunication may result in metabolic complications during 
pregnancy including gestational diabetes, and promoting healthy maternal-fetal metabolic 
communication may prove an important therapeutic approach for metabolic disorders of 
pregnancy. 
 
 4.6  Future Directions 
To address the sufficiency of β-hydroxybutyrate to suppress fetal lactate accumulation in 
the Mpc1-deficient mouse model, pregnant dams will be infused with β-hydroxybutyrate (βHB) 
or PBS using Alzet osmotic minipumps implanted subcutaneously early in gestation (244). We 
expect the infusion of βHB will largely recapitulate the effects of maternal fasting on fetal 
metabolism in Mpc1-deficient fetal tissues. The same approach can be used in the liver-specific 
Cpt2 loss-of-function mouse model, with the expectation that βHB infusion will largely rescue 
the metabolic and transcriptional defects in fetuses from liver-specific Cpt2 KO dams. 
Additionally, a dietary rescue approach could be attempted using a diet rich in medium-chain 
fatty acids to restore ketogenesis in the Cpt2 KO liver, as medium-chain fatty acids do not require 
the carnitine shuttle system to gain access to the mitochondrial matrix. Finally, we are using a 
genetic approach to define the contributions of liver fatty acid oxidation to maternal adaptation in 
Mpc1-deficient pregnant dams by generating double knockout mice such that dams heterozygous 
for Mpc1 deficiency will also have liver-specific loss of Cpt2. We expect that loss of Cpt2 on top 
of Mpc1 deficiency may prevent the rescue of fetal lactate concentrations by maternal fasting. 
Furthermore, heterozygosity for Mpc1 may affect the capacity of other tissues to compensate for 
the loss of liver fatty acid oxidation.  
To further address the metabolic fates of mitochondrial pyruvate, the lab has acquired a 
hypomorphic allele and a floxed allele of pyruvate carboxylase (Pcx). The loss-of-function allele 
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and liver-specific deletion of pyruvate carboxylase will be used to probe the developmental and 
metabolic requirements for mitochondrial pyruvate-mediated anaplerosis during fetal 
development and the maternal response to fasting. Preliminary data suggests that the whole-body 
hypomorphic allele results in early postnatal lethality, consistent with the prognosis for human 
patients with mutations in PCX (245-247). This allele may help define the contribution of 
mitochondrial pyruvate and Pcx-derived oxaloacetate to fetal growth and de novo lipogenesis. In 
addition, this model can be used to determine the contribution of maternal and fetal 
gluconeogenesis during maternal nutrient deprivation. We expect impaired gluconeogenesis in 
liver-specific Pcx KO dams, which may result in elevated rates of ketogenesis as a compensatory 
mechanism. 
In addition, we would like to address how the intrauterine environment primes the 
neonate for early postnatal life. Preliminary studies on the effects of maternal contributions to 
early postnatal metabolism are addressed in the next section. 
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5.  Maternal Lipid Metabolism Directs Postnatal Metabolism 
Not only does the transition to independent life at birth initiate dramatic changes in 
neonatal metabolism as compared to fetal metabolism, but maternal whole-body metabolic 
homeostasis and energy budgets shift during the transition from pregnancy to lactation, too. Here 
we describe both the maternal and neonatal changes in energy metabolism after parturition and 
we examine preliminary studies of impaired neonatal metabolism in our mouse models of 
impaired fatty acid oxidation. 
 
5.1 Maternal Metabolic Changes Support Lactation 
After parturition, neonatal mammals receive nutritional support from the mother’s milk. 
While there are vast differences across species in how independent and precocious the neonate is, 
what the nutrient content of milk is, how milk composition changes over lactation, and how long 
is the duration of lactation, all mothers must adopt new strategies to meet the metabolic demands 
of lactation. These strategies may change maternal energy expenditure, mobilization of adipose 
stores, and metabolic/hormonal communication to coordinate milk production. 
Two of the primary hormones that promote and regulate lactation are prolactin and 
oxytocin, secreted by the anterior and posterior pituitary, respectively (4). Prolactin works in 
concert with insulin and cortisol to promote milk fat and milk protein production by the secretory 
cells of the mammary gland. Oxytocin is part of the neuroendocrine loop that promotes milk 
expression (4). Fgf21 is another secreted molecule recently implicated to play metabolic 
regulatory roles in pregnancy and lactation based on studies in whole-body Fgf21 knockout mice 
(248, 249). In mice, hepatic Fgf21 expression increases throughout the course of pregnancy 
(232), and Fgf21 levels remain 2.4-fold higher than non-pregnant, non-lactating levels by 7 days 
of lactation and remain high, even three weeks after weaning (249). Fgf21 was required for 
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pregnancy-induced cardiac remodeling (248), and a comprehensive study of bone remodeling 
during lactation found that Fgf21 KO mice were protected from loss of bone mass during 
lactation (249). It is unknown whether Fgf21 could play additional roles in mediating changes in 
maternal energy expenditure during pregnancy and lactation, although we have shown that liver-
derived Fgf21 does not affect maternal glucose homeostasis during late gestation. 
In humans, maternal energy expenditure and basal metabolic rate were higher during 
pregnancy than during lactation, based on longitudinal studies conducted in late-gestation 
pregnant women and then 3 and 6 months postpartum in both lactating and non-lactating mothers 
(33). Lactating mothers also had higher energy expenditure and basal metabolic rate than non-
lactating mothers, and the higher respiratory quotient and net carbohydrate utilization measured 
in pregnancy was also sustained during lactation (33). This suggests that the increased energy 
costs of milk synthesis by mammary gland are largely met with glucose. Maternal blood glucose 
is the precursor for the synthesis of lactose, the major carbohydrate found in human milk (4). 
Butte and King offer a comprehensive review on human energy expenditure and energy 
requirements during lactation (250). 
In small mammals, lactation is more energetically expensive than pregnancy (251). In 
rodents, in particular, hyperphagia meets the increased energy demands of lactation. In addition, 
rodents exhibit suppressed brown adipose tissue thermogenesis and enhanced mobilization of 
maternal adipose depots that also contribute to meeting the high metabolic demand of lactation 
(251). Because marsupials are born at a much earlier stage of development, lactation plays a 
greater role in marsupial development, emulating later stages of eutherian in utero development 
(45). Remarkably, some pinnipeds do not eat during lactation, and, in these species, mobilization 
of maternal fat stores is the principal or only route for funding milk production (252, 253). These 
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examples highlight some of the extreme metabolic adaptations in place to support lactation and its 
key role in early postnatal development across mammalian species. 
Given that the largest proportion of calories in the milk of many species comes from 
lipids (254), we turn our attention back to maternal adipose tissue and lipid mobilization. Despite 
the increased metabolic demand of lactation in small mammals, overall efficiency of energy 
utilization does not change over the course of pregnancy/lactation (251). Brown adipose tissue 
thermogenic activity, however, is reduced during lactation, as a result of decreased sympathetic 
activation. Expression of the mitochondrial uncoupling protein, Ucp1, was decreased in the 
brown adipose tissue of mice during early lactation (249). It has been proposed that this 
“functional atrophy” of brown adipose tissue provides a net savings in energy expenditure that 
can reduce the energy requirements of lactation (251). Another way to reduce the energy costs of 
lactation is to mobilize adipose stores to fuel milk production. During pregnancy, the 
concentrations of circulating lipid metabolites increase over the course of gestation (17). While 
maternal serum triglyceride concentrations drop after parturition, lactation further decreases 
circulating triglyceride levels to pre-conception levels by 8 to 12 weeks after birth (185). This 
suggests that tissue-specific utilization of VLDL for milk synthesis by the mammary gland could 
underlie the decrease in circulating TG during lactation. The use of preformed fat should be more 
biochemically efficient for milk production than de novo lipogenesis or utilization of dietary fats, 
for example (250). The life histories, neonatal requirements, and dietary patterns of different 





5.2 Metabolic Adaptations of Early Postnatal Life 
While dogma posits that fetal metabolic needs are largely met by glucose, we have 
observed remarkable metabolic plasticity during late-gestation fetal development that permits 
compensation by amino acid and lipid utilization, particularly during times of nutrient deprivation 
(130, 210). Some of these fetal metabolic adaptations hint at an accelerated shift towards a 
metabolic program that resembles postnatal metabolic strategies. Here we describe some of the 
key adaptations in neonatal metabolism that promote energy acquisition from a high-fat milk diet. 
At birth, maternal and fetal metabolic exchange is immediately interrupted. As such, 
neonates must rely on glucose mobilized from glycogen stores or produced from gluconeogenesis 
in the early postnatal period before suckling begins (24). Elevated glucagon (and decreased 
insulin) is an important metabolic signal that increases neonatal liver glycogenolysis and 
gluconeogenic flux. The activities of key gluconeogenic enzymes, including pyruvate 
carboxylase, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase, increase after birth 
(24). In neonatal liver, as in adult liver, fatty acid oxidation provides the energy to fuel 
gluconeogenesis. In the early postnatal period, lipolysis from adipose depots provides this fuel, as 
demonstrated from increased circulating free fatty acids and ketones after birth, particularly in 
human neonates with adequate adipose depots at birth (17). Measurement of oleate oxidation 
from fetal hepatocytes vs fasted newborn hepatocytes demonstrated increased fatty acid oxidation 
at later postnatal ages. The increase in fatty acid oxidation was concurrent with decreased de novo 
lipogenesis and lower levels of malonyl-CoA, which serves as a negative allosteric regulator of 
CPT1 of the carnitine shuttle for long-chain fatty acid import by mitochondria (255). 
Once milk consumption begins, dietary fats are used to fuel fatty acid oxidation for 
ketogenesis and to support gluconeogenesis if dietary carbohydrates from milk are low. 
Importantly, young neonates are heavily reliant on carnitine provided from the mother’s milk 
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until the capacity for carnitine biosynthesis by the liver fully develops (238). The importance of 
milk in providing carnitine is evident in mice lacking the carnitine transporter OCTN2, which 
only survive 3 to 4 weeks (at the time of weaning) unless carnitine supplementation is 
administered (239). These mice deficient in carnitine transport, which limits carnitine availability 
both from diet and from endogenous synthesis in the liver, have severe hepatic steatosis and 
cardiomyopathy, as to be expected with severe defects in fatty acid oxidation (239). Dietary 
sources of carnitine are also important in adult humans, as 75% of carnitine comes from the diet 
(238), but the dietary significance of carnitine is particularly important during early postnatal 
development. Systemic levels of carnitine are balanced by ingestion/intestinal uptake; 
biosynthesis in liver; uptake/release by other tissues; and clearance by kidney. Newborn urine 
contains higher levels of acetylcarnitine than free carnitine, and this trend is reversed in adults, 
suggesting that when the neonate is dependent on mother’s milk for carnitine, free carnitine 
concentrations are carefully guarded (256). Carnitine supplementation for neonates with 
metabolic acidurias may assist in urinary clearance of some of these metabolites as carnitine 
esters (238). Carnitine supplementation has also been recommended for low birth weight 
neonates, as carnitine can enhance fatty acid oxidation and increase ketogenesis (238, 256). The 
importance of ketones as a metabolic substrate for neonates will be addressed in the next section. 
It would be interesting to determine the effect of carnitine on fatty acid utilization and fetal 
growth in the Mpc1-deficient mouse model. Our plans to generate Mpc1; Cpt2 double knockout 
mice may address some of these questions as dams heterozygous for Mpc1 with liver-specific 
deletion of Cpt2 would be expected to have lower carnitine and impaired ketogenesis. Maternal 




Ketones, products of mitochondrial β-oxidation of fatty acids, are an important oxidizable 
substrate during times of nutrient deprivation but also throughout early postnatal development as 
the neonate consumes a high-fat milk diet. We have demonstrated that fetal uptake of β-
hydroxybutyrate (βHB) is based on maternal circulating concentrations and that endogenous fatty 
acid oxidation does not contribute appreciably to βHB levels in fetal liver (210). Administration 
of a ketogenic diet during gestation can alter fetal and neonatal brain structures (183, 184). Rather 
unexpectedly, ketogenic feeding of lactating dams was associated with increased risk of fatal 
ketoacidosis during lactation in wild-type mice, and removal of the suckling neonates was 
sufficient to reverse and prevent critical ketoacidosis (184). This highlights the extreme metabolic 
demand that lactation places on maternal metabolism. In terms of neonatal metabolism, 
ketogenesis from dietary milk is particularly important during the early postnatal period and 
ketogenic capacity declines at weaning and the transition to a high-carbohydrate diet (144). The 
developing brain is particularly reliant on ketones for energy production (43), although the 
contribution of local ketone production vs peripheral ketogenesis is another question of interest in 
the Wolfgang laboratory. In addition to the utilization of ketones, it has been shown that 
astrocytes in the developing rat brain have the capacity for long-chain fatty acid oxidation and the 
expression of genes involved in mitochondrial β-oxidation of long-chain fatty acids are increased 
over early postnatal development and may be correlated with increased concentrations of long-
chain acylcarnitines in brain tissue (257). The genetic requirement for ketone oxidation by 
peripheral tissues has been characterized using mouse models of tissue-specific deletion of Oxct1, 
the succinyl-CoA transferase that mediates the first step in ketone oxidation (258-260). 
Remarkably, while whole-body impairment in ketolysis is lethal within 48h of birth, tissue-
specific deletion of this enzyme in neurons, cardiomyocytes, or skeletal myocytes is permissive 
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for neonatal life, and adult tissue-specific Oxct1 KO mice tolerate starvation with only modest 
increases in ketone levels (260).  
Altogether, these observations and genetic models demonstrate the importance of fatty 
acid oxidation, ketogenesis, and gluconeogenesis during the early postnatal period when neonatal 
metabolism relies on high-fat milk. To specifically understand the role of liver mitochondrial β-
oxidation of long-chain fatty acids during early postnatal metabolism, we have begun to study 
neonatal mice at postnatal day 2 with liver-specific deletion of carnitine palmitoyltransferase 2, 
Cpt2, born to and reared by WT or liver-specific Cpt2 KO dams. This is a logical continuation of 
our studies in utero in which we can decipher maternal and fetal effects in response to metabolic 
challenge. Here, maternal effects and neonate-autonomous effects are being described based on 
cross-fostering experiments in which pups born to WT dams are switched to being reared by 
liver-specific KO dams (and vice versa) on the day of birth. There are many interesting questions 
about fetal-neonatal metabolic transitions as well as the transition from pregnancy to lactation 
that can begin to be addressed using these genetic models. 
 
 
5.3  Maternal-Dependent Regulation Persists to the Early Postnatal Period 
To determine the requirements for hepatic mitochondrial β-oxidation of long-chain fatty 
acids in early postnatal metabolism, mice with liver-specific deletion of Cpt2 and littermate 
controls were born to and reared by Cpt2L-/- (C;ff) and ff control dams. By postnatal day 2 (P2), ff 
and C;ff pups born to C;ff dams were significantly smaller than ff pups born to ff dams (Fig. 
5.1A). There was also a trend toward lower blood glucose and decreased milk consumption, as 
measured by stomach weight, in pups reared by C;ff dams (Fig. 5.1A). There was a slight but not 
significant increase in liver triglyceride content in C;ff pups compared to ff controls reared by ff 
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or C;ff dams (Fig. 5.1B). Despite this, livers of P2 C;ff pups were noticeably paler than ff livers, 
and more lipid-laden as can be seen from histological sections of these livers (Fig. 5.1C). 
Postnatal day 2 was chosen as an endpoint because PPARα-/- mice were found to have marked 
hepatic lipid accumulation by P2 (227), as we have also observed (Fig. 5.1B).  
We next measured the gene expression for two genes which are known to be highly up-
regulated in adult Cpt2 KO liver upon fasting, Acot1 and Fgf21 (213). Acot1 was up-regulated at 
both the transcript and protein level in C;ff livers (Fig. 5.1D,E). This transcriptional response in 
P2 liver represents the earliest significant difference observed between ff and C;ff livers, as all 
fetal outcomes measured were unaffected by fetal genotype (210). The up-regulation of Acot1 by 
neonatal liver is likely PPARα-independent, as PPARα-/- neonates also demonstrated increased 
expression of Acot1 (Fig. 5.1D). The expression of Fgf21, on the other hand, was highly PPARα-
dependent, as others have also shown in neonatal liver (227, 261). Fgf21 expression was barely 
detectable in PPARα-/- liver, and levels in pups born to C;ff dams were equally low (Fig. 5.1D). 
Fgf21 expression was slightly higher in C;ff pups relative to ff pups. Remarkably, when pups 
born to C;ff dams were cross-fostered to ff dams on the day of birth, Fgf21 expression was 
markedly increased over pups reared by C;ff dams (Fig. 5.1D). Similarly, when pups born to ff 
dams were cross-fostered by C;ff dams, there was a slight suppression in Fgf21 expression (Fig. 
5.1D,E). Acot1 followed a similar trend in that it was robustly induced in litters born to C;ff dams 
but cross-fostered to ff dams (Fig. 5.1E). These findings suggest that maternal effects 
communicated via milk can override neonatal transcriptional responses programmed from 
development in utero. 
We also measured the abundances of blood acylcarnitines in P2 pups, as is routinely done 
to screen for inborn errors of metabolism (228). Interestingly, despite differences in liver 
transcriptional responses between ff and C;ff pups from the same litters, there were no differences 
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in free carnitine or acetylcarnitine abundances between ff and C;ff pups. This, too, suggests that 
maternal effects dominate, supplied via milk composition. Even more remarkable is that for 
cross-fostered litters, despite two days of nutrition from a dam of the opposite genotype, the 
carnitine concentrations more closely resembled the carnitine abundances of litters from the birth 
mother (Fig. 5.1F). For example, litters born to ff dams did not become carnitine-deficient when 
fostered by a C;ff dam, and pups born to C;ff dams failed to increase free carnitine concentrations 
when nursed by ff dams. This may indicate that more time may be necessary to increase or 
deplete carnitine concentrations in the early postnatal circulation. Interestingly, acetylcarnitine 
was up-regulated by both cross-fostering conditions relative to birth mother. Neither carnitine nor 
acetylcarnitine was significantly regulated by PPARα deficiency (Fig. 5.1F). 
These preliminary studies demonstrate that the fetal transcriptional response can be very 
different from adult liver, and that maternal effects on neonatal transcription and metabolism are 
mostly determined by the genotype of the dam providing milk to the neonate rather than the birth 
dam. An exception to this was neonatal carnitine concentrations which were more reflective of 
intrauterine environment than current milk provision. Different genes may also display unique 
patterns of transcriptional regulation based on in utero environment vs postnatal nutrition. 
Interestingly, Fgf21 is suppressed in neonatal fasting liver (261), which is the opposite regulation 
as in adult liver where fasting dramatically increases expression (213), and this may be partly 
mediated by histone acetylation and β-hydroxybutyrate-mediated inhibition of histone 
deacetylase (HDAC3) (227). Immunoblotting for lysine acetylation revealed a slight increase in 
acetylation of a protein of unknown identity in neonatal liver of pups reared by C;ff dams (Fig. 
5.1E). Preliminary studies suggest that neonatal genotype did not affect protein acetylation, but it 
may be of interest to characterize histone acetylation status in these models. 
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The neonatal liver model of impaired fatty acid oxidation is different from fetal liver 
because the effects of liver fatty acid oxidation are now apparent as differences in liver 
triglyceride content and transcriptional differences. It is interesting that PPARα-/- livers exhibited 
significantly more triglyceride accumulation than Cpt2 KO livers, and PPARα-/- neonates were 
not carnitine-deficient like pups born to C;ff dams were. One possibility is that the dramatic 
increase in triglyceride accumulation in PPARα-/- livers may be the result of whole-body 
impairments in fatty acid oxidation. It would also be of interest to characterize differences in 
heart and brain metabolism in liver-specific Cpt2 KO neonates, for example. It will be necessary 
to measure liver β-hydroxybutyrate concentrations in ff and C;ff pups to demonstrate impaired 
ketogenesis. If C;ff pups fail to generate ketones like C;ff adult liver (as would be expected), this 
may represent an excellent model in which to characterize the effects of peripheral ketones on 
brain metabolism and development. 
In order to determine the maternal factors affecting neonatal response, it may be 
necessary to characterize the milk composition of ff and C;ff dams. At the least, it may be 
interesting to measure acylcarnitine concentrations in milk since free carnitine and long-chain 
acylcarnitine concentrations are known to be different in maternal serum of ff and C;ff late 
gestation dams (210). In humans, maternal plasma acylcarnitines are similarly reflected in milk 
composition, with the exception that maternal serum acylcarnitines are always lower than 
acylcarnitine concentrations in milk (238). It may also be necessary to determine how long it 
takes for cross-fostering to reverse some of the metabolic effects such as carnitine levels. In 
addition, it may be interesting to determine when C;ff pups become carnitine-deficient like C;ff 
adults, or if milk provision of free carnitine prevents this until weaning. If defects in protein 
acetylation are detected in C;ff livers, it may be interesting to try metabolic rescue by injection of 
β-hydroxybutyrate or increasing the medium-chain fatty acid content of the milk. Attempts to 
103 
 
rescue liver-specific Cpt2 KO phenotypes may affect metabolism, post-translational 
modifications, or transcriptional regulation, and it will be of interest to determine which factors 
reverse which of these phenotypes. Furthermore, a more global assessment of transcriptional 
regulation may provide insight into the factors that affect transcriptional responses to impaired 
mitochondrial oxidative metabolism between different nutritional conditions or even between 
different developmental stages. By studying transitions in macronutrient metabolism at different 
stages of life, it may be possible to identify unifying features regulating these metabolic 
adaptations. 
Here, we have demonstrated that early postnatal metabolic responses are sensitive to 
maternal genotype. Cross-fostering experiments have demonstrated that some, but not all, of the 
metabolic responses of pups born to dams with impaired lipid metabolism can be reversed. We 
have defined a useful genetic system to characterize factors that affect neonatal fatty acid 
metabolism in the transition to independent life at birth. These studies complement our 
investigations into fetal mitochondrial oxidative metabolism in response to maternal nutrient 




6. Frontiers in Defining Maternal-Fetal Metabolic Communication 
Gestational success requires metabolic, hormonal, and immunological communication 
between mother and fetus. Using mouse models of impaired mitochondrial pyruvate and fatty 
acid metabolism we have characterized fetal and maternal responses to nutrient deprivation. The 
use of genetic models and biochemical approaches to obtain a greater mechanistic understanding 
of maternal-fetal metabolic communication may inform interventions for common conditions 
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such as gestational diabetes (201) as well as rare disorders with a genetic component (208). In 
addition, these same genetic models are providing insight into metabolic adaptations during early 
postnatal life and how maternal contributions affect neonatal responses. Future studies will 
include mouse models combining genetic deficiency of both mitochondrial pyruvate and fatty 
acid metabolism. In addition, metabolic rescue experiments will be employed to determine the 
sufficiency of particular substrates to reverse the observed phenotypes. Advances in isotopic 
labeling approaches and imaging technologies in vivo will also serve to advance the field of 
maternal-fetal metabolic communication. Significant metabolic communication and cooperation 
are necessary between mother and fetus. Fetal demands and maternal countermeasures are always 
at work to compromise for a balance that will suit both mother and fetus, and there is both 
harmony and conflict under nearly all maternal-fetal interactions. 
Advances in systems biology and longitudinal studies of human pregnancy across large 
populations with data about neonatal outcomes will also prove instrumental in the next wave of 
investigations into maternal-fetal metabolic communication. These may inform new animal 
models and genetic approaches to define and treat metabolic disorders of pregnancy. Moreover, 
an entirely new field of investigation in fetal-maternal communication includes the study of 
exosomes, which are membrane-bound extracellular vesicles that contain cytoplasmic 
components of the cells from which they were released. Exosomes derived from the placenta are 
evident in the maternal circulation as early as six weeks gestation (262). Placental exosomes may 
also play an important role in placental development and syncytiotrophoblast fusion (263), and 
exosomes derived from maternal adipose tissue could mediate cross-tissue communication 
between the placenta and maternal tissues (264). Exosomes may also be a way of delivering 
maternal cargo to the fetus; however, placental exosomes have not been identified in the fetal 
circulation in humans, although exosomes from syncytiotrophoblast and from umbilical cord 
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mesenchymal stem cells have been detected in umbilical blood (265). Milk exosomes may even 
contribute to neonatal nutrition and immunity (266). Altogether, exosomes and their cargo may 
provide an additional means of communication between mother and offspring. 
Given that pregnancy may be the most nutritionally sensitive stage in the life cycle, 
nutritional interventions during pregnancy may have the greatest capacity to benefit maternal, 
fetal, and infant health. Improved nutrition during gestation and early postnatal life may improve 
overall health and reduce the likelihood of chronic disease in adulthood. Studies of macronutrient 
metabolism during pregnancy and lactation may inform therapeutic approaches to improve 




Appendix:  The Mammalian Malonyl-CoA Synthetase ACSF3 Is Required for 
Mitochondrial Protein Malonylation and Metabolic Efficiency 
 
Adapted from (222): Bowman CE, Rodriguez S, Selen Alpergin ES, Acoba MG, Zhao L, Hartung 
T, Claypool SM, Watkins PA, Wolfgang MJ. 2017. The Mammalian Malonyl-CoA Synthetase 
ACSF3 Is Required for Mitochondrial Protein Malonylation and Metabolic Efficiency. Cell Chem 
Biol 24:673-684 e674. 
 
SUMMARY 
Malonyl-CoA is a central metabolite in mammalian fatty acid biochemistry generated and 
utilized in the cytoplasm; however, little is known about noncanonical organelle-specific 
malonyl-CoA metabolism. Intramitochondrial malonyl-CoA is generated by a malonyl-CoA 
synthetase, ACSF3, that produces malonyl-CoA from malonate, an endogenous competitive 
inhibitor of succinate dehydrogenase. To determine the metabolic requirement for mitochondrial 
malonyl-CoA, ACSF3 knockout (KO) cells were generated by CRISPR/Cas-mediated genome 
editing. ACSF3 KO cells exhibited elevated malonate and impaired mitochondrial metabolism. 
Unbiased and targeted metabolomics analysis of KO and control cells in the presence or absence 
of exogenous malonate revealed metabolic changes dependent on either malonate or malonyl-
CoA. While ACSF3 was required for the metabolism and therefore detoxification of malonate, 
ACSF3-derived malonyl-CoA was specifically required for lysine malonylation of mitochondrial 
proteins. Together, these data describe an essential role for ACSF3 in dictating the metabolic fate 







Malonyl-CoA is positioned at a central regulatory node in mammalian metabolism to 
coordinate the synthesis and oxidation of fatty acids. Malonyl-CoA is generated in the cytoplasm 
and mitochondrial outer membrane by the biotin-dependent carboxylation of acetyl-CoA by the 
highly regulated Acetyl-CoA Carboxylase (267-271). Malonyl-CoA can then be used by Fatty 
Acid Synthase (FASN) to generate long-chain fatty acids, or be used for chain-elongation of fatty 
acids (267). Therefore, malonyl-CoA represents the rate-determining and committed metabolite 
in de novo fatty acid synthesis. Concomitantly, malonyl-CoA acts as an allosteric inhibitor of 
Carnitine Palmitoyltransferase 1 (CPT1), the rate-setting step in the mitochondrial β-oxidation of 
long-chain fatty acids; therefore, malonyl-CoA is the metabolite that mediates the basic metabolic 
logic whereby fatty acid synthesis and oxidation do not occur simultaneously. Both acetyl-CoA 
and malonyl-CoA are membrane-impermeable and all of the canonical biosynthetic machinery 
for malonyl-CoA that has been described is localized exclusively to the cytoplasm. Even tissues 
with limited expression of FASN, such as mammalian muscle, generate cytoplasmic malonyl-
CoA to regulate fatty acid oxidation (272, 273). Muscle regulates malonyl-CoA largely by its 
decarboxylation via Malonyl-CoA Decarboxylase, MLYCD (162, 274). Inborn errors of MLYCD 
result in a combined malonic and methylmalonic aciduria (275-277). Curiously, MLYCD 
contains putative peroxisomal and mitochondrial targeting sequences and can be readily found in 
mitochondria (275, 278-280). How malonyl-CoA, which is membrane-impermeable, can be 
generated in the mitochondrial matrix has been a longstanding mystery. This has been at least 
partly resolved by the discovery of a eukaryotic mitochondrial malonyl-CoA synthetase, ACSF3 
(281, 282).  
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ACSF3 was originally described as an orphan member of the Acyl-CoA Synthetase 
(ACS) family of enzymes (283). Recently, the Arabidopsis ACSF3 ortholog, Acyl Activating 
Enzyme 13, was described as a eukaryotic malonyl-CoA synthetase essential for plant growth and 
viability, especially in the presence of exogenous malonate (282, 284). Like other acyl-CoA 
synthetases, ACSF3 ligates Coenzyme A to its co-substrate, malonate, in an ATP-dependent 
manner (Figure A.1A). Human ACSF3 localizes to the mitochondrial matrix to produce malonyl-
CoA from malonate within that organelle (281). Mitochondrial malonate is an endogenous 
metabolite that is a classic competitive inhibitor of succinate dehydrogenase, a component of the 
tricarboxylic acid (TCA) cycle and Complex II of the electron transport chain (285). As such, 
malonate is often used as a metabolic toxin to destroy striatal neurons in models of Parkinson’s 
disease (286-288). The severe malonic and methylmalonic aciduria characteristic of MLYCD 
deficiency is also accompanied by developmental delay, seizure disorders, hypoglycemia, and 
cardiomyopathy. Recently, patients that presented with combined malonic and methylmalonic 
aciduria without mutations in MLYCD were found to have nonsynonymous mutations in the 
ACSF3 gene (289, 290). The similarities in the phenotypes of MLYCD and ACSF3 deficiencies 
suggest that they exist in the same biochemical pathway. This presents a metabolic rationale for 
why MLYCD is localized within mitochondria—toxic malonate may be metabolized within 
mitochondria through the subsequent activities of ACSF3 and MLYCD. 
Here we have taken advantage of CRISPR/Cas9-mediated genome editing to mutate 
ACSF3 in a human cell line that robustly expresses the enzyme. Using a combination of 
metabolic flux assays and measurement of steady-state metabolite concentrations, we 
demonstrate the requirement for ACSF3 in mitochondrial metabolism and reveal the metabolic 
fate of malonate in human cells. Furthermore, we demonstrate that ACSF3-derived malonyl-CoA 
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is required for mitochondrial protein malonylation, a recently identified posttranslational lysine 




Engineering ACSF3 Genomic Mutations in Human Cells 
Human patient fibroblasts can be difficult to obtain and can have limited utility. Engineering 
mutations in well-characterized human cell lines is advantageous for elucidating the function of 
enzymes in cellular metabolism and bypasses the transient and often insufficient knockdown by 
RNA interference. Here we have taken advantage of CRISPR/Cas9-mediated genome 
engineering to induce mutations in the ACSF3 gene in human HEK293T cells (130, 131). ACSF3 
is a 576 amino acid protein encoded by an 11-exon gene on human chromosome 16. We targeted 
a site in exon 3, the first protein-coding exon, by transfecting cells with a plasmid co-expressing 
human codon-optimized Cas9 nuclease and the designed guide RNA targeting ACSF3. 
Concomitantly, control cells were transfected with Cas9 without a guide RNA. Individual clones 
were selected by limited dilution plating and screened for loss of ACSF3 protein by 
immunoblotting (Figure A.1B). Select clones were analyzed for genomic mutations in ACSF3 
which are the result of non-homologous end-joining repair after Cas9-mediated endonuclease 
activity (Figure A.S1A). Consistent with its biochemical function, ACSF3 knockout (KO) cells 
have a 5-fold higher concentration of the enzyme’s substrate, malonate, relative to control cells 
(Figure A.1C). Total malonyl-CoA and acetyl-CoA abundance was unchanged in ACSF3 KO 
cells, demonstrating that compartment-specific defects in malonyl-CoA metabolism may not 
affect the cellular concentration of the enzyme’s product (Figure A.S1B). Cytoplasmic routes of 
malonyl-CoA synthesis likely account for a greater proportion of cellular malonyl-CoA than 
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ACSF3-derived mitochondrial malonyl-CoA. In this way, we have engineered cells with a similar 
biochemical phenotype to humans with inborn errors in ACSF3 in a cell line that can be easily 
cultured and manipulated in vitro. 
 
ACSF3 is Required for Malonate Oxidation 
Loss of ACSF3 resulted in increased steady-state levels of malonate (Figure A.1C), but the 
metabolic fate of malonate in human cells remained unclear. Malonate is an endogenous 
metabolite that acts as a classic competitive inhibitor of succinate dehydrogenase (285). As such, 
malonate is cytotoxic by blocking cellular respiration, and the effects of malonate are especially 
detrimental in cells that rely heavily on oxidative metabolism (286-288). To determine if loss of 
ACSF3 would exacerbate malonate-induced toxicity, ACSF3 KO and control cells were treated 
with increasing concentrations of malonate and cell survival was assayed after 72 hours of 
exposure (Figure A.S1C). Malonate impairs proliferation of ACSF3 KO and control cells to the 
same extent, with only subtle differences in cell viability by genotype across the malonate 
concentrations tested. This suggests that, while ACSF3 participates in the clearance of 
mitochondrial malonate, loss of ACSF3 does not affect cell growth under normal culture 
conditions. 
Consistent with the action of malonate as a potent inhibitor of succinate dehydrogenase, 
exposure of cells to 5 mM malonate for 24 hours dramatically increased steady-state succinate 
levels, and ACSF3 KO cells had 1.5-fold higher succinate accumulation than control cells upon 
malonate exposure (Figure A.1D). In the absence of exogenous malonate, steady-state 
intracellular succinate concentrations were not different between ACSF3 KO and control cells, 
likely due to the ability of succinate to exit cells via the dicarboxylic acid transporter. Consistent 
with this, we observed that succinate secretion increased in a dose-dependent manner with 
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increasing malonate exposure in both control and ACSF3 KO cells (Figure A.1D). At baseline, 
ACSF3 KO cells had higher malonate levels, providing evidence that the endogenous malonate-
clearance machinery may operate at low concentrations of substrate. 
To determine the ACSF3-dependent metabolic fate of malonate, ACSF3 KO and control 
cells were labeled with [1,3-13C]malonate, and isotopomer distribution into short-chain acyl-
carnitines, TCA cycle intermediates, and select amino acids was determined by LC-MS/MS 
(Figure A.1E). ACSF3 KO cells had less m+1 labeled acetyl-L-carnitine, indicative of less 
acetyl-CoA formation from labeled malonate, which results from malonyl-CoA decarboxylase 
activity on labeled malonyl-CoA in either the cytoplasm or mitochondria. The abundances of 
m+1 mass isotopomers of TCA cycle intermediates were decreased in ACSF3 KO cells, 
suggestive of a decrease in malonyl-CoA-derived acetyl-CoA entering the TCA cycle in the 
absence of ACSF3. These data provide evidence that malonate can be metabolized by mammalian 
cells in a manner that depends on its activation to malonyl-CoA by ACSF3. 
 
Loss of ACSF3 Perturbs Mitochondrial Metabolism 
In addition to decreased labeling of TCA cycle intermediates from malonate in ACSF3 KO cells, 
the total abundances of α-ketoglutarate and fumarate were decreased while malate and citrate 
concentrations were unchanged by loss of ACSF3 (Figure A.S1D). Again, in the presence of 
exogenous malonate, cellular succinate increased in ACSF3 KO cells, consistent with the action 
of malonate as a succinate dehydrogenase inhibitor. To determine how impaired mitochondrial 
malonate metabolism would affect overall mitochondrial function, cellular oxygen consumption 
was measured in the presence of 10 mM glucose, 2 mM glutamine, and 1 mM pyruvate. ACSF3 
KO cells exhibited significantly lower basal respiration than control cells, as well as lower 
CCCP-stimulated maximal respiration, with no difference in non-mitochondrial respiration 
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(Figure A.2A). These data demonstrate an ACSF3-dependent defect in mitochondrial oxidative 
metabolism. 
To test for differences in substrate-specific oxidative metabolism, glucose, glutamine, 
and alanine oxidation rates in ACSF3 KO and control cells were determined with radiolabeled 
substrates (Figure A.2B). Rates of oxidation of [U-14C]D-glucose to 14CO2 in ACSF3 KO cells 
were 65-75% of control cells, and the complete oxidation of [U-14C]L-glutamine and [U-14C]L-
alanine was similarly impaired (Figure A.2B). These defects in catabolic substrate utilization 
suggest a general impairment of mitochondrial metabolism in ACSF3 KO cells, consistent with a 
model of malonate-induced mitochondrial toxicity.  
 To determine whether the generalized impairment of mitochondrial metabolism in 
ACSF3 KO cells was a result of reduced mitochondrial content, immunoblotting for several 
mitochondrial proteins was conducted on ACSF3 KO and control cells (Figure A.2C). While the 
abundance of the outer mitochondrial membrane voltage-dependent anion channel (VDAC) and 
the matrix enzyme aconitase (ACO2) was unchanged between ACSF3 KO and control cells, 
several subtle differences were observed among inner mitochondrial membrane proteins that are 
components of the oxidative phosphorylation machinery. Among these, the abundances of a 
Complex I subunit (NDUFB8) and a Complex III subunit (UQCRC2) were significantly lower in 
ACSF3 KO cells while ATP synthase subunit ATP5A expression was unchanged (Figure A.2C). 
We next tested for complex-specific differences in respiratory chain function between ACSF3 
KO and control cells in isolated mitochondria. No differences were observed in the individual 
activities of Complex I, Complex II, Complex IV, or Complex V (Figure A.S2A, A.S3B). These 
data suggest that the subtle differences in mitochondrial protein abundance were not contributing 
to the overall defects in mitochondrial metabolism observed in ACSF3 KO cells and the 
113 
 
suppression in oxidative metabolism was due mainly to the competitive inhibition of SDH by 
malonate. 
 
Impaired Mitochondrial Malonate Metabolism Affects Cellular Energy Status and Impairs 
De Novo Lipogenesis 
To determine how impaired mitochondrial oxidative metabolism in ACSF3 KO cells affected 
cellular energy status, we tested the phosphorylation status of acetyl-CoA carboxylase (ACC). 
ACC is a substrate of the canonical energy-sensing AMP-activated protein kinase (AMPK), 
whose activity generates cytoplasmic malonyl-CoA. ACSF3 KO cells had more phosphorylated 
ACC (Ser79) than control cells (Figure A.3A), with no difference in total ACC expression 
(Figure A.S2C). Since malonate inhibits succinate dehydrogenase, we reasoned that malonate 
treatment might also affect cellular energy status and therefore AMPK signaling. The degree of 
ACC phosphorylation in both ACSF3 KO and control cells was unchanged by malonate exposure 
(Figure A.3A). 
Because phosphorylation and inactivation of ACC affects cytoplasmic production of 
malonyl-CoA and, therefore, de novo lipogenesis, we next measured the flux of radiolabeled 
substrates into total cellular lipids. Consistent with the phosphorylation status of ACC, 
[3H]acetate incorporation into lipid was decreased in ACSF3 KO cells relative to controls (Figure 
A.3B). Interestingly, the presence of malonate significantly decreased lipid synthesis from acetate 
in control cells while ACSF3 KO cells were unaffected by malonate exposure. This observation 
supports a role for ACSF3 in promoting malonate clearance to prevent a mitochondrial 
bioenergetic stress. While acetate incorporation into lipid does not require mitochondrial 
metabolism to generate acetyl-CoA, the synthesis of cellular lipids from the oxidative metabolism 
of glucose, glutamine, and alanine requires mitochondrial production of citrate. Consistent with 
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impaired oxidation of these substrates in ACSF3 KO cells (Figure A.2B), the flux into total 
cellular lipids was decreased to a similar degree (Figure A.3C, Figure A.S2D). These deficits 
provide further evidence of suppressed mitochondrial metabolic capacity upon loss of ACSF3. 
 
Protein Lipoylation is Unaffected by ACSF3 Deficiency 
Mitochondrial malonyl-CoA derived from ACSF3 has been implicated as a significant source of 
carbon for type II fatty acid synthesis in the mitochondrial matrix (281, 284). The octanoyl-ACP 
(acyl-carrier protein) produced by de novo fatty acid synthesis in the mitochondrial matrix is a 
substrate for the synthesis of lipoic acid, an essential cofactor for α-ketoacid dehydrogenase 
complexes (reviewed in (291, 292)). To test the contribution of ACSF3-derived malonyl-CoA to 
total cellular lipids, cells were labeled with [2-14C]malonate and contribution to the total lipid 
fraction was determined (Figure A.3D). ACSF3 KO cells had significantly lower malonate 
incorporation into lipid than control cells, consistent with a requirement for ACSF3 in malonate 
metabolism. In order to more specifically evaluate protein lipoylation status, immunoblotting of 
ACSF3 KO and control cell lysates was performed with an antibody that recognizes lipoylated 
residues (Figure A.3E). No defects in lipoylation of DLAT (E2 of pyruvate dehydrogenase) or 
DLST (E2 of α-ketoglutarate dehydrogenase) were detected in ACSF3 KO cells, suggesting that 
lipoic acid deficiency is not contributing to the impaired mitochondrial metabolic phenotypes in 
ACSF3 KO cells. 
 
Unbiased Metabolomics of ACSF3 KO Cells Reveal Malonate- and Malonyl-CoA-
Dependent Metabolic Alterations 
To gain a more global understanding of how ACSF3 regulates cellular metabolism, we performed 
unbiased global steady-state metabolomics on ACSF3 KO and control cells in the presence or 
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absence of 5 mM malonate for 24 hours. No signs of toxicity were observed at this concentration 
of malonate (Figure A.S1C). There were 355 unique metabolites detected, and 186 were changed 
greater than two-fold in either direction by genotype or malonate treatment or both. Metabolic 
alterations that were dependent upon malonate inhibition of SDH were clearly present (Figure 
A.3F; Table A.S1). However, these steady-state data demonstrate broad metabolic changes that 
cannot be easily explained by SDH inhibition alone and likely reflect both malonate- and 
malonyl-CoA-dependence. The differences observed by the loss of ACSF3 and exogenous 
malonate reveal intriguing and unique metabolic effects of the reaction’s substrate and product. 
 
ACSF3 Is Required for Mitochondrial Protein Malonylation 
The complexity of metabolic changes observed in ACSF3 KO cells suggests a more complex role 
for malonate than inhibition of SDH alone. Malonate and other structurally similar dicarboxylic 
acids traverse membranes via dedicated transporters in a concentration-dependent manner. 
ACSF3-derived mitochondrial malonyl-CoA, however, is trapped within that organelle. To 
further delineate the fate of malonate and mitochondrial malonyl-CoA, cells were labeled with [2-
14C]malonate and a biphasic extraction protocol was used to separate and recover polar, non-
polar, protein, and nucleic acid fractions (293). ACSF3 KO cells had higher [2-14C]malonate 
accumulation than control cells (total counts) and higher 14C signal in the polar metabolite 
fraction (Figure A.4A), consistent with the elevated steady-state malonate concentrations 
observed in ACSF3 KO cells (Figure A.1C). Interestingly, although malonate incorporation into 
protein only accounted for ~5% of total label incorporation in control cells (Figure A.S2E), 
ACSF3 KO cells had significantly lower malonate incorporation into protein (~1% of total label 
incorporation). These results suggest that the ACSF3-dependent incorporation of malonate into 
the protein fraction may be part of an adaptive response to cellular malonate exposure. 
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Furthermore, an inability to direct malonate toward this fate may account for some of the 
metabolic derangements observed in ACSF3 KO cells, particularly in the presence of exogenous 
malonate. 
 Protein malonylation has been recognized as a dynamically regulated posttranslational 
lysine modification that can affect mitochondrial and nucleocytoplasmic proteins (294-296), and 
malonyl-CoA is the likely substrate for protein malonylation (297-299). Using an antibody that 
specifically recognizes malonylated lysine residues, we immunoblotted for this modification in 
whole cell lysates and after enriching for mitochondria. Exogenous malonate treatment robustly 
increased mitochondrial protein malonylation and the majority of protein malonylation signal was 
localized to mitochondria (Figure A.4B). Importantly, ACSF3 was required for mitochondrial 
protein malonylation, and transient re-expression of ACSF3 was sufficient to rescue the impaired 
mitochondrial malonylation in ACSF3 KO cells (Figure A.4B). Transient re-expression of 
ACSF3 in KO cells did not alter the observed differences in protein abundance of particular inner 
mitochondrial membrane components of the oxidative phosphorylation machinery (Figure 
A.4B). Interestingly, immunoprecipitation of a mitochondrially-targeted YFP and 
immunoblotting for malonylated lysine residues demonstrated that a heterologous protein can be 
malonylated in the mitochondrial matrix of control cells but not in ACSF3 KO cells (Figure 
A.S3). This suggests that protein malonylation may be proportional to malonyl-CoA 
concentrations, as others have suggested (300), and that ACSF3 is the principal source of 






Mitochondrial Protein Malonylation Is a Stable Posttranslational Modification that Alters 
Cellular Metabolism 
We next sought to define the metabolic effects of mitochondrial protein malonylation through a 
malonate washout paradigm where cells were cultured in the presence of 5 mM malonate for 24 
hours before a washout with malonate-free growth media for up to 24 hours. We observed that 
mitochondrial protein malonylation is a stable modification that persists after removing malonate 
from the media (Figure A.5A). To understand potential roles of mitochondrial malonylation, we 
performed a malonate washout experiment with steady-state metabolite concentrations 
determined by 1H-NMR over the time course. Cellular succinate concentrations decreased rapidly 
(within 3h) after removal of exogenous malonate, consistent with the acute and reversible 
inhibition of SDH by malonate (Figure A.5B). Across the same time course, cellular lactate and 
pyruvate increased, while threonine concentrations remained consistently lower in ACSF3 KO 
cells, independent of time from malonate washout (Figure A.5B). These data further demonstrate 
malonate-dependent and malonyl-CoA-dependent effects of ACSF3 deficiency.  
 
ACSF3 Enables Metabolite-Specific Mitochondrial Protein Acylation 
We reasoned that global changes in protein malonylation may affect other lysine acyl 
modifications that are altered by cellular metabolism. Despite the defects in mitochondrial 
metabolism in ACSF3 KO cells related to SDH inhibition by malonate, neither malonate 
treatment nor loss of ACSF3 dramatically affected mitochondrial lysine acetylation (Figure 
A.6A). The removal of the malonyl-lysine modification is catalyzed by the mitochondrial sirtuin 
SIRT5 (294, 295), which also removes the structurally similar succinyl-lysine modification (295, 
301). The loss of Sirt5 enhances both malonylation and succinylation and has clear metabolic 
effects (296, 301). We hypothesized that the increase in cellular succinate upon SDH inhibition 
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by malonate may concurrently increase lysine succinylation and malonylation. Surprisingly, 
exogenous malonate did not affect mitochondrial protein succinylation, and ACSF3 KO and 
control cells exhibited no differences in mitochondrial protein succinylation (Figure A.6B, 
A.6C). In order to increase succinate and succinyl-CoA concentrations by an orthogonal method, 
cells were treated with the SDH suicide inhibitor, 3-nitropropanoate (3-NP). Cellular succinate 
concentrations were dramatically increased by 3-NP (Figure A.S5) and corresponded with 
increased mitochondrial protein succinylation independent of ACSF3 (Figure A.6C). Lysine 
succinylation and malonylation may occur on the same residues, so we also treated cells with 
both 3-NP and malonate simultaneously to test whether there is a propensity for one modification 
over the other. The presence of both malonate and 3-NP decreased the intensity of the malonyl-
lysine and succinyl-lysine signals relative to their respective controls with only one inhibitor 
(Figure A.6B, A.6C). These results show that ACSF3, by being required for protein 
malonylation, participates in the metabolite-specific acylation of mitochondrial proteins. 
 
Tissue-specific Differences in Mitochondrial Protein Malonylation Reflect Acsf3 Abundance 
ACSF3 expression across tissues and under different physiological conditions may provide 
insight into the regulation of mitochondrial malonate metabolism in vivo. ACSF3 mRNA is highly 
expressed in mitochondria-rich tissues in mouse such as brown adipose tissue (BAT), soleus 
muscle, kidney, and liver (85). Others have shown that protein malonylation is higher in fed liver 
than fasted liver (296), and obese leptin-deficient ob/ob mice exhibit a dramatic increase in 
hepatic protein malonylation (302). Both fed liver and ob/ob liver are characterized by high rates 
of de novo fatty acid synthesis and, therefore, elevated cytoplasmic malonyl-CoA. We posit that 
hydrolysis of cytoplasmic malonyl-CoA and transport into the mitochondrial matrix could 
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represent a significant source of malonate for ACSF3-derived malonyl-CoA that can be 
metabolized or modify mitochondrial proteins.  
 In four mitochondria-rich tissues (liver, kidney, heart, and BAT), we observed different 
levels of mitochondrial protein malonylation that positively correlated with Acsf3 expression 
(Figure A.7A). Malonylation of mitochondrial proteins was most robust in BAT, kidney, and 
liver. We confirm the findings of Du et al. that showed increased total protein malonylation in 
livers of ob/ob mice; and furthermore, we demonstrate that mitochondrial proteins from ob/ob 
mice have higher lysine malonylation than wild-type (WT) mitochondrial extracts (Figure A.7B) 
(302). Interestingly, mitochondrial protein succinylation was the same in WT and ob/ob liver 
(Figure A.7B), suggesting that the regulation observed in ob/ob mice is metabolite-specific. In 
BAT, both malonylation and succinylation of mitochondrial proteins was reduced in ob/ob mice 
relative to WT consistent with diminished nonshivering thermogenesis and BAT function in this 
model. Here we demonstrate that mitochondrial protein malonylation is positively correlated with 
Acsf3 expression and that alterations in lysine acylation in ob/ob mice may reflect tissue- and 




Cytoplasmic malonyl-CoA is a well-characterized metabolite that simultaneously drives 
de novo fatty acid synthesis while inhibiting the rate-setting step in mitochondrial β-oxidation of 
long-chain fatty acids (reviewed in (268-271)). The role and requirement for malonyl-CoA in the 
mitochondrial matrix is poorly understood, yet two enzymes have (so far) been identified as 
participants in the metabolism of this metabolite. Acyl-CoA synthetase family member 3 
(ACSF3) uses ATP and Coenzyme A to activate malonate to malonyl-CoA within the 
mitochondrial matrix (281-283), and mitochondrially-localized malonyl-CoA decarboxylase 
(MLYCD) can decarboxylate malonyl-CoA to generate acetyl-CoA and CO2. Malonate is an 
endogenous metabolic intermediate and a well-characterized competitive inhibitor of succinate 
dehydrogenase (SDH) (285). As such, malonate is cytotoxic by blocking the TCA cycle and 
cellular respiration. We propose that ACSF3 and MLYCD work in concert to clear malonate from 
mammalian mitochondria. In addition, another fate of mitochondrial malonyl-CoA is 
modification of lysine residues of mitochondrial proteins. To this end, we have shown that 
mammalian cells are capable of metabolizing labeled malonate in an ACSF3-dependent manner 
and that ACSF3 is required for mitochondrial protein malonylation.  
Acetyl-CoA derived from MLYCD-catalyzed decarboxylation of mitochondrial malonyl-
CoA can enter the TCA cycle and be fully oxidized, analogous to some bacterial species (303, 
304). Indeed, in legume plants, rhizobacteria are significant utilizers of malonate; however, the 
exact molecular source of malonate in eukaryotic cells is not well defined. We suggest that much 
of the mitochondrial malonate may derive from hydrolysis of cytoplasmic malonyl-CoA and 
subsequent transport into the mitochondrial matrix via dicarboxylic acid transporters of the inner 
mitochondrial membrane. In this way, ACSF3 may play a critical role in metabolic proofreading 
of a toxic side reaction (305). In plants and in pig heart, malonate was shown to be generated 
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from the decarboxylation of oxaloacetate (306, 307). Additionally, some bacterial species can 
generate malonate from pyrimidines (308). Interestingly, several pyrimidine-related metabolites 
were up-regulated in ACSF3 KO cells (Table A.S1). It has also been proposed that malonate can 
be formed from the oxidation of malondialdehyde, a product of lipid peroxidation, that is often 
used as an indicator of oxidative stress (282, 309). Alternatively, prior to the identification of 
ACSF3 as the eukaryotic malonyl-CoA synthetase, it was proposed that malonyl-CoA could be 
non-specifically synthesized by propionyl-CoA carboxylase from acetyl-CoA in the 
mitochondrial matrix, albeit at a much lower rate than propionyl-CoA carboxylation (310, 311). 
Although the relative contributions of each of these potential sources of mitochondrial malonate 
remains to be determined, our model describes the roles for ACSF3 and MLYCD in regulating 
mitochondrial malonate concentrations. Consistent with our model, mutations in human ACSF3 
or MLYCD result in toxic accumulation of malonate and systemic metabolic acidosis (289, 290). 
To further determine the metabolic role of ACSF3 in mammalian cells, we generated an 
ACSF3 loss-of-function genetic model in cultured cells by CRISPR/Cas9-mediated genome 
editing. Prior to recent advances in genome editing in mammalian cells, the use of patient primary 
cells has been the preferred model to study inborn errors of metabolism and to determine the 
molecular mechanisms behind human disease. However, these cultured patient fibroblasts or 
lymphoblasts often do not sufficiently express the genes of interest to determine the consequence 
of the mutations (312). Here we demonstrate the utility of generating stable mutations in well-
defined cultured cells to accomplish this same purpose. ACSF3 knockout (KO) cells have 
elevated steady-state malonate and succinate concentrations (Figure A.1C and Table A.S1), 
consistent with the biochemical function of ACSF3 and the inhibitory role of its substrate 
malonate. Although methods are currently lacking to measure concentrations of malonate and 
malonyl-CoA with subcellular resolution (313), mitochondrial protein malonylation may be a 
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reasonable proxy for mitochondrial matrix malonyl-CoA concentrations. Indeed, fibroblasts from 
patients with MLYCD deficiency had higher protein malonylation, consistent with an inability to 
catabolize malonyl-CoA to acetyl-CoA (298, 300). Elevated protein malonylation in MLYCD-
deficient cells also corresponded with impaired mitochondrial function, and here we demonstrate 
that a lack of mitochondrial protein malonylation in ACSF3-deficient cells also correlated with 
impaired mitochondrial function. The similar metabolic phenotypes observed in MLYCD- and 
ACSF3-deficient cells corroborate the similar clinical presentation of ACSF3 and MLYCD 
mutations in combined malonic and methylmalonic aciduria (CMAMMA). 
Elevated levels of malonate in plasma (2-10 µM) and urine (15-70 µM) have been 
described in patients with mutations in ACSF3 (290). Loss of the plant homolog of ACSF3 also 
resulted in dramatically elevated malonate concentrations in plant shoots as well as a dose-
dependent increase in both malonate and succinate upon treatment with exogenous malonate 
(282). In a similar manner, we expected cells deficient in ACSF3 to be more sensitive to 
malonate-induced cytotoxicity. Surprisingly, ACSF3-deficient cells were as sensitive to 
increasing concentrations of malonate as control cells. The doses of malonate tested are 
comparable to the concentrations used to treat plants (282) and lower than the concentrations used 
to induce cytotoxicity in neuronal cultures (10-75 mM) (288, 314); however, it is possible that 
these doses simply overwhelm the endogenous malonate-clearance machinery. Like other 
metabolite proofreading systems, we suggest that mitochondrial malonate metabolism operates at 
low levels of substrate (305), and, consistent with this, malonyl-CoA concentrations were lower 
than other short-chain acyl-CoAs in vivo (315). Additionally, in cell culture models, the culture 
media represents a significant metabolic sink, and toxic intermediates may be secreted into the 
media instead of being accumulated to the same extent as might occur in vivo. Specifically, we 
propose that malonate-induced inhibition of SDH does not result in dramatic accumulation of 
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succinate because this metabolite is free to exit the cell via dicarboxylic acid transporters. 
Nevertheless, the observation that there is no difference in malonate-induced cytotoxicity 
between ACSF3 KO and control cells facilitates interpretation of differences in metabolic flux 
data and steady-state metabolite concentrations, as these are not complicated by differences in 
cell viability. 
ACSF3 KO cells demonstrate impaired mitochondrial metabolism as evidenced by 
decreased oxygen consumption and impaired flux of glucose and glutamine to CO2 and to total 
cellular lipids. Additionally, steady-state concentrations of several TCA cycle intermediates were 
slightly decreased in ACSF3 KO cells relative to controls. This generalized impairment of 
mitochondrial flux is not the result of defective protein lipoylation, as ACSF3 KO cells have 
normal levels of lipoylated proteins. Instead, we hypothesize that malonate-induced toxicity 
accounts for the impaired mitochondrial metabolism observed in ACSF3 KO cells, and impaired 
mitochondrial protein malonylation may also contribute to the observed impairments. Widespread 
changes in malonylation as a result of ACSF3 deficiency could have the capacity to broadly 
affect several metabolic pathways, and metabolites identified from our steady-state metabolomic 
analysis as being regulated in a malonyl-CoA-dependent manner could represent candidate 
pathways that are regulated by malonylation. 
ACSF3 is a recently identified mitochondrial malonyl-CoA synthetase. Patients with 
mutations in ACSF3 or MLYCD display genetic concordance with systemic malonic aciduria and 
clinical features such as developmental delay, seizure disorders, hypoglycemia, and 
cardiomyopathy (289, 290), although the tissue-autonomous role for mitochondrial malonate 
metabolism is unknown. While there is much to be learned about the role and requirement for 
ACSF3 in vivo, we have generated ACSF3-deficient human cells using CRISPR/Cas9-mediated 
genome engineering to begin deciphering the cell-autonomous requirements for mitochondrial 
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malonate metabolism. Using a combination of metabolic flux assays and measurement of steady-
state metabolite concentrations, we have shown that malonate can be oxidized by mammalian 
cells and that ACSF3 plays an important role in preventing malonate-induced impairment of 
mitochondrial metabolism. Our approach is broadly applicable to target other metabolic enzymes 
implicated in human disease and may yield mechanistic insight into metabolic regulation in 




The regulation of cytoplasmic malonyl-CoA to promote fatty acid synthesis and inhibit 
mitochondrial β-oxidation of long-chain fatty acids is well described, but the source and 
metabolic fate of mitochondrial malonyl-CoA has remained a mystery until the recent 
identification of a mitochondrial malonyl-CoA synthetase, ACSF3. By engineering loss-of-
function mutations in ACSF3 in cultured human cells, we defined the requirement for 
mitochondrial malonate metabolism and gained mechanistic insight into disease-causing genetic 
deficiencies in malonyl-CoA metabolism. Malonate is an endogenous metabolite that potently 
inhibits succinate dehydrogenase, and we demonstrated that ACSF3 is required for malonate 
detoxification to promote mitochondrial metabolic flux. Malonate can be oxidized by human cells 
via the subsequent activities of ACSF3 and mitochondrial malonyl-CoA decarboxylase. ACSF3-
deficient cells exhibited elevated malonate concentrations and impaired mitochondrial 
metabolism. A combination of steady-state metabolite measurements and metabolic flux studies 
was used to describe malonate- and malonyl-CoA-dependent metabolic alterations. Lysine 
malonylation of mitochondrial proteins was identified as another significant fate of ACSF3-
derived malonyl-CoA. ACSF3 was specifically required for malonylation but did not affect lysine 
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acetylation or succinylation. ACSF3-deficient cells represent an excellent model system to define 
the regulation and metabolic consequences of mitochondrial protein malonylation to delineate the 
metabolic underpinnings of human metabolic disease. 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Cell Lines 
HEK293T cells were grown in DMEM supplemented with 10% bovine calf serum and 1% 
pen/strep antibiotic (Invitrogen) at 37°C in a humidity-controlled incubator at 10% CO2. As 
described in Method Details, ACSF3 KO cells were generated by transfecting hCas9 and the 
hACSF3 gRNA or hCas9 alone and deriving individual clones that were screened by 
immunoblotting and sequencing the ACSF3 target site. 
 
Mice 
All procedures were performed in accordance with the NIH’s Guide for the Care and Use of 
Laboratory Animals and under the approval of the Johns Hopkins Medical School Animal Care 
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and Use Committee. Male, 8-week-old, chow-fed, wild-type and ob/ob mice (C57BL/6J) were 
housed in a facility with ventilated racks on a 14h light/10h dark cycle with ad libitum access to a 




CRISPR/Cas9 Cloning Strategy 
Human codon-optimized Cas9 expression vector was obtained from Addgene, plasmid #41815 
(131), and hCas9 was cloned into a pEF6 expression vector, downstream and in-frame with a 
nuclear-localized YFP, linked by a viral 2A bicistronic peptide, such that nls-YFP and Cas9 are 
expressed in approximate equimolar quantities. A guide RNA (gRNA) targeting human ACSF3 
(Figure S1A) was designed according to the recommendations of Mali et al. (131) and was 
computed as a candidate unique gRNA target. The gRNA, including the U6 promoter, was 
synthesized as a 500bp gBlocks fragment (Integrated DNA Technologies) and was cloned into 
the pEF6-nls-YFP-2A-Cas9 vector by In-Fusion Cloning (Clontech), as previously described 
(130). 
 
Derivation of ACSF3 KO clones 
HEK293T cells were grown in DMEM supplemented with 10% bovine calf serum and 1% 
pen/strep antibiotic (Invitrogen) at 37°C in a humidity-controlled incubator at 10% CO2. Cells 
were transfected with plasmid expressing both hCas9 and the hACSF3 gRNA or hCas9 alone 
using Fugene HD (Promega) transfection reagent according to manufacturer’s instructions. 
Selection with 7.5 µg/mL blasticidin was started 48 hours post-transfection and continued for two 
weeks. Individual clones were selected by limited dilution plating and screened for loss of 
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ACSF3 protein by immunoblotting. For transient addback experiments, ACSF3 KO cells were 
transfected with a human ACSF3 expression vector and control cells were transfected with a 
plasmid encoding mitochondrially-targeted YFP (Clontech). Assays were conducted 48-72 h 
post-transfection. For cell viability assay, cells were counted, plated in 96-well format, and 
treated with 0, 2.5, 5, or 10 mM malonate (Sigma-Aldrich) for 72 hours, and cell viability was 
determined by CellTiter 96 Aqueous One Solution tetrazolium-based cell proliferation assay 
(Promega). 
 
Characterization of ACSF3 Mutations 
Genotyping primers were designed to span the gRNA target in exon 3 of ACSF3 (F: 
5’ACACAGAGGAAGTGGTCTTCT3’/ R:5’CGTTAGCGCATAGGAAGGAGA3’) and PCR 
was conducted on genomic DNA from ACSF3 KO clones by standard methods. PCR products 
were separated on agarose gels, and bands were excised, gel-extracted, and cloned into pCRII 
vector (Invitrogen) for Sanger sequencing. 
 
Measurement of Cellular Oxygen Consumption 
Oxygen consumption was measured using the Seahorse XFe96 extracellular flux analyzer 
(Seahorse Bioscience). 24,000 cells were plated in poly-L-lysine-coated 96-well microplates 18h 
before assaying cellular respiration. Cells were incubated with Seahorse base medium 
supplemented with 10mM glucose, 2 mM glutamine, 1 mM pyruvate for 1h before starting the 
assay. Oxygen consumption was measured repeatedly over the course of the experiment as the 
following inhibitors were added sequentially at the specified concentrations: 2 µM oligomycin A, 
250 nM CCCP, 0.5 µM rotenone/0.5 µM antimycin A. Cell number was determined by 
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CyQUANT (Invitrogen) staining of cellular nucleic acids and was used to normalize oxygen 
consumption rate in pmol/min. 
 
Mitochondrial Isolation and Functional Assays 
Mitochondria were isolated as previously described (316). Briefly, cells were scraped into cold 
isolation buffer (10 mM Tris, 10 mM MOPS, 1 mM EGTA, 200 mM sucrose, supplemented with 
20 mM nicotinamide, pH 7.4) and homogenized on ice with a glass homogenizer for 45 strokes 
before centrifuging at 600g, resuspending the pellet, and centrifuging again at 600g. All 
centrifugation steps were for 10 min at 4°C. The supernatant was transferred to new tubes and 
centrifuged at 7,000g. The supernatant was discarded and the pellet was resuspended, and 
centrifuged at 7,000g followed by a resuspension of the pellet and centrifugation at 10,000g. The 
mitochondrial pellet was resuspended in lysis buffer, sonicated, and protein concentration 
determined by BCA assay prior to SDS-PAGE and immunoblotting. 
For in-gel assays of respiratory complex function, mitochondria were solubilized in 
1.25% digitonin in basic lysis buffer (20mM HEPE-KOH, pH 7.4, 100mM NaCl, 20mM 
imidazole, 1mM CaCl2, 10% glycerol) with protease inhibitors (1mM PMSF, 10µM leupeptin, 
2µM pepstatin A) on ice for 30 min. Insoluble material was pelleted at 21,000g for 30min at 4°C 
and supernatant was combined with 10X native sample buffer (5% Coomassie Brilliant Blue G-
250, 0.5M 6-aminocaproic acid, 100mM BisTris-HCl, pH 7.0). 150µg of solubilized 
mitochondria were loaded per well and separated on 5-12% or 6-16% BisTris acrylamide gels. 
For Complex I NADH Nitrotetrazolium blue (NTB) reductase activity assay, gels were incubated 
in 2.5mg/mL NTB, 0.1mg/mL NADH, and 5mM Tris-HCl, pH 7.4 for 2h at room temperature, 
then fixed in 50% (v/v) methanol, 10% (v/v) acetic acid and destained. For Complex IV 
cytochrome c oxidase activity, native gels were incubated in 0.5mg/mL diaminobenzidine, 
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0.025mM equine heart cytochrome c, 50mM potassium phosphate, pH 7.4 for 5h at room 
temperature, protected from light, then fixed in 50% (v/v) methanol, 10% (v/v) acetic acid and 
destained. For Complex V ATP hydrolysis activity, native gels were equilibrated in 270mM 
glycine, 35mM Tris-HCl for 1h at room temperature, then switched to assay buffer containing 
270mM glycine, 35mM Tris-HCl with 14mM MgSO4, 0.2% Pb(NO3)2, and 8mM ATP, and 
incubated overnight. Gels were fixed in 50% (v/v) methanol and destained before imaging. 
Complex II activity was assayed by immunoaffinity microplate-based colorimetric assay (Abcam 
ab109908). Mitochondria were solubilized as per manufacturer’s recommendations and 50µg of 
mitochondria were used per well. Activity is quantified as the rate of decrease in absorbance at 
600nm as the production of ubiquinol reduces the blue dye DCPIP to a colorless product. 
 
Immunoblotting 
Cells were harvested in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100) 
with protease inhibitor cocktail (Roche) followed by brief sonication and pelleting of cellular 
debris at 12,000g (5 min at 4°C). 20 mM nicotinamide was included in the lysis buffer for 
immunoblotting for lysine acylation. Protein concentration of lysate was determined by 
bicinchoninic acid (BCA) assay (Thermo Scientific), and 30µg of cell lysate was separated by 
Tris-Glycine SDS-PAGE (12% polyacrylamide). Proteins were transferred to PVDF membranes 
(Immobilon), blocked in 5% nonfat-milk TBST, and incubated with primary antibodies overnight. 
Primary antibodies used include: ACSF3 rabbit polyclonal at 1:1000 (ThermoFisher PA5-25803), 
heat shock chaperone 70 (HSC70) mouse monoclonal at 1:1000 (Santa Cruz sc-7298), 
MitoProfile total OXPHOS mouse monoclonal antibody cocktail at 1:500 (Abcam ab110413), 
voltage-dependent anion channel 1 (VDAC1) rabbit polyclonal at 1:1000 (Calbiochem 
AB10527), aconitase 2 (ACO2) rabbit polyclonal at 1:1000 (Cell Signaling 6922), α-lipoic acid 
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rabbit polyclonal at 1:1000 (Calbiochem #437695), phospho-ACC (Ser79) rabbit polyclonal at 
1:1000 (Cell Signaling 11818), total ACC rabbit polyclonal at 1:1000 (Cell Signaling 3676), 
malonyl-lysine rabbit monoclonal mix at 1:1000 (Cell Signaling 14942), acetyl-lysine rabbit 
polyclonal at 1:1000 (Cell Signaling 9441), succinyl-lysine rabbit polyclonal at 1:1000 (PTM 
Biolabs 401), GFP mouse monoclonal at 1:1000 (Santa Cruz sc-9996). Cy3-conjugated anti-
mouse secondary antibodies (Invitrogen M30010) at 1:1500 or horseradish peroxidase (HRP)-
conjugated anti-mouse (GE Healthcare NA931V) or anti-rabbit secondary antibodies (GE 
Healthcare NA934V) at 1:2000 were incubated with washed membranes, and proteins were 
visualized with Amersham Prime enhanced chemiluminescent substrate (GE Healthcare) or 
epifluorescence on an Alpha Innotech MultiImage III instrument. Protein abundance was 
quantified using Alpha Innotech FluorChem Q software (Santa Clara, CA) and was normalized to 
HSC70 expression. For amido black total protein staining, PVDF membranes were incubated in 
0.1% naphthol blue black (w/v), 10% methanol (v/v), 2% acetic acid (v/v) for 5 min and 
destained in 10% acetic acid (v/v), 25% isopropanol (v/v) for 1 min before imaging. For GFP 
immunoprecipitation (IP), cells were lysed in lysis buffer with 20 mM nicotinamide, and 800 µg 
of protein was incubated with 10 µL of GFP nanobody magnetic beads (Allele Biotechnology) 
for 4h at 4°C in 400 µL final volume binding buffer (10 mM Tris HCl, 150 mM NaCl, 20 mM 
nicotinamide). Beads were washed once in binding buffer and twice in wash buffer (10 mM Tris 
HCl, 500 mM NaCl, 20 mM nicotinamide) before eluting with 40 µL elution buffer (200 mM 
glycine, pH 2.5) and neutralizing with 4 µL 1M Tris. IP samples from an equivalent of 200 µg 






Radiolabeled Substrate Metabolic Flux Assays 
For glucose oxidation assays, cells were incubated in stoppered T-25 flasks with 0.1µCi/flask [U-
14C]D-glucose (Moravek Biochemicals) in serum-free DMEM containing 2.5 mM glucose, 2 mM 
glutamine, 0.5 mM pyruvate for 4 h. 14CO2 was trapped on a filter paper suspended in the 
headspace of the flask by addition of 200µL 70% perchloric acid to the flask and 150µL 1M 
NaOH to the filter paper and incubating the samples at 55°C for 1 h. The filter paper was placed 
in scintillation fluid and counted, and counts were normalized to total protein. Glutamine and 
alanine oxidation assays were performed as described for glucose except 0.2µCi/flask [U-14C]L-
glutamine (New England Nuclear Radiochemicals/PerkinElmer) with 0.5 mM cold glutamine or 
0.2µCi/flask [U-14C]L-alanine (Moravek Biochemicals) with 0.1 mM cold alanine were used, 
respectively. 
To determine substrate incorporation into the total lipid fraction, cells were plated in 24-
well dishes and labeled with 14C-labeled substrate for 4h. Total lipids were extracted with 2:1 
chloroform:methanol via the Folch method (132), and radioactivity was counted by liquid 
scintillation. For [3H]acetate incorporation, cells were labeled for 4h with 0.2µCi/well in DMEM 
supplemented with 10% bovine calf serum. For glucose, glutamine, and alanine incorporation, 
0.2µCi/mL of radioactivity was used with the same media compositions as used for oxidation 
assays. For [2-14C]malonate incorporation, cells were labeled for 4h with 0.2µC/well in 0.1mM 
unlabeled malonate. All counts were normalized to total protein as determined by BCA assay 
(Thermo Scientific). In order to separate and recover polar, non-polar, protein, and nucleic acid 
fractions from cells labeled with 0.2µCi/well [2-14C]malonate (0.1mM unlabeled malonate) for 





Metabolite Extraction and Analysis 
For LC-QTOF, control and ACSF3 KO cells were exposed to 0 or 5 mM malonate for 24h prior 
to collection of cell extracts in ice-cold HPLC-grade 80:20 methanol: water and rapid quenching 
in liquid nitrogen. Cellular debris was pelleted by centrifugation, and the supernatant was dried 
by vacuum centrifugation prior to resuspension and unbiased metabolomics analysis by LC-
QTOF (130, 134).  
For stable isotope labeling experiments, cells (5E6 cells plated 24h before labeling) were 
incubated with 2.5 mM [1,3-13C]malonate (Sigma-Aldrich) for 4 hours and washed twice in PBS 
before cell extracts were collected in ice-cold 80:20 methanol:water with rapid quenching in 
liquid nitrogen. The abundance and isotopic enrichment of select water-soluble metabolites 
(including short-chain acyl-carnitines, TCA cycle intermediates, and select amino acids) were 
quantified by LC-MS/MS on an Agilent 6490 triple-quadropole system (Agilent Technologies, 
Santa Clara, CA), as previously described (130). Briefly, the MS/MS experiment was performed 
in positive/negative switching electrospray mode, as described previously (133), and all data 
processing was performed with the Mass Hunter Quantitative Analysis software package. Raw 
metabolite abundances were normalized to protein content. 
For capillary electrophoresis-MS (CE-MS), cells were washed with 5% mannitol and 
extracted with methanol spiked with an internal standard solution as specified by Human 
Metabolome Technologies. Insoluble material was pelleted and supernatant was filtered through 
centrifugal filters. Filtrate was dried under vacuum and resuspended for analysis by CE-TOF MS 
for cationic metabolites and CE-QqQ MS for anionic metabolites. Metabolite abundances were 
normalized to protein content. 
For 1H-NMR, cells were washed with ice-cold PBS and scraped into ice-cold methanol 
and snap frozen in liquid nitrogen before two additional freeze-thaw rounds with methanol 
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extraction. For 1H-NMR of culture medium for succinate measurements, 600µL of media was 
extracted with twice the volume ice-cold methanol, snap frozen in liquid nitrogen and thawed. 
Cell extracts and media samples were subjected to a final spin at 15,000g for 1 min at 4°C, then 
the supernatant was dried under vacuum and the extract resuspended in 20 mM phosphate buffer, 
pH 7.4 ± 0.1, with 0.1 mM TMSP as an internal reference and 0.1 mM sodium azide. 1H spectra 
were recorded on a Bruker Avance III 500MHz (Bruker Instruments, Germany) NMR 
spectrometer, operating at 499.9MHz and equipped with room temperature quadruple nuclei 
probe. Typical 1H spectra were acquired using presaturation solvent suppression pulse sequence 
(noesyprld). Acquisition parameters were set as follows; spectral width of 8012.820 with a 64K 
data points, 512 scans, with a relaxation delay of 7s for a total collection time of 1.14h. Samples 
were automatically tuned and match, and shimmed to TMSP signal. Spectra were exported into 
Bruker format and were processed with Chenomx NMR Suit 8.2 Professional (Chenomx Inc, 
Edmonton, Alberta, Canada). TMSP signal (0.0 ppm) was used as a reference peak, spectra 
manually phase corrected and spline function was applied for the baseline correction. Metabolites 
were profiled and quantified using built-in Chenomx 500MHz library. Metabolite concentrations 
were normalized to protein content. 
 
Protein Malonylation in Mouse Tissue Lysates 
Mitochondria were isolated based on Frezza et al. 2007, and tissue lysates and mitochondrial 
extracts were prepared in RIPA buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% 
Triton X-100, 0.25% deoxycholate) with protease inhibitor, supplemented with 20mM 





QUANTIFICATION AND STATISTICAL ANALYSIS 
Student’s t-test was used to evaluate statistical significance for quantitation of metabolic flux 
assays and quantitation of immunoblots between control and ACSF3 KO cells. Repeated 
measures ANOVA with Bonferroni post-tests were used to test statistical significance in cellular 
oxygen consumption experiments and 1H-NMR time course. For steady-state metabolomics 
analysis, two-way ANOVA was conducted using the freely available, web-based MetATT 
metabolomics tool for two-factor datasets (317). Statistical details of individual experiments can 










Table 2.1. Primer sequences 
Gene RefSeq ID Forward primer (5’3’) Reverse primer (5’3’) 
18S 
rRNA 
NR_003278.3 GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA 
Rpl22 NM_009079.3 AGCAGGTTTTGAAGTTCACCC CAGCTTTCCCATTCACCTTGA 
Β-actin NM_007393.5 GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Gapdh NM_001289726.1 AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
Mpc1 NM_018819.4 ATGTCCGGAGCAAGGACTTC ACAGAGGGCGAAAGTCATCC 
Mpc2 NM_027430.2 AATGGGGATTGGTGTGTGCT TGACCAAATAAACCCTGTAGCCA 
mt-Nd1 NC_005089.1 AATCGCCATAGCCTTCCTAACAT GGCGTCTGCAAATGGTTGTAA 
nuc-H19 NC_000073.6 GTACCCACCTGTCGTCC GTCCACGAGACCAATGACTG 
nuc-
Chr12 
NC_000078.6 GGGCTGACCTAAATGTGGCT CTCCCTCGTTTTCAGACCCC 
Pck1 NM_011044.2 GGAAGGACAAAGATGGCAAGTTC AGGCGTTTTCCTTAGGGATGTAG 
Pck2 NM_028994.2 ATGGCTGCTATGTACCTCCC GCCACAAAGTCTCGAACTCC 
 
Table 2.S1 
Metabolites significantly regulated by Mpc1 deficiency in e17.5 brain or liver. Values 
shown are fold-change over WT and p-value as determined by Welch’s two-sample t-test (n=8). 
Metabolites significantly regulated by Mpc1 deficiency in e17.5 brain 




hypotaurine 15.51 0.0000 
pyruvate 5.04 0.0000 
4-imidazoleacetate 3.16 0.0000 
phenyllactate (PLA) 2.98 0.0001 
histamine 2.77 0.0113 
sphingomyelin (d18:1/15:0, d16:1/17:0)* 2.35 0.0025 
N-acetylglycine 2.34 0.0000 
N-acetylhistidine 2.30 0.0000 
sarcosine (N-Methylglycine) 2.24 0.0000 
serine 2.19 0.0000 
sphingomyelin (d18:1/14:0, d16:1/16:0)* 2.06 0.0007 
4-vinylphenol sulfate 2.00 0.0210 
proline 1.98 0.0000 
glycine 1.94 0.0000 
guanidinoacetate 1.93 0.0003 
lactate 1.89 0.0000 
phenylacetylglycine 1.88 0.0009 
3-indoxyl sulfate 1.88 0.0033 
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N-acetylserine 1.84 0.0000 
imidazole propionate 1.84 0.0013 
aspartate 1.83 0.0000 
anserine 1.83 0.0000 
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) 1.81 0.0025 
catechol sulfate 1.80 0.0028 
beta-alanine 1.78 0.0000 
hippurate 1.76 0.0396 
N6-acetyllysine 1.75 0.0219 
phenol sulfate 1.72 0.0150 
4-acetamidobutanoate 1.71 0.0000 
cysteine 1.68 0.0000 
cysteine sulfinic acid 1.67 0.0413 
2-aminophenol sulfate 1.63 0.0137 
methylsuccinate 1.61 0.0000 
carnosine 1.61 0.0081 
isovalerylcarnitine 1.60 0.0036 
ethylmalonate 1.59 0.0000 
2-methylcitrate/homocitrate 1.59 0.0001 
N-acetyltaurine 1.55 0.0002 
gamma-glutamyl-epsilon-lysine 1.55 0.0009 
orotate 1.55 0.0001 
1-methylimidazoleacetate 1.54 0.0004 
beta-hydroxyisovalerate 1.54 0.0001 
palmitoyl dihydrosphingomyelin (d18:0/16:0)* 1.54 0.0211 
beta-hydroxyisovaleroylcarnitine 1.52 0.0001 
3-ureidopropionate 1.52 0.0037 
4-hydroxyphenylpyruvate 1.49 0.0091 
N-acetylalanine 1.48 0.0010 
N-formylmethionine 1.48 0.0001 
N-acetylvaline 1.46 0.0003 
N-acetylmethionine 1.46 0.0001 
1,2-dioleoyl-GPS (18:1/18:1) 1.46 0.0087 
N-acetylthreonine 1.45 0.0001 
betaine 1.42 0.0011 
methylmalonate (MMA) 1.42 0.0013 
N-acetylphenylalanine 1.41 0.0001 
N-methylproline 1.41 0.0071 
pyrraline 1.41 0.0027 
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N-acetylputrescine 1.38 0.0015 
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)* 1.38 0.0116 
N-acetylarginine 1.36 0.0040 
trigonelline (N'-methylnicotinate) 1.35 0.0032 
N-glycolylneuraminate 1.35 0.0360 
1-oleoyl-GPE (18:1) 1.34 0.0434 
sphinganine 1.34 0.0352 
succinylcarnitine 1.33 0.0275 
arginine 1.32 0.0102 
3-hydroxyisobutyrate 1.29 0.0150 
2-hydroxyglutarate 1.26 0.0006 
N-acetyltyrosine 1.25 0.0488 
argininosuccinate 1.25 0.0243 
1,2-dioleoyl-GPC (18:1/18:1)* 1.25 0.0411 
carnitine 1.20 0.0373 
1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) 1.20 0.0403 
lysine 1.18 0.0038 
prolylglycine 1.18 0.0001 
acetylcarnitine 1.18 0.0353 
1-palmitoleoyl-GPC (16:1)* 1.17 0.0403 
N-acetyl-aspartyl-glutamate (NAAG) 1.16 0.0177 
N-acetylglucosaminylasparagine 1.09 0.0027 
glycerophosphoglycerol 0.93 0.0174 
ribitol 0.90 0.0107 
glycerate 0.89 0.0076 
gulonic acid* 0.88 0.0157 
allantoin 0.87 0.0138 
tartronate (hydroxymalonate) 0.87 0.0363 
myo-inositol 0.86 0.0227 
oxalate (ethanedioate) 0.86 0.0023 
trans-4-hydroxyproline 0.84 0.0054 
glucosamine-6-phosphate 0.84 0.0469 
adenosine 5'-diphosphate (ADP) 0.84 0.0295 
1-methylnicotinamide 0.84 0.0462 
gamma-aminobutyrate (GABA) 0.82 0.0064 
erythronate* 0.82 0.0001 
leucine 0.81 0.0105 
oleoyl ethanolamide 0.81 0.0005 
palmitoyl ethanolamide 0.80 0.0001 
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2'-deoxycytidine 0.79 0.0087 
threonate 0.79 0.0003 
valine 0.78 0.0149 
gamma-glutamylisoleucine* 0.78 0.0228 
glycerophosphoethanolamine 0.78 0.0001 
hexanoylcarnitine 0.77 0.0170 
citrate 0.76 0.0077 
pseudouridine 0.76 0.0000 
N-palmitoyltaurine 0.75 0.0134 
spermidine 0.74 0.0002 
mannitol/sorbitol 0.73 0.0017 
palmitoylcarnitine 0.73 0.0030 
glutamate 0.72 0.0000 
glutamate, gamma-methyl ester 0.72 0.0012 
gamma-glutamylvaline 0.72 0.0034 
isocitrate 0.71 0.0012 
docosapentaenoate (n6 DPA; 22:5n6) 0.71 0.0275 
stearoylcarnitine 0.71 0.0061 
glutathione, oxidized (GSSG) 0.70 0.0001 
5-oxoproline 0.70 0.0314 
galactose 1-phosphate 0.70 0.0188 
galactonate 0.70 0.0036 
laurylcarnitine 0.70 0.0014 
citrulline 0.69 0.0063 
2-aminoheptanoate 0.69 0.0003 
octanoylcarnitine 0.69 0.0033 
glycerophosphorylcholine (GPC) 0.69 0.0000 
glycerol 0.69 0.0045 
2-aminoadipate 0.68 0.0207 
kynurenine 0.67 0.0033 
S-adenosylhomocysteine (SAH) 0.67 0.0078 
ascorbate (Vitamin C) 0.67 0.0061 
1-methylhistidine 0.66 0.0000 
cystathionine 0.66 0.0024 
ophthalmate 0.66 0.0202 
myristoleoylcarnitine* 0.66 0.0003 
2-aminobutyrate 0.65 0.0039 
gamma-glutamylmethionine 0.65 0.0376 
succinate 0.65 0.0012 
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myristoylcarnitine 0.65 0.0000 
gamma-glutamylleucine 0.62 0.0006 
tryptophan 0.60 0.0000 
isoleucine 0.60 0.0015 
3-methyl-2-oxovalerate 0.60 0.0059 
methionine sulfone 0.60 0.0008 
S-methylglutathione 0.60 0.0170 
homocitrulline 0.59 0.0005 
glutathione, reduced (GSH) 0.58 0.0013 
gamma-glutamylthreonine* 0.56 0.0004 
gamma-glutamylglutamine 0.54 0.0001 
glycerol 3-phosphate 0.54 0.0001 
S-methylcysteine 0.53 0.0018 
N-delta-acetylornithine 0.53 0.0000 
3-methylhistidine 0.47 0.0000 
3-methoxytyrosine 0.45 0.0000 
nicotinamide adenine dinucleotide reduced (NADH) 0.45 0.0001 
2-hydroxyadipate 0.42 0.0003 
glutamine 0.39 0.0000 
alanine 0.32 0.0000 
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3-methylglutarylcarnitine (2) 3.68 0.0003 
heme 2.99 0.0005 
pyruvate 2.61 0.0017 
4-imidazoleacetate 2.41 0.0021 
sphingomyelin (d18:1/14:0, d16:1/16:0)* 2.41 0.0000 
1-linoleoyl-GPE (18:2)* 2.35 0.0024 
1-arachidonylglycerol (20:4) 2.35 0.0079 
palmitoyl dihydrosphingomyelin (d18:0/16:0)* 2.30 0.0000 
histamine 2.19 0.0002 
1-palmitoyl-2-linoleoyl-GPG (16:0/18:2) 2.16 0.0000 
1-arachidonoyl-GPE (20:4)* 2.10 0.0069 
biliverdin 2.03 0.0283 
sphingomyelin (d18:1/15:0, d16:1/17:0)* 2.00 0.0000 
docosahexaenoate (DHA; 22:6n3) 1.96 0.0066 
sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0) 1.96 0.0000 
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2-arachidonoylglycerol (20:4) 1.95 0.0424 
indolepropionate 1.94 0.0371 
sphinganine 1.92 0.0004 
1-stearoyl-GPS (18:0)* 1.90 0.0090 
stearoyl sphingomyelin (d18:1/18:0) 1.90 0.0000 
adenosine 3',5'-diphosphate 1.84 0.0230 
1-docosahexaenoyl-GPE (22:6)* 1.80 0.0267 
eicosapentaenoate (EPA; 20:5n3) 1.77 0.0023 
N-acetylhistidine 1.73 0.0049 
methylsuccinate 1.72 0.0035 
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) 1.69 0.0003 
1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) 1.67 0.0003 
sphingomyelin (d18:1/20:0, d16:1/22:0)* 1.66 0.0000 
N-acetyltaurine 1.64 0.0012 
gamma-carboxyglutamate 1.62 0.0005 
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)* 1.62 0.0005 
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)* 1.60 0.0000 
p-cresol-glucuronide* 1.56 0.0479 
1-oleoyl-GPE (18:1) 1.55 0.0164 
N-acetylmethionine sulfoxide 1.53 0.0211 
gamma-glutamylglycine 1.53 0.0350 
1-palmitoyl-GPE (16:0) 1.53 0.0058 
2-palmitoleoyl-GPC (16:1)* 1.51 0.0377 
sphingomyelin (d18:1/18:1, d18:2/18:0) 1.50 0.0004 
palmitoyl sphingomyelin (d18:1/16:0) 1.49 0.0000 
N-acetylphenylalanine 1.48 0.0009 
phenylacetylglycine 1.48 0.0300 
ethylmalonate 1.48 0.0000 
1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* 1.45 0.0008 
flavin adenine dinucleotide (FAD) 1.45 0.0185 
N-acetylglycine 1.44 0.0040 
guanosine 5'- monophosphate (5'-GMP) 1.43 0.0007 
1-stearoyl-GPE (18:0) 1.42 0.0020 
histidine 1.41 0.0498 
glycine 1.40 0.0015 
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) 1.40 0.0014 
1,2-dilinoleoyl-GPC (18:2/18:2) 1.40 0.0003 
N-palmitoyl-sphingosine (d18:1/16:0) 1.40 0.0175 
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)* 1.40 0.0016 
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1-stearoyl-2-oleoyl-GPS (18:0/18:1) 1.39 0.0153 
N-acetyltyrosine 1.38 0.0445 
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) 1.38 0.0104 
sulfate* 1.38 0.0106 
phosphoethanolamine 1.37 0.0061 
1-stearoyl-2-linoleoyl-GPC (18:0/18:2)* 1.36 0.0084 
serine 1.35 0.0022 
3-indoxyl sulfate 1.35 0.0453 
1-methylhistamine 1.34 0.0241 




1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2)* 1.32 0.0028 
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* 1.32 0.0124 
sphingomyelin (d18:2/24:1, d18:1/24:2)* 1.31 0.0082 
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4)* 1.30 0.0006 
anserine 1.29 0.0244 
adenosine 5'-diphosphate (ADP) 1.29 0.0116 
1-oleoyl-2-linoleoyl-GPC (18:1/18:2)* 1.25 0.0010 
1,2-dipalmitoyl-GPC (16:0/16:0) 1.24 0.0034 
1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) 1.23 0.0024 
1-palmitoyl-2-oleoyl-GPE (16:0/18:1) 1.23 0.0362 
sphingomyelin (d18:2/16:0, d18:1/16:1)* 1.23 0.0013 
pyridoxamine phosphate 1.23 0.0131 
proline 1.22 0.0366 
lactate 1.21 0.0015 
palmitoyl ethanolamide 1.21 0.0360 
beta-hydroxyisovaleroylcarnitine 1.18 0.0185 
adenosine 5'-monophosphate (AMP) 1.18 0.0207 
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4) 1.16 0.0154 
N-acetylglucosaminylasparagine 1.12 0.0104 
carnitine 0.87 0.0149 
methionine sulfoxide 0.86 0.0373 
threonate 0.85 0.0158 
2'-deoxyuridine 0.84 0.0390 
pro-hydroxy-pro 0.81 0.0451 
2-aminoheptanoate 0.81 0.0030 
glutamate 0.79 0.0304 
thiamin diphosphate 0.79 0.0091 
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erythronate* 0.78 0.0008 
tryptophan 0.77 0.0073 
trans-4-hydroxyproline 0.77 0.0003 
ribitol 0.77 0.0022 
erythritol 0.77 0.0029 
alanine 0.76 0.0005 
1-methylhistidine 0.76 0.0022 
citrulline 0.76 0.0003 
5-methylthioadenosine (MTA) 0.75 0.0012 
mannitol/sorbitol 0.75 0.0244 
glycerol 0.75 0.0115 
oxalate (ethanedioate) 0.75 0.0000 
N6,N6,N6-trimethyllysine 0.74 0.0023 
3-methoxytyrosine 0.74 0.0496 
putrescine 0.74 0.0249 
gamma-glutamylisoleucine* 0.74 0.0006 
gamma-glutamylleucine 0.73 0.0076 
orotate 0.73 0.0499 
2'-deoxycytidine 0.73 0.0236 
glycerol 3-phosphate 0.72 0.0279 
thymidine 0.72 0.0363 
orotidine 0.71 0.0003 
pseudouridine 0.71 0.0000 
S-adenosylhomocysteine (SAH) 0.70 0.0226 
5-methyl-2'-deoxycytidine 0.70 0.0118 
ergothioneine 0.70 0.0004 
homocitrulline 0.69 0.0017 
gamma-glutamylvaline 0.69 0.0002 
N6-succinyladenosine 0.69 0.0403 
N4-acetylcytidine 0.68 0.0010 
2-aminobutyrate 0.67 0.0475 
creatine 0.67 0.0000 
N-acetylglucosamine 6-phosphate 0.67 0.0344 
maleate 0.67 0.0001 
nicotinamide adenine dinucleotide (NAD+) 0.67 0.0156 
dimethylglycine 0.66 0.0000 
N-delta-acetylornithine 0.66 0.0001 
arabitol/xylitol 0.66 0.0085 
methionine sulfone 0.65 0.0005 
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cysteine-glutathione disulfide 0.64 0.0182 
gamma-glutamylthreonine* 0.64 0.0085 
gamma-glutamyltryptophan 0.64 0.0119 
alpha-ketoglutarate 0.62 0.0001 
2-hydroxyglutarate 0.62 0.0091 
S-methylglutathione 0.61 0.0139 
gamma-glutamylalanine 0.61 0.0010 
fumarate 0.61 0.0000 
3-methylhistidine 0.60 0.0014 
alpha-hydroxyisocaproate 0.59 0.0376 
malate 0.59 0.0001 
gulonic acid* 0.59 0.0000 
ophthalmate 0.57 0.0398 
argininosuccinate 0.56 0.0007 
N-acetyl-glucosamine 1-phosphate 0.55 0.0102 
5-ketogluconate 0.55 0.0000 
creatinine 0.54 0.0000 
pipecolate 0.53 0.0006 
glutamine 0.51 0.0152 
isovalerylcarnitine 0.50 0.0414 
glutarylcarnitine (C5) 0.49 0.0104 
3-methylglutarylcarnitine (1) 0.43 0.0003 
pregn steroid monosulfate* 0.43 0.0000 
N-carbamoylaspartate 0.37 0.0013 
creatine phosphate 0.33 0.0011 











Table 4.1  Primers for maternal-fetal metabolic communication study 
Gene RefSeq ID Forward primer (5’3’) Reverse primer (5’3’) 
Acadl NM_007381.4 TTTCCTCGGAGCATGACATTTT GCCAGCTTTTTCCCAGACCT 
Acadm NM_007382.5 AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
Acot1 NM_012006.2 AACATCACCTTTGGAGGGGAG TCCCCAACCTCCAAACCATCA 
Acot2 NM_134188.3 AGTCAACGACGCAAAATGGTG GCTCTTCCAATCCTGTTGGC 
Acox1 NM_015729.3 ACGCCACTTCCTTGCTCTTC AGATTGGTAGAAATTGCTGCAAA 
Acsl1 NM_001302163.1 ATCTGGTGGAACGAGGCAAG TCCTTTGGGGTTGCCTGTAG 
Bdh1 NM_175177.4 TGACACCCGTCGGACCTAC TTCTCAGTCGGTCACTCTTCA 
Cpt1a NM_013495.2 CCATCCTGTCCTGACAAGGTTTAG CCTCACTTCTGTTACAGCTAGCAC 
Cpt1b NM_009948.2 GGTCCCATAAGAAACAAGACCTCC CAGAAAGTACCTCAGCCAGGAAAG 
Cpt2 NM_009949.2 CAACTCGTATACCCAAACCCAGTC GTTCCCATCTTGATCGAGGACATC 
Ehhadh NM_023737.3 CAGATGAAGCACTCAAGCTTG ACCTTGGCAATGGCTTCTGCA 
Fabp3 NM_010174.1 AGTCACTGGTGACGCTGGACG AGGCAGCATGGTGCTGAGCTG 
Fasn NM_007988.3 GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
Fgf21 NM_020013.4 CCTCTAGGTTTCTTTGCCAACAG AAGCTGCAGGCCTCAGGAT 
Glud1 NM_008133.4 ACTCTGGCTTGGCCTACACAATG CGGCTGTGAGCTGTCTATGTGAA 
Got1 NM_010324.2 CATCAGTCTTTGCCCAGGTTC GCTGAGATTCATCTGTGCGGTA 
Got2 NM_010325.2 TCACCGGCCTAAAGCCAGA TGAATGGCATGGGCAAGGTA 
Gpt1 NM_182805.3 CGTGGTGGCTATGTGGAAGT CTCCTGCCTCTCTGCTTGAAA 
Gpt2 NM_173866.3 TGATGGCACTCTGCACCTAC GCACTGTAAGATCCCAAGCTG 
Hadha NM_178878.2 TGCATTTGCCGCAGCTTTAC GTTGGCCCAGATTTCGTTCA 
Mpc1 NM_018819.4 ATGTCCGGAGCAAGGACTTC ACAGAGGGCGAAAGTCATCC 
Mpc2 NM_027430.2 AATGGGGATTGGTGTGTGCT TGACCAAATAAACCCTGTAGCCA 
Pck1 NM_011044.2 GGAAGGACAAAGATGGCAAGTTC AGGCGTTTTCCTTAGGGATGTAG 
Pck2 NM_028994.3 ATGGCTGCTATGTACCTCCC GCCACAAAGTCTCGAACTCC 
Pcx NM_001162946.1 GGAGCTTATCCCGAACATCC CGGAAGACGTCCATACCATTC 
Pdk4 NM_013743.2 ATCTAACATCGCCAGAATTAAACC GGAACGTACACAATGTGGATTG 
Pgc1α NM_008904.2 CAACATGCTCAAGCCAAACCAACA CGCTCAATAGTCTTGTTCTCAAATGGG 
PPARα NM_011144.6 GCGTACGGCAATGGCTTTAT GAACGGCTTCCTCAGGTTCTT 
Scd1 NM_009127.4 CCCTGCGGATCTTCCTTATC TGTGTTTCTGAGAACTTGTGGTG 
Trib3 NM_175093.2 GGCCTTATATCCTTTTGGAACGA CGCTGGCAGGGTACACCTT 
Reference genes:   
Rpl22 NM_009079.3 AGCAGGTTTTGAAGTTCACCC CAGCTTTCCCATTCACCTTGA 
Gapdh NM_001289726.1 AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 
18S NR_003278.3 GCAATTATTCCCCATGAACG GGCCTCACTAAACCATCCAA 





Table A.S1. Malonate- and Malonyl-CoA-Dependent Metabolic Alterations in ACSF3 KO 
Cells Revealed by Steady-State Metabolite Abundances 
Average metabolite abundances expressed as fold change relative to untreated control cells, 
displayed as “average (SEM)”, n=10 per condition. Select metabolites are organized by molecular 
class or metabolic pathway and are ranked by most highly up-regulated in KO cells to most 
down-regulated in KO cells under baseline conditions (0mM malonate). Also shown is fold 
change of metabolite abundance of control and ACSF3 KO cells after 24 hour exposure to 5 mM 
malonate relative to untreated control cells. Statistical significance of genotype effects, malonate 
treatment, and/or interaction between genotype and treatment determined by two-way ANOVA 
and indicated in rightmost columns (* p<0.01, ** p<0.001). 



















Malonate 1.00 (0.27) 4.86 (0.63) 772.8 (37.8) 1304 (159) * ** * 
TCA Cycle Intermediates 
Succinate 1.00 (0.13) 1.21 (0.08) 26.81 (1.50) 39.38 (2.65) ** ** * 
Citrate 1.00 (0.09) 1.00 (0.10) 0.83 (0.06) 0.59 (0.10)  *  
Isocitrate 1.00 (0.07) 0.74 (0.04) 0.76 (0.04) 0.64 (0.01) ** *  
cis-Aconitate 1.00 (0.02) 0.59 (0.05) 0.52 (0.01) 0.37 (0.04) ** ** * 
Amino Acid Metabolism 
Glutamine 1.00 (0.18) 3.82 (0.42) 0.74 (0.32) 4.84 (0.32) **   
Histidinol 1.00 (0.14) 1.15 (0.29) 0.15 (0.22) 1.27 (0.22) *   
Histidinal 1.00 (0.17) 1.14 (0.30) 0.13 (0.23) 1.26 (0.23) *   
Glutamate 1.00 (0.03) 0.99 (0.01) 0.76 (0.01) 0.98 (0.01) ** ** ** 
Imidazole-4-acetate 1.00 (0.12) 0.81 (0.22) 0.26 (0.34) 1.78 (0.34) *  * 
Leucine / Isoleucine 1.00 (0.04) 0.74 (0.06) 1.17 (0.03) 0.80 (0.09) **   
Glycine 1.00 (0.06) 0.72 (0.03) 1.20 (0.03) 0.79 (0.03) ** *  
Valine 1.00 (0.03) 0.71 (0.05) 0.94 (0.06) 0.63 (0.06) **   
Glutathione 1.00 (0.04) 0.68 (0.07) 1.08 (0.08) 0.68 (0.08) **   
Methionine 1.00 (0.04) 0.64 (0.04) 1.36 (0.07) 0.82 (0.07) ** **  
Proline 1.00 (0.03) 0.63 (0.04) 1.06 (0.02) 0.47 (0.02) **  * 
Tryptophan 1.00 (0.04) 0.62 (0.04) 1.07 (0.10) 0.65 (0.10) **   
Phenylalanine 1.00 (0.03) 0.62 (0.04) 1.10 (0.08) 0.66 (0.08) **   
Asparagine 1.00 (0.07) 0.60 (0.06) 0.91 (0.16) 1.54 (0.16)  ** ** 
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Lysine 1.00 (0.05) 0.59 (0.05) 0.81 (0.10) 0.63 (0.10) **   
Threonine 1.00 (0.03) 0.50 (0.06) 1.12 (0.05) 0.57 (0.05) **   
Serine 1.00 (0.04) 0.46 (0.02) 1.25 (0.14) 2.70 (0.14) ** ** ** 




1.00 (0.20) 0.38 (0.01) 0.46 (0.02) 0.16 (0.02) ** *  
Alanine 1.00 (0.02) 0.33 (0.07) 1.45 (0.02) 0.88 (0.05) ** **  
 
 



















Carbohydrate / Nucleotide Metabolism 
2-Deoxy-ribose 1-phosphate 1.00 (0.12) 2.78 (0.53) 1.29 (0.11) 3.98 (0.59) **   
Ribitol 1.00 (0.07) 0.86 (0.11) 1.13 (0.06) 0.46 (0.06) **  * 
Deoxyribose 1.00 (0.02) 0.49 (0.02) 1.07 (0.02) 0.61 (0.02) ** **  
AMP 1.00 (0.05) 1.69 (0.13) 0.75 (0.06) 1.32 (0.15) ** *  
ADP 1.00 (0.07) 1.29 (0.07) 1.04 (0.09) 0.70 (0.05)  ** ** 
UDP 1.00 (0.14) 1.66 (0.32) 5.97 (0.61) 1.32 (0.29) ** ** ** 
UMP 1.00 (0.11) 0.46 (0.08) 0.46 (0.11) 0.37 (0.06) * *  
2'-Deoxyinosine 5'-phosphate 1.00 (0.19) 0.16 (0.02) 0.84 (0.19) 0.16 (0.03) **   




1.00 (0.32) 1.24 (0.47) 17.32 (4.49) 1.00 (0.33) * * * 
Cytidine 1.00 (0.12) 1.68 (0.15) 1.47 (0.16) 2.70 (0.17) ** **  
Deoxycytidine 1.00 (0.05) 0.90 (0.10) 1.23 (0.04) 0.51 (0.03) **  ** 
Adenine 1.00 (0.09) 0.73 (0.10) 0.15 (0.03) 0.20 (0.05)  **  
3-Ureidopropionate 1.00 (0.07) 0.59 (0.06) 1.01 (0.10) 1.54 (0.16)  ** ** 
Uridine / Pseudouridine 1.00 (0.21) 0.56 (0.14) 0.74 (0.14) 0.31 (0.09) *   
5-Methylcytosine 1.00 (0.17) 1.14 (0.30) 0.13 (0.03) 1.26 (0.23) *   
1-Methyladenosine 1.00 (0.15) 0.46 (0.03) 1.03 (0.08) 0.63 (0.06) **   
Methylglyoxal / Propenoate 1.00 (0.23) 0.90 (0.28) 44.43 (2.58) 65.42 (4.40) ** ** * 
Lipid Metabolism 
5-Phosphomevalonate 1.00 (0.12) 2.80 (0.54) 1.30 (0.11) 4.02 (0.60) **   
Glycerol 3-phosphate 1.00 (0.19) 2.76 (0.43) 1.25 (0.22) 0.90 (0.08)  * * 
sn-glycero-3-
Phosphoethanolamine 1.00 (0.08) 1.97 (0.11) 2.11 (0.16) 2.08 (0.07) ** ** ** 
Glycerol 1.00 (0.06) 0.75 (0.09) 1.13 (0.06) 0.40 (0.05) **  * 




Pantothenate 1.00 (0.03) 0.66 (0.06) 0.78 (0.02) 0.54 (0.04) ** **  
Biotin 1.00 (0.07) 0.64 (0.11) 0.35 (0.04) 0.93 (0.12)   ** 
 
 
Table A.S2 Key Resources Table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Acyl-CoA synthetase family member 3 (ACSF3), rabbit 
polyclonal 
ThermoFisher Cat#PA5-25803; RRID: 
AB_2543303 
Heat shock chaperone 70 (HSC70), mouse monoclonal Santa Cruz Cat#sc-7298; RRID: 
AB_627761 
MitoProfile total OXPHOS, mouse monoclonal antibody 
mix 
Abcam Cat#ab110413; RRID: 
AB_2629281 
Voltage-dependent anion channel 1 (VDAC1), rabbit 
polyclonal 
Calbiochem Cat#AB10527; RRID: 
AB_10806766 
Aconitase 2 (ACO2), rabbit polyclonal Cell Signaling Cat#6922; RRID: 
AB_10828218 
α-lipoic acid, rabbit polyclonal Calbiochem Cat#437695; RRID: 
AB_212120 
Phospho-acetyl-CoA carboxylase (ACC) (Ser79), rabbit 
polyclonal 
Cell Signaling Cat#11818 
Total ACC, rabbit polyclonal Cell Signaling Cat#3676; RRID: 
AB_2219397 
α-malonyl-lysine, rabbit monoclonal antibody mix Cell Signaling Cat#14942 
α-acetyl-lysine, rabbit polyclonal Cell Signaling Cat#9441; RRID: 
AB_331806 
α-succinyl-lysine, rabbit polyclonal PTM Biolabs Cat#401 
GFP, mouse monoclonal Santa Cruz Cat#sc-9996; RRID: 
AB_627695 
Cy3-conjugated anti-mouse secondary antibody Invitrogen Cat#M30010; RRID: 
AB_2536619 
Horseradish peroxidase (HRP)-conjugated anti-mouse 
secondary antibody 
GE Healthcare Cat#NA931V 
HRP-conjugated anti-rabbit secondary antibody GE Healthcare Cat#NA934V 
GFP nanobody magnetic beads Allele Biotechnology Cat#ABP-NAB-GFPM050 
Chemicals, Peptides, and Recombinant Proteins 
















[1,3-13C]malonate Sigma-Aldrich 490199; CAS: 99524-14-8 
3-Nitropropionic acid Sigma-Aldrich N5636; CAS: 504-88-1 
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Critical Commercial Assays   
CellTiter 96 Aqueous One Cell Proliferation Assay Promega Cat#G3582 
Amersham Prime Enhanced Chemiluminescent Substrate GE Healthcare Cat#RPN2232 
XFe96 Extracellular Flux Assay Kit Seahorse Bioscience Cat#102601-100 
CyQUANT Cell Proliferation Assay Kit Invitrogen Cat#C7026 
Complex II Enzyme Activity Microplate Assay Abcam Cat#ab109908 
 
Experimental Models: Cell Lines 
Human: HEK293T ATCC Cat#CRL-3216; RRID: 
CVCL_0063 
Experimental Models: Organisms/Strains 
Mouse: Wild-type C57BL/6J The Jackson 
Laboratory 
RRID: IMSR_JAX:000664 
Mouse: ob/ob obese, leptin-deficient: B6.Cg-Lepob/J The Jackson 
Laboratory 
RRID: IMSR_JAX:000632 
Oligonucleotides   
ACSF3 Forward: 5’-ACACAGAGGAAGTGGTCTTCT-3’ This paper N/A 
ACSF3 Reverse: 5’-CGTTAGCGCATAGGAAGGAGA-
3’ 
This paper N/A 
Recombinant DNA   
Human codon-optimized Cas9 expression vector Mali et al., 2013 Addgene Plasmid #41815 
pEF6-nls-YFP-2A-Cas9 for bicistronic expression of 
nuclear YFP and Cas9 
Bowman et al., 2016 N/A 
Mitochondrially-targeted YFP expression vector (pEYFP-
Mito) 
Clontech Cat#6115 
Cytoplasmic YFP expression vector (pEYFP-C1) Clontech Cat#6341 
Other 
FuGENE HD Transfection Reagent Promega Cat#E2311 
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Fig. 1. Overview of pyruvate and fatty acid metabolism. 
MPC, mitochondrial pyruvate carrier; CPT, carnitine-palmitoyltransferase; 
OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; 
TCA, tricarboxylic acid; OAA, oxalacetate; LDH, lactate dehydrogenase; 
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Fig 2.1. The mitochondrial pyruvate carrier is developmentally regulated 
in a tissue-specific manner. 
(A) Western blot for Mpc1 and Mpc2 in mouse brain, heart, and liver across early postnatal 
development with Atp5a (mitochondrial inner membrane), aconitase 2 (Aco2, mitochondrial 
matrix), and Hsc70 (cytosol), demonstrating that tissue-specific differences in MPC 
expression are specific to the MPC. Mpc2 is present in embryonic tissues, although not readily 
visualized on the same exposure as adult tissues (see Fig. 2.4). (B) Relative mRNA abundance 
of Mpc1 and Mpc2 in brain, heart, and liver across mouse development by qRT-PCR and 
mitochondrial DNA content as determined by qRT-PCR of the mitochondrially-encoded Nd1 
























Fig 2.2. Tissue-specific developmental regulation of MPC components, 
Mpc1 and Mpc2. 
(A) Western blots of MPC expression in mouse brain, heart, and liver at three 
developmental time points (postnatal day 3, 7, and 21). (B) Mpc1 and Mpc2 
are expressed in equal ratios in adult mouse cerebral cortex, heart, and liver as
determined by immunoblotting. Adult cortex image from same blot and same 
exposure. Hsc70 is shown as loading control. No significant differences in the 
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Fig 2.S1. Gene targeting strategy for Mpc1 hypomorphic allele in mouse. 
Related to Fig 2.3 and Fig 2.4. (A) Exon diagram of Mpc1 locus and schematic of 
Mpc1 knock-in allele. Mpc1 is encoded by a five exon gene, and the knock-in 
reporter construct was targeted to the last three exons of the Mpc1 locus. The Mpc1 
deletion allele was generated by germline expression of a Cre recombinase transgene 
and subsequent inheritance of the deletion allele without Cre. (B) Body weights 
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Fig 2.3. Developmental and metabolic requirement for mitochondrial pyruvate 
metabolism. (A) Photograph of WT, heterozygous, and homozygous Mpc1 deletion late-gestation 
(e17.5) embryos. (B) Timed matings between Mpc1 D/+ mice reveal expected Mendelian ratios. Body 
weight distribution of Mpc1 D/D e17.5 embryos and D/+ and wild-type (WT) littermate controls 
(mean ± SD, n=23-30). (C) Cell proliferation assay in primary Mpc1 WT and D/D mouse embryonic 
fibroblasts (MEFs), mean ± SD, n=3, representative of two independent experiments with cells derived 
from two embryos of each genotype. (D) Glucose uptake in primary Mpc1-deficient MEFs labeled with 
0.5µCi [1,2-3H]2-deoxy-glucose at a final concentration of 6.5mM 2-deoxy-glucose for 5, 10, and 20 
minutes (mean ± SEM, n=6). (E) Incorporation of radiolabeled substrates into the total lipid fraction in 
Mpc1 D/D primary MEFs (black bars) with wild-type (WT, white bars) and heterozygous (D/+, gray) 
controls. Counts were normalized to protein and are displayed as mean ± SEM (n=3). Significant 
differences among group means determined by Tukey multiple comparison test after one-way ANOVA 
and indicated by asterisks relative to WT and D/+ controls (***p<0.001, **0.001<p<0.01). D/D = 




















Age # of litters WT KI/+ KI/KI
Expected 
ratio p-value
P21 15 26 52 0 1:2:1 26.00 2.3E-65
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Fig 2.4. Mpc1 hypomorphic allele reveals requirement for mitochondrial pyruvate 
metabolism in mammalian embryonic development. (A) Western blotting and qRT-PCR (B) 
for Mpc1 and Mpc2 in tissues from e17.5 embryos carrying 0, 1, or 2 copies of the Mpc1 hypomorphic 
knock-in (KI) allele. Hsc70 is shown as a loading control. RT-PCR data was normalized to the average of 
four reference genes as described in Methods and is presented as mean ± SEM relative to WT (n=7-8 per 
genotype). (C) [2-14C]pyruvate incorporation into the total lipid fraction in Mpc1-deficient primary MEFs 
in the presence of MPC inhibitor UK-5099 or vehicle (DMSO) (mean ± SEM, n=5). (D) Matings between 
mice heterozygous for the Mpc1 knock-in (KI) allele do not yield expected Mendelian ratios of offspring 
at weaning at postnatal day 21 (P21); however, expected Mendelian ratios are observed in late-gestation 
litters (embryonic day 17.5). (E) Body weights (mean ± SD, in mg) of e17.5 embryos from KI/+ intercrosses 
(n=17-34 from 8 litters). (F) Steady-state lactate concentrations in Mpc1 KI/KI e17.5 liver and brain as 
determined by enzymatic assay (mean ± SEM, n=6) (G) Steady-state ATP concentrations in liver and brain 
of Mpc1 KI/KI e17.5 embryos and littermate controls (mean ± SEM, n=5). Significant differences among 
group means determined by Tukey multiple comparison test after one-way ANOVA and indicated by 






































































Fig 2.5. Normal mitochondrial abundance and energy-sensing signaling in 
tissues from Mpc1 KI hypomorph embryos. (A) Representative immunoblot 
for phosphorylation of canonical energy-sensing components of AMPK and mTOR 
signaling pathways. (B) No difference in mitochondrial DNA content as determined 
by qRT-PCR with primers specific to the mitochondrially-encoded Nd1 gene relative 
to nuclear loci on Chr7 and Chr12 (mean ± SEM, n=7-8). (C) Representative 
immunoblot for mitochondrial proteins in WT and Mpc1 KI/KI cerebral cortex, heart, 
and liver, with Hsc70 as a loading control. (Aco2=aconitase 2; CV=Complex V; 
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Fig 2.6. Mpc1 hypomorphic allelic series reveals threshold requirement for 
mitochondrial pyruvate metabolism during development. 
(A) Mpc1 transcript abundance in cerebral cortex, heart, and liver of e17.5 embryos across 
an allelic series of Mpc1-deficient genetic models (mean ± SEM, n=8). (B) Nestin-Cre-
mediated deletion of Mpc1 in embryonic nervous system does not affect e17.5 body weight 
(mean ± SD, n=10-24 from 11 litters) and conforms to expected Mendelian ratios (χ2=2.44, 
p=0.786). (C) Matings between Mpc1 D/+ females and Mpc1 KI/+ males yield expected 
Mendelian ratios in e17.5 litters (χ2=2.18, p=0.535), and D/KI offspring are viable, although 
significantly smaller than littermate controls (***p<0.001 by Tukey multiple comparison test
after one-way ANOVA). See also Figure S1B. (D) Immunoblotting for inner mitochondrial 
membrane proteins in e17.5 cerebral cortex across Mpc1 hypomorphic allelic series, with 


























































































































































































































































































































































































































































Fig 2.7. Alterations in energy balance and lipid metabolism in 
Mpc1-deficient fetal liver. (A) Liver total fatty acid content determined by GC-MS 
(mean ± SEM, n=5). (B) Triglyceride levels in e17.5 liver determined enzymatically 
(mean ± SEM, n=6). (C) Liver total cholesterol levels (mean ± SEM, n=4). (D) e17.5 
liver glycogen content determined enzymatically after acid hydrolysis (mean ± SEM, n=5). 
(*p<0.05, **p<0.02) (E) Transmission electron micrographs of WT (left) and Mpc1 KI 
(right) e17.5 liver. Inset images showing normal mitochondrial morphology, inset scale 
bar = 100nm, LD=lipid droplet. (F) Pck1 and Pck2 mRNA abundance in e17.5 liver across
Mpc1 hypomorphic allelic series (mean ± SEM, n=8) Significant differences as determined
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Fig 2.8. Steady-state metabolite concentrations reveal effects of MPC deficiency 
and compensatory metabolic adaptations. (A) Distribution of total metabolites identified 
by unbiased metabolomics across molecular classes compared to the distribution of significantly 
regulated metabolites in brain and liver. (B) Metabolites detected in both brain and liver that were 
significantly regulated by Mpc1 deficiency. Values shown are fold-change relative to WT, and red and 
green indicate significant up- and down-regulation, respectively (p<0.05 by Welch’s two-sample t-test, 
n=8). Shown here are select metabolites directly related to pyruvate metabolism, TCA cycle 
intermediates, select amino acids, and select lipid metabolites. Additional list of significantly regulated
metabolites in Table S1. (C) Steady-state concentrations of alanine (ala), glutamate (glu), and aspartate 
(asp) in Mpc1 D/D primary MEFs relative to WT MEFs. (D) [2-13C]pyruvate flux. m+1 labeled 
metabolites over total metabolite abundance, determined by LC-MS, shown relative to WT 
(mean±SEM, n=4). (*0.01<p<0.05, **p<0.01 by pairwise comparison to WT after one-way ANOVA; 







































































































































































































































Fig 2.9. Mitochondrial amino acid utilization increases upon impaired mitochondrial 
pyruvate transport. (A) Alanine and pyruvate can be interconverted in either the cytosol or the mitochondrial 
matrix by the transaminase activity of glutamic-pyruvate transaminase 1 (GPT1, cytosolic) or glutamic-pyruvate 
transaminase 2 (GPT2, mitochondrial). Both transaminases utilize glutamate or α-ketoglutarate as co-substrates for the
interconversion of pyruvate and alanine. While pyruvate enters the mitochondrial matrix via the MPC, alanine likely 
traverses the inner mitochondrial membrane (IMM) via a member of the solute carrier family 25 of inner membrane 
transporters. (B) [U-14C]alanine incorporation into the total lipid fraction is dramatically upregulated in Mpc1 D/D 
MEFs (mean ± SEM, n=3). In HEK293T cells, pharmacological inhibition of the MPC with UK-5099 robustly impairs 
mitochondrial pyruvate metabolism (Fig. 2.S4) while simultaneously stimulating mitochondrial flux of alanine (C) 
and glutamine (D) in a dose-dependent manner as determined by incorporation of radiolabeled substrates into the 
total lipid fraction. (E) To determine the relative contributions of GPT1 and GPT2 to this phenomenon, HEK293T cells 
lacking GPT1, GPT2, or both (pan GPT) were derived by CRISPR/Cas9 genome editing. The increase in mitochondrial 
flux of alanine is independent of cytosolic GPT1, and mitochondrial GPT2 alone is necessary and sufficient for the 
increase in alanine flux that accompanies impaired mitochondrial pyruvate transport (mean ± SEM, n=6). 
(F) Glutamine incorporation into lipid in GPT-deficient HEK293T cells in the presence or absence of UK-5099. 
Significant differences among group means are represented by letters and were determined by Tukey multiple 
comparison test (p<0.05) after one-way ANOVA. In E and F, italicized letters are used for comparison of vehicle-
treated cells, bold letters are used for UK-5099-treated cells, and asterisks indicate significant up- or down-regulation
 of flux in response to UK-5099 treatment. 180
GPT1 KO
   M  A  S  S  T  G  D  R  S  Q  A  V  R  ...
   ATGGCCTCGAGCACAGGTGACCGGAGCCAGGCGGTGAGG    WT           (496 aa)
   ATGGCCTCGAGCACAGGTGACCGGT--CAGGCGGTGAGG      -2 deletion          (G10fsX90)

























...C  W  A  L  N  V  N  E  L  R  R  A  V  Q  E  ...
   TGCTGGGCGCTGAATGTGAATGAGCTCCGGCGGGCGGTGCAGGAG    WT        (523 aa)
   TGCTGGGC-----------------------GGGCGGTGCAGGAG    -23 deletion      (G243fsX252)
     .....CTCGACGCCATC(del 130)CAGGCCAGGTAC.....    -130 deletion    (Q130_T173del_fsX139)
pan GPT KO
GPT1
...A  V  Q  V  D  Y  Y  L  D  E  E  R  A  ...
   GCAGTGCAGGTGGATTACTACCTGGACGAGGAGCGTGCC  WT          (496 aa)
   GCAGTGCAGGTGGATTACTACCTG-ACGAGGAGCGTGCC        -1 deletion    (T209fsX258)
   GCAGTGCAGGTG----------------AGGAGCGTGCC        -16 deletion  (R205fsX253)
GPT2
...A  I  Q  V  N  Y  Y  L  D  E  E  N  C  ...
   GCCATCCAGGTGAATTACTACCTGGACGAGGAGAACTGC      WT                (523 aa)
   GCCATCCAGGTGAATT--------GACGAGGAGAACTGC            -8 deletion     (Y233X)
       GCCATCCAGGTGAATT--------GACGAGGAGAACTGC..(del 34)..  -42 deletion   (Y233X)
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Fig 2.S4. Generation of GPT KO HEK293T cells. Related to Fig 2.9. (A) Dose-dependent 
impairment of [2-14C]pyruvate incorporation into the total lipid fraction in HEK293T cells treated with 
UK-5099, an inhibitor of the MPC (mean ± SEM, n=3). (B) Genomic mutations identified in GPT1, 
GPT2, and pan GPT knockout (KO) HEK293T clones used for flux experiments in Fig 9. The guide RNA 
(gRNA) target site is shown in blue with the protospacer-adjacent motif in red. Predicted mutations at the 
protein level are listed at right. (C) Alanine aminotransferase activity assay in select GPT KO HEK293T 
clones (mean ± SEM, n=4). Significant differences as determined by Tukey post-hoc test (p<0.05) after 





















































































































































































































































































Fig. 4.1. Maternal response to late-gestation nutrient deprivation with 
impaired mitochondrial pyruvate transport.
(A) Immunoblot for Mpc1 and Mpc2 in maternal liver, 17.5 dpc, fed or 24h fasted. (B) 
Late-gestation (e17.5) fetal body weights from fed or fasted Mpc1 KI/+ dams. (C) 
Maternal blood glucose and serum β-hydroxybutyrate, non-esterified fatty acids (NEFA), 
and triglyceride (TG) concentrations (mean ± SEM, n=5-6). Maternal liver triglyceride 
content normalized to protein content (mean ± SEM, n=5-6). (D) Blood glucose and 
lactate concentrations during oral glucose tolerance test in pregnant dams at 17.5 dpc 
(mean ± SEM, n=10,9). Glucose (2g/kg) administered by oral gavage after 6h fast. 
Statistically significant differences (p<0.05) for pairwise comparisons after ANOVA 
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Fig. 4.S1. Maternal response to late-gestation nutrient deprivation.
(A) Maternal body weights at 17.5 dpc (mean ± SEM, n=8-11) and body weight differences from 
16.5-17.5 dpc (8.01±1.20 % in WT dams and 8.05±0.67% in Mpc1 KI/+ dams, mean ± SEM, 
n=7,6)  (B) WT fetal body weights at e17.5 from fed or 24h fasted WT or Mpc1 KI/+ dams. (C) 
Maternal blood lactate and serum triglyceride levels at 17.5 dpc (mean ± SEM, n=5-6). (D) 
Immunoblot of proteins regulated by fasting and nutritional status in maternal liver at 17.5 dpc, 
fed or 24h fasted. Mpc1 and Mpc2 blots also shown in Figure 4.1A. (E) Transcriptional 
regulation in WT and Mpc1-deficient maternal liver determined by qRT-PCR (mean ± SEM, 
n=5-6). (F) Steady-state metabolite abundances in maternal liver determined by 1H-NMR, 
normalized to protein content (mean ± SEM, n=4-6). Statistically significant differences (p<0.05) 
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Fig. 4.2. Maternal fasting ameliorates fetal metabolic derangements in Mpc1 mutants.
185
Fig. 4.2. Maternal fasting ameliorates fetal metabolic derangements in Mpc1 mutants.
(A) Immunoblotting for MPC components in e17.5 fetal liver from fed or fasted MpcKI/+ 
dams. (B) Transcriptional regulation in e17.5 fetal liver across an allelic series of Mpc1-
deficiency and in WT or KI/KI fetal liver in response to 24h fasting of Mpc1KI/+ dams, 
determined by qRT-PCR (mean ± SEM, n=5-8). (C) mRNA abundance of fasting-regulated 
genes in fetal liver during late gestation from e16.5-e18.5 (mean ± SEM, n=6). 
(D) Steady-state metabolite abundances from e17.5 fetal liver, determined by 1H-NMR. 
Normalized to protein content and shown relative to WT fed (mean ± SEM, n=6). 
(E) Lactate concentrations from fetal brain and heart measured enzymatically (mean ± SEM, 
n=6) and intracellular lactate concentrations from Mpc1 deletion (D/D) mouse embryonic 
fibroblasts (MEFs) under standard culture conditions ± 1mM β-hydroxybutyrate (βHB) for 
24h, determined by 1H-NMR (mean ± SEM, n=3). (F) Triglyceride content of placenta and 
liver at e17.5, determined enzymatically (mean ± SEM, n=5-8). Data from WT fetuses of 
WT dams are shaded green. (G) Hematoxylin & eosin staining of e17.5 fetal liver of WT 
and KI/KI littermates from fed or 24h fasted Mpc1 KI/+ dams. Statistically significant 
















































































Fig. 4.S3. Liver-specific defect in fatty acid oxidation as a model of impaired 
maternal fasting metabolism.
(A) Schematic of breeding scheme for generation of fetuses with liver-specific deletion of 
carnitine palmitoyltransferase 2 (Cpt2) [Albumin-Cre; Cpt2 ff (C;ff)] with ff controls in 
late-gestation litters from both ff and C;ff dams. C;ff dams were chosen as a model of impaired 
fasting metabolism since the inability to perform mitochondrial β-oxidation of long-chain fatty 
acids prevents ketogenesis during fasting. (B) Maternal liver triglyceride content and serum 
triglyceride levels at 17.5 dpc, fed or 24h fasted (mean ± SEM, n=6-8). 
Cpt2L-/-
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Fig. 4.3. The maternal response to fasting drives the fetal transcriptional program.
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Fig. 4.3. The maternal response to fasting drives the fetal transcriptional program.
(A) Blood glucose and serum NEFA and β-hydroxybutyrate levels from fed and 24h fasted 
liver-specific Cpt2 knockout pregnant dams (C;ff) and ff controls at 17.5 dpc (mean ± 
SEM, n=6-8). (B) Fetal body weights of ff and C;ff progeny from ff and C;ff pregnancies 
(mean ± SEM, sample size indicated). (C) Fetal liver β-hydroxybutyrate concentrations 
determined by 1H-NMR (mean ± SEM, n=6). (D) Triglyceride content of placenta and 
liver at e17.5, determined enzymatically (mean ± SEM, n=5-6). (E) mRNA abundance of 
select fasting-regulated genes in e17.5 liver (mean ± SEM, n=6). Statistically significant 





























































































































Fig. 4.4. The maternal response to fasting drives the fetal metabolic program.
(A) Maternal blood acylcarnitine abundances at 17.5 dpc determined from dried blood spots 
after extraction, butylation, and tandem mass spectrometry (mean ± SEM, n=5-8). (B) Fetal 
liver acylcarnitine abundances at e17.5 (mean ± SEM, n=5). For each pair of colored bars, 
the left bar represents ff fetuses and the right bar represents C;ff fetuses from the maternal 
genotype-nutritional combinations represented in A. (C) Fetal liver branched-chain amino 
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Fig. 4.5. Loss of hepatic fatty acid oxidation improves maternal glucose 
tolerance.
(A) Cpt2L-/- (C;ff) dams and ff controls were subjected to an oral glucose tolerance test 
(2g/kg) at 17.5 dpc after a 6h fast (mean ± SEM, n=7,9). 
(B) Serum insulin concentrations at baseline and 15 minutes after glucose gavage, 
determined by ELISA (mean ± SEM, n=7,8). 
(C) Oral glucose tolerance test on liver-specific Cpt2 KO, liver-specific Fgf21 KO, and 
Cpt2;Fgf21 double-knockout pregnant dams at 17.5 dpc. Area under the curve (AUC) 
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Fig. 4.6. PPARα-dependent fetal response to maternal fasting is potentiated 
by impaired maternal lipid metabolism.
(A) e17.5 body weights from WT dams, PPARα-/- dams carrying heterozygous or 
homozygous PPARα deletion litters (shaded in yellow), or all three fetal genotypes (WT, 
+/-, and -/-) from PPARα+/- intercrosses (shaded in orange). Circles are from fed litters 
and squares are from fasted litters. (B) mRNA abundance of several fasting-regulated 
genes in fetal liver, same genotypes as described in A. Open bars for fed samples; filled 
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Fig. 5.1.  Maternally-mediated effects of impaired liver fatty acid oxidation 
persist into the early postnatal period.
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Fig. 5.1.  Maternally-mediated effects of impaired liver fatty acid oxidation 
persist into the early postnatal period.
(A) Body weight, blood glucose, and stomach weight at postnatal day 2 (P2) (mean ± 
SEM, n=9-22). 
(B) Triglyceride content of P2 liver of ff and C;ff pups from ff and C;ff dams as well as 
PPARα-/- pups from PPARα-/- dams (mean ± SEM, n=6). 
(C) Hematoxylin & eosin staining of P2 livers from C;ff dam (scale bar is 0.2µm). 
(D) Transcriptional regulation of Acot1 and Fgf21 in P2 livers from pups reared by birth 
mother or cross-fostered to dam of opposite genotype from P0-P2 (mean ± SEM, n=3-6). 
(E) Immunoblot for Acot1, Fgf21, and acetyl-lysine (acetyl-K) in P2 livers from pups 
reared by birth mother or cross-fostered to dam of opposite genotype, and quantification 
of Fgf21 protein abundance relative to Hsc70 (mean ± SEM, n=3-4). 
(F) Blood acylcarnitine concentrations from P2 pups (mean ± SEM, n=3-14). For each 
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Fig. A.1. ACSF3 is a mitochondrial malonyl-CoA synthetase.
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Fig. A.1. ACSF3 is a mitochondrial malonyl-CoA synthetase.
(A) The reaction catalyzed by acyl-CoA synthetase family member 3 (ACSF3), 
a mammalian mitochondrial malonyl-CoA synthetase. 
(B) Immunoblot for ACSF3 in three control clones that were transfected with Cas9 
only and three ACSF3 knockout (KO) clones. HSC70 is shown as a loading control. 
See Figure S1 for characterization of genomic mutations. (ns = non-specific band)
(C) Steady-state intracellular malonate and succinate (D) concentrations, in the 
presence or absence of 5 mM malonate for 24 hours (mean ± SEM, n=10).
(D) Succinate secretion into the culture medium upon increasing dose of malonate 
for 24h (mean ± SEM, n=4). Effect of concentration significant by 2-way ANOVA.
(E) [1,3-13C]malonate flux. % abundance of m+1-labeled metabolites determined 
by LC-MS/MS that are significantly down-regulated in ACSF3 KO cells labeled 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. A.2. ACSF3 regulates mitochondrial metabolic efficiency.
(A) Oxygen consumption rate of ACSF3 KO cells in the presence of 10 mM glucose, 2 mM glutamine, 
and 1 mM pyruvate upon sequential administration of the specified mitochondrial inhibitors, normalized 
to cell number (mean ± SEM, n=5, representative of three independent experiments).
(B) Oxidation of [U-14C]D-glucose, [U-14C]L-glutamine, and [U-14C]L-alanine to 14CO2 in ACSF3 KO 
cells (mean ± SEM, n=6).
(C) Immunoblot of several mitochondrial proteins. VDAC (voltage-dependent anion channel 1) as outer 
mitochondrial membrane marker; ATP5A component of ATP synthase, Complex III subunit 2 
(UQCRC2), SDHB subunit of Complex II, and NDUFB8 subunit of Complex I of the inner 
mitochondrial membrane; aconitase (ACO2) and ACSF3 of the mitochondrial matrix; and HSC70 as 
cytoplasmic loading control. Protein abundance was normalized to HSC70, and values shown are fold 
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Fig. A.S2. ACSF3 promotes mitochondrial metabolic efficiency.
(A) Native gel electrophoresis and in-gel assays of respiratory complex function for Complex I, 
IV, and V. Coomassie shown as loading control (n=3 clones of each genotype, representative of 
three independent experiments) (B) Complex II activity by immunocapture and colorimetric assay 
(mean ± SEM, n=11-14 from three independent experiments). (C) Total ACC protein abundance is 
unchanged in ACSF3 KO cells (mean +/- SEM, n=6). Shown also is ACC phosphorylation and 
total ACC in ACSF3 KO and control cells as in Figure 3 with another n=2. Images were cropped 
from the same blot and exposure. (D) [U-14C]alanine incorporation into the total lipid fraction 
(mean ± SEM, n=6, *p<0.05). (E) [2-14C]malonate incorporation into different classes of 
biomolecules by biphasic extraction after 4h incubation with 0.2 µCi at 0.1 mM malonate 
(mean ± SEM, n=3, representative of two independent experiments, *p<0.05, **p<0.01). 
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Fig. A.S3. ACSF3 is required for malonylation of a heterologous protein.
Immunoprecipitation of YFP and immunoblotting for malonylated lysine residues in ACSF3 
KO and control cells transiently transfected with YFP or a mitochondrially-targeted YFP 
(mito-YFP) in the presence or absence of 5 mM malonate for 24h. The higher molecular 
weight band in the mito-YFP lanes is YFP with the mitochondrial targeting sequence intact 









































































































































































































































































































































































































































Fig. A.3. Metabolic alterations in ACSF3-deficient cells.
(A) Acetyl-CoA carboxylase (ACC) phosphorylation (Ser79) in ACSF3 KO and control 
cells in the presence or absence of 5 mM malonate for 24 hours (mean ± SEM, n=6 
from two independent experiments, **p<0.01 for genotypic effect, with no effect of 
malonate treatment, determined by posttest after two-way ANOVA). See also Fig. A.S2.
(B) [3H]acetate incorporation into total cellular lipids in the presence or absence of 
malonate (5mM) (mean ± SEM, n=6, representative of two independent experiments, 
**p<0.01 for genotypic effect, malonate treatment effect p=0.001 with significant 
interaction (p<0.05), determined by two-way ANOVA). (CPM = counts per minute)
(C) [U-14C]glucose and [U-14C]glutamine incorporation into the total lipid fraction 
(mean ± SEM, n=6, *p<0.05).
(D) [2-14C]malonate into total cellular lipids (n=12, pooled from two independent 
experiments).
(E) Immunoblotting for lipoic acid-modified proteins, DLAT (E2 of pyruvate dehydro-
genase) and DLST (E2 of α-ketoglutarate dehydrogenase), with HSC70 as loading 
control.
(F) Select metabolite levels in the presence or absence of 5 mM malonate for 24 hours 
(mean ± SEM, n=10, **p<0.01 by posttest after two-way ANOVA). More metabolites 
































B Whole cell Mitochondria



























































































Fig. A.4. ACSF3 is required for mitochondrial protein malonylation.
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Fig. A.4. ACSF3 is required for mitochondrial protein malonylation.
(A) [2-14C]malonate incorporation into different classes of biomolecules by biphasic 
extraction after 4h incubation with 0.2 µCi at 0.1 mM malonate (mean ± SEM, n=3, 
representative of two independent experiments, *p<0.05, **p<0.01). 
See also Fig. A.S2C.
(B) Immunoblotting for malonylated lysine residues in whole cell and mitochondrial 
extracts of cells in the presence or absence of 5 mM malonate for 24h. ACSF3 KO 
cells were transiently transfected with a human ACSF3 expression vector, and control 
cells were transfected with a mitochondrially-targeted YFP. Total protein staining by 
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Fig. A.S4. Mitochondrial protein malonylation persists in the 
absence of malonate.
Mitochondrial protein malonylation in three independent ACSF3 KO 
and control clones after 6h washout in malonate-free culture medium, 




































































































































































































































































































































































































































































































































































Fig. A.S5. SDH-inhibition by 3-nitropropanoate increases cellular 
succinate levels.
Steady-state succinate concentrations in cells treated with 5 mM 
3-nitropropanoate (3-NP, a suicide inhibitor of SDH) for 24h, determined 
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Fig. A.7. Tissue-specific differences in mitochondrial protein malonylation 
reflect Acsf3 abundance.
(A) Immunoblot of malonylated lysine residues in mitochondrial extracts from liver, kidney, 
heart, and brown adipose tissue (BAT) of wild-type (WT) and ob/ob mice. Total protein 
staining by amido black shown as loading control.
(B) Immunoblot of malonylated and succinylated lysine residues in mitochondrial extracts 
(mito) and total lysates (TL) of liver and BAT in WT and ob/ob mice. Complex V Atp5a 
subunit and Complex III component Uqcrc2 shown as loading control. Representative of n=3.
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